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Abstract  
Enteropathogenic E. coli inhibits phosphoinositide 3 (PI-3) kinase dependent phagocytosis via 
a Type Three Secretion System (T3SS) that delivers up to twenty effector proteins into target 
cells. The T3SS components are encoded on the Locus of Enterocyte Effacement (LEE) 
pathogenicity island alongside genes for a surface protein, Intimin, and seven effectors (Tir, 
Map, EspF, EspG, EspZ, EspH and EspB; latter also needed to deliver effectors). Inhibiting 
phagocytosis is linked to EspB, EspH, EspG and EspF activities with inhibitory mechanisms 
described for all except EspF. The aim of this study was to determine if EspF alone could inhibit 
phagocytosis and define the inhibitory mechanism.  
Initial anti-phagocytosis studies, with J774A.1 macrophages, not only confirmed EspF 
and T3SS-dependent inhibition but suggested a T3SS-independent contribution. Moreover, 
studies with effectors-deficient EPEC and non-pathogenic E. coli carrying LEE on a plasmid 
argued for LEE sufficiency. Surprisingly, delivering EspF into macrophages without most 
(EPEC multi-mutant) or all (via T3SS of another pathogen, Yersinia) other EPEC effectors 
argued against EspF sufficiency. Interestingly, the data also argued against EspG driving the 
anti-phagocytosis process but suggested that EspF’s contribution required Map, EspH, Tir, 
and/or the Intimin activities. Surprisingly, screening EspF/Map/EspH/Tir/Intimin single, 
double, triple, quadruple and quintuple mutants failed to confirm the critical roles for EspF or 
EspH that are linked to phenotypic instability and/or indirect contributions. Preliminary 
investigations on EspF’s involvement revealed possible features and domains required for its 
efficient expression, secretion and/or inhibiting phagocytosis. Crucially, the screening data 
provided many hypotheses including Tir and Intimin being able to drive T3SS-dependent anti-
phagocytosis, an idea supported by complementation studies. Collectively, this study provides 
important new insights on EPEC’s ability to inhibit its uptake by J774A.1 macrophages and 
reveals unknown levels of complexity.                  
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Chapter 1. Introduction 
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1.1 Gastrointestinal tract  
The gastrointestinal tract is a complex organ which has many important functions including the 
digestion and absorption of nutrients (Vereecke et al., 2011). The gastrointestinal tract can be 
divided into two main regions: the small intestine, from which 95% of nutrients are absorbed, 
and the large intestine which is primarily responsible for the absorption of most of the remaining 
water in the gut lumen (Vereecke et al., 2011). The gastrointestinal epithelium consists of a 
monolayer of cells composed of goblet (mucus-secreting), enteroendocrine (hormone-
secreting), paneth (antimicrobial peptide-secreting) and microfold (M) cells (antigen-sampling) 
as well as enterocytes (absorptive cells) (Abreu, 2010; Vereecke et al., 2011). Enterocytes are 
the dominant cell type (~80%) of the small intestinal cell lining (Abreu, 2010) that have two 
distinct surfaces- apical and basolateral (Figure 1) (Snoeck et al., 2005; Abreu, 2010). The 
apical membrane is distinguished by the presence of microvilli (Snoeck et al., 2005; Abreu, 
2010). Microvilli increase the absorptive surface area and facilitate the uptake of nutrients, ions 
and fluid (Halbleib et al., 2007). Microvilli are covered by large, negatively charged, mucin-
like glycoproteins (glycocalyx) that are integrated in the membrane (Snoeck et al., 2005; Abreu, 
2010). 
The glycocalyx contains adsorbed pancreatic enzymes thereby providing a highly 
degradative microenvironment that promotes nutrient absorption. It also hinders macro-
particles (for example gut micro-organisms and antigens) from accessing the epithelia (Snoeck 
et al., 2005). The basolateral membrane also has distinct features including specific proteins to 
mediate cell-substratum interactions or transport absorbed nutrients into the blood. The 
basolateral membrane is enriched in antigen-sensing receptors which trigger an immune 
response against foreign antigens that penetrate across the epithelia (Abreu, 2010). All types of 
gastrointestinal epithelial cells are connected by tight junctions (TJ) (Abreu, 2010; Vereecke et 
al., 2011) (Figure1). These belt-like structures have two main functions, a dynamic barrier 
function that regulates paracellular movement of molecules between adjacent cells. In addition, 
TJ have a fence function to block intermixing of molecules between the apical and basolateral 
membranes, thus maintaining the polarised nature of the epithelium (Tsukita et al., 2008; Zihni 
et al., 2016). Given the key role of the tight junctions and microvilli in fluid, ion and nutrient 
uptake, disruption of these structures by pathogenic micro-organisms can lead to diarrheal 
diseases (Guttman and Finlay, 2009; Thanabalasuriar et al., 2010; Singh and Aijaz, 2015). As 
the tightly-packed microvilli and the thick glycocalyx are effective barriers to protect 
enterocytes against micro-organisms, some pathogens target M-cells which have a reduced  
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Figure 1. Schematic representation of an enterocyte. Enterocytes are composed of two discreet 
membrane regions: the apical membrane also known as brush-border, increases the absorption 
and secretory capacity of epithelial cells and protects against invading pathogens. The brush-
border is made up of a number of finger like projections, named microvilli. The second 
membrane region is the basolateral region. Epithelial cells are connected by belt-like structures 
called tight junctions, which have two main function, a dynamic barrier function that regulates 
paracellular movement of molecules between adjacent cells and a fence function to block 
intermixing of molecules between the apical and basolateral membranes, thus maintaining the 
polarised nature of the epithelium.  
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number of microvilli (Mabbott et al., 2013). Moreover, M-cells actively sample gut content and 
present it to immune cells located at the basolateral surface via transcellular vesicular 
trafficking. M-cells transport antigens without modifying their antigenic properties (Miller et 
al., 2007; Mabbott et al., 2013). M-cells are mostly clustered in Peyer's patches, dome-like 
structures associated with focal centres of immune cells, that display reduced glycocalyx 
covering to aid antigen sampling (Miller et al., 2007; Mabbott et al., 2013). 
 
1.2 Escherichia coli (EPEC) in gut health and disease  
E. coli is a gram negative, facultative anaerobic, commensal bacterium of the human and 
mammalian intestine. E. coli has been widely studied and utilized as a host for general 
molecular biology techniques in laboratory science as it can be easily grown and genetically 
manipulated. Although E. coli forms part of the normal gut flora, commensal strains can be 
transformed into human pathogens by acquiring genetically mobile material. These acquired 
virulence elements promote the adaptation to a new lifestyle and enable the bacteria to cause 
diseases such as gastrointestinal disease, urinary tract infection, septicaemia and meningitis 
(Kaper et al., 2004; Greenwood et al., 2012). Traditionally, E. coli has been divided into eight 
pathogenic groups which cause diarrhoeal disease using different mechanisms. These include 
six long-established pathotypes: enterotoxigenic E. coli (ETEC), enteroaggregative E. coli 
(EAEC), diffusely adherent E. coli (DAEC), enteroinvasive E. coli (EIEC), enteropathogenic 
E. coli (EPEC) and enterohemorrhagic E. coli (EHEC), as well as two more recently identified 
pathotypes: adherent invasive E. coli (AIEC) and Shiga toxin (Stx) producing 
enteroaggregative E. coli (STEAEC) (Table 1)(Croxen and Finlay, 2010; Croxen et al., 2013).  
 
1.3 Enteropathogenic Escherichia coli                                                
EPEC is a non-invasive bacteria which was first linked to enteric disease in studies of 
hospitalised infants in the UK and USA during the 1940s and 1950s (Bray, 1945). However, 
enteric disease is now rare in developed countries but remains a major cause of infant morbidity 
in developing countries, causing profuse diarrhoea, often with fever and vomiting (Greenwood 
et al., 2012). Comprehending the strategies which pathogenic E. coli strains such as EPEC use 
to cause disease is of increasing importance due to approximately 526 000 diarrhoea related 
deaths every year (Bhutta and Das, 2013; UNICEF, 2016). In spite of the significant advances 
in the understanding of EPEC pathogenesis, the precise molecular mechanism causing watery 
diarrhoea is not completely understood (Singh and Aijaz, 2015). 
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Pathogen name Site of infection Disease symptoms 
Enteropathogenic 
E. coli (EPEC) 
Small intestine 
Watery diarrhoea 
Enterotoxigenic  
E. coli (ETEC) 
Watery diarrhoea 
Diffusely adherent 
E. coli (DAEC) 
Watery diarrhoea 
Enteroaggregative 
E. coli (EAEC) 
Small and large intestine 
Watery diarrhoea, can be 
bloody 
Enterohemorrhagic E. coli 
(EHEC) 
Large intestine 
Bloody diarrhoea, may lead to 
haemolytic  uremic syndrome  
Enteroinvasive 
E. coli (EIEC) 
Bloody diarrhoea and bacillary 
dysentery 
Uropathogenic 
E. coli (UPEC) 
Urinary tract and kidneys 
Urinary tract infections and 
acute pyelonephritis in the 
kidneys 
Neonatal meningitis E. coli 
(NMEC) 
Gastrointestinal tract and can 
cross blood-brain barrier 
Meningitis 
 
Table 1. List of the main pathogenic E. coli. This table illustrate the strains name and their site of infection and 
disease symptoms (Croxen and Finlay, 2010).  
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1.3.1 Attaching/Effacing phenotype and Locus of Enterocyte Effacement (LEE) region 
EPEC is a member of the attaching and effacing (A/E) family of pathogens, which also includes 
the human pathogen enterohemorrhagic E. coli (EHEC), the mouse pathogen Citrobacter 
rodentium (CR) and rabbit pathogenic E. coli (RPEC). This family of A/E pathogens promotes 
the formation of characteristic histopathological lesions (Knutton et al., 1989). These intestinal 
lesions are caused by intimate attachment of the microbes to the host plasma membrane 
followed by the dissolution of microvilli of the intestinal epithelial cells. The latter process is 
known as effacement (Moon et al., 1983; Knutton et al., 1989). Considerable cytoskeletal 
changes lead to the formation of pedestals consisting of polymerized actin beneath adherent 
bacteria (Figure 2) (Knutton et al., 1989). Previous studies have suggested that the pedestal 
structure is critical for full virulence in both animal and human models and also enhances the 
colonization of bacteria, however, the precise role of pedestals remains incompletely 
understood (Donnenberg et al., 1993a; Deng et al., 2003; Ritchie et al., 2003).  
The formation of A/E lesions is dependent on the highly conserved 35.6 kb 
pathogenicity island named the Locus of Enterocyte Effacement (LEE; Figure 3) in the genome 
of pathogenic bacteria. Introducing the LEE region of the EPEC (E2348/69) strain into 
commensal E. coli K12 strain proved that the LEE region possess all the essential genes which 
are required to induce A/E lesions (McDaniel and Kaper, 1997). The LEE region of EPEC 
(E2348/69) includes 41 open reading frames (ORFs) organised in five polycistronic operons. 
The LEE region encodes the proteins that form the type 3 secretion system (T3SS) as well as 
gene regulators, chaperones, effector proteins and the bacterial outer membrane protein Intimin 
(McDaniel et al., 1995; Elliott et al., 1998) as discussed below. 
 
1.3.2 Structure and function of T3SS  
The T3SS is an important virulence factor for A/E pathogens, due to its role in delivering the 
effector proteins into host cells (Gaytan et al., 2016). Similar to A/E pathogens, pathogenicity 
of several other Gram negative bacteria, including Shigella flexneri and Salmonella enterica is 
dependent on the delivery of many effector proteins into host cells through T3SS; subverting 
cellular systems to promote their colonisation (Coburn et al., 2007). The T3SS is a syringe-like 
structure that transfers effector proteins from the bacterial cytosol directly into target host cells 
(Gaytan et al., 2016). The proteins which form the T3SS of A/E pathogens are encoded by LEE, 
a total of around 20 proteins that form a needle-like complex which extends across both the 
inner and outer bacterial membranes (Figure 4)(Garmendia et al., 2005; Coburn et al., 2007). 
The last part of the T3SS is known as the translocon, which links the T3SS with the host cell. 
The translocon consists of three secreted  
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Figure 2. Intimate attachment of EPEC to the host plasma membrane induces effacing lesions 
and actin rich pedestals. Illustrative images by scanning electron microscopy (SEM) of EPEC 
induced infection characteristics. (A) The dissolution of microvilli of the intestinal epithelial 
cells (effacement) is shown after four hours of infection of a Caco-2 cell model with wild type 
EPEC. Figure taken from Dean et al., (Dean et al., 2006). (B) The formation of actin-rich 
pedestals beneath adherent bacteria revealed by SEM, using a HeLa cell model. Taken from 
Rosenshine et al., (Rosenshine et al., 1996b). 
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Figure 3. Diagram demonstrating the genetic organization of the locus of enterocyte effacement (LEE) region from 
EPEC E2348/69. The locus of enterocyte effacement (LEE) region is a highly conserved 35.6 kb pathogenicity 
island in the genome of pathogenic bacteria. The LEE region of EPEC (E2348/69) includes 41 open reading frames 
organised in five polycistronic operons indicated LEE1-LEE5. The LEE region encodes proteins which form the 
T3SS including Esc (Blue) and Sep (White), regulatory factors (Ler, GrlA, GrlR, and Mpc; Purple), chaperones 
(Green), translocator proteins (Orange), effector proteins (Esp; Red; that include Tir & Map), the bacterial outer 
membrane protein Intimin (eae; sky Blue) and other putative open reading frames (Orf; Yellow). Adapted from 
Wong et al.,(Wong et al., 2011). 
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Figure 4. Schematic of the EPEC T3SS. The T3SS is a multi-complex apparatus, a total of around 20 proteins 
which form a needle-like complex. The proteins that forms T3SS are Esc and Sep. Esc traverses the inner 
membrane loop which is composed of spanning proteins EscR, EscS, EscT, EscU and EscV as well as EscJ, 
spanning the periplasmic space and the external layer ring which is formed from the subunit EscC. The secretion 
and polymerisation of the subunit EscF forms the external needle known as translocon which links the T3SS with 
the host cell. The translocon consists of three secreted proteins: EspA which forms a long filamentous structure, 
and membrane inserted proteins EspB and EspD which from a translocation pore within the host cell membrane 
to deliver of effector proteins (for example Tir and EspF) directly into the host cell cytosol. The energy to release 
these effector proteins is provided by the ATPase, EscN. The switch secretion of translocator proteins to the 
secretion of EPEC effectors is regulated by proteins SepD, SepL and SepQ via the T3SS. The efficient 
translocation is dependent on chaperone such as CesF and CesT, however, EspG, NleD and NleF are translocated 
independently of both chaperones. Adapted from Garmendia et al., (Garmendia et al., 2005).  
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proteins; EspA, EspB and EspD, that are also essential for EPEC virulence (Donnenberg et al., 
1993b; Kenny et al., 1996; Frankel et al., 1998; Deng et al., 2004). The EspA protein 
polymerises at the end of the T3SS to form a filamentous extension that links the bacteria to the 
membrane of the host target where EspB and EspD insert to form a protein-delivery pore in the 
host membrane (Frankel et al., 1998; Knutton et al., 1998; Hartland et al., 2000; Daniell et al., 
2001; Luo and Donnenberg, 2011). When the secretion component of the translocon is 
completed the bacteria can then begin to inject its effector proteins into target cells. Thus, the 
T3SS and translocator system form a continuous conduit that is critical for successful 
translocation and transferring a suite of ‘effector’ proteins into gut epithelia to subvert cellular 
processes in a manner that promotes the bacteria’s lifecycle (Coburn et al., 2007; Gaytan et al., 
2016). 
 
1.3.3 EPEC effector proteins (LEE and Nle)  
The LEE region encodes seven identified effector proteins, Tir, Map, EspF, EspG, EspZ, EspH 
and EspB as well as the outer membrane protein Intimin. In addition, the LEE region encodes 
three translocator proteins (EspA, EspB and EspD). The secreted proteins that form the 
translocon have already been discussed. The EspB translocator is also known to have effector 
functions as it is also found in the host cytoplasm and interacts with host proteins to subvert 
cellular processes (Taylor et al., 1998; Iizumi et al., 2007).  
The first A/E effector to be delivered is named Tir, translocated Intimin receptor. Tir is 
inserted into the host membrane where it acts as a receptor for Intimin to mediate intimate host-
pathogen interactions and to induce pedestal formation (Kenny et al., 1997b). The insertion of 
Tir into the host membrane is linked to distinct shifts in apparent molecular mass leading to the 
T’ and T’’ forms, due to the addition of phosphate groups onto serine residues by host kinases, 
followed by additional phosphorylation (a tyrosine phosphorylation mediated by host tyrosine 
kinases) of T’’ producing the T’’pY form (Kenny and Warawa, 2001; Phillips et al., 2004; 
Swimm et al., 2004). Intimin interaction with T’’pY triggers the recruitment of the Nck adapter 
protein, which in turn leads to sequestration of the neural Wiskott–Aldrich syndrome protein 
(N-WASP) and activation of the Arp2/3 actin-nucleating machinery to produce pedestals 
(Campellone et al., 2002; Lai et al., 2013). In contrast, Tir from EHEC O157:H7 does not 
employ this mechanism but uses a second effector, Tccp (Tir cytoskeleton-coupling protein), 
also known as EspFu, which directly activates N-WASP and the insulin receptor tyrosine kinase 
substrate (IRTKS) that triggers pedestal formation (Campellone et al., 2004b; Vingadassalom 
et al., 2009). Although Tir-Intimin interaction triggers downstream signalling events leading to 
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the formation of actin-rich pedestals beneath the adherent bacteria (Kenny et al., 1997b) and 
causing microvilli effacement (Kenny et al., 1997b; Dean et al., 2006), Tir also has functions 
independent of Intimin. For example, Tir inhibits signalling pathways that induce anti-microbial 
and inflammatory responses (Ruchaud-Sparagano et al., 2011). Moreover, Tir induces cell 
survival through supressing the ability of EspG/EspG2 to promote calpain activity whose 
function is to induce host cell detachment and cleavage of the host proteins (Dean et al., 2010a). 
A second LEE effector, mitochondrial-associated protein (Map) is named after the 
observation that it targets and alters the function of mitochondria via its N-terminal sequence 
(Kenny and Jepson, 2000; Kenny, 2001b; Papatheodorou et al., 2006). Map is a guanine 
nucleotide exchange factor (GEF) that possess a WxxxE motif which activates host Rho 
GTPase Cdc42 at the cell membrane, leading to filopodia formation during the early stages of 
EPEC infection (Kenny et al., 2002; Alto et al., 2006; Huang et al., 2009).  Activation of Cdc42 
leads to the recruitment of N-WASP which triggers Arp2/3-mediated actin nucleation and 
filopodia formation (Miki et al., 1998; Svitkina et al., 2003; Wong et al., 2011). There is 
coordinated regulation between Map and other effectors; for example, Tir and Map regulate 
each other during infection (Kenny et al., 2002). Tir downregulates Map through the 
downstream target N-WASP and Arp2/3-mediated actin nucleation (Kenny, 2002).  
As a consequence, filopodia formation is transient due to a down-regulatory pathway 
dependent on the expression of Tir or Intimin (Dean et al., 2005). On the other hand, there is 
cooperativity with other effectors in altering host cell activity illustrated by the coordinated 
action of Map, Tir, EspF and Intimin to disrupt TJs (Dean and Kenny, 2004). Indeed, Tir and 
Map work synergistically mediating the uptake of bacteria by HeLa cells (Jepson et al., 2003).   
The EspF effector can be detected in several cellular compartments including the 
cytoplasm, mitochondria, apical and lateral membranes, and it has the ability to interact with at 
least 12 host cell proteins (Dean and Kenny, 2009; Holmes et al., 2010). EspF, like other LEE 
effectors, has multifunctional behaviour and induces various specific cellular responses (Dean 
and Kenny, 2009; Holmes et al., 2010). For instance, targeting mitochondria causes 
permeabilisation of the mitochondrial membrane and the release of cytochrome c from 
mitochondria into the cytoplasm followed by activation of caspase to trigger apoptosis 
(Nougayrède and Donnenberg, 2004; Nagai et al., 2005). Furthermore, EspF works 
synergistically with other effectors, for example EspF and Map decrease mitochondrial 
membrane potential and change the mitochondrial shape during EPEC infection (Kenny and 
Jepson, 2000; Nougayrède and Donnenberg, 2004). Moreover, it acts with Map and Intimin to 
disrupt intestinal barrier function (Dean and Kenny, 2004). In addition, EspF works 
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cooperatively with three effectors Tir, Map and Intimin (outer membrane protein) to trigger the 
effacement of absorptive microvilli (Dean et al., 2006). 
Like EspF, the EspG effector has multifunctional behaviour, with the major activities 
associated to actin cytoskeleton remodelling (Glotfelty and Hecht, 2012). EspG is a 398-amino-
acid protein that is also delivered into host cells via T3SS (Elliott et al., 2001). EspG displayes 
21% amino acids identity with the Shigella flexneri effector VirA (Elliott et al., 2001). The 
latter triggers the destabilization of host microtubule (Elliott et al., 2001). The EspG effector 
protein has a Nle homologue EspG2 (discussed below) which works together with EspG to 
disrupt the barrier function (Dean et al., 2010a). However, the presence of Tir suppresses this 
activity during infection (Dean et al., 2010a). In addition, disintegration of microtubules into 
tubulin subunits is ascribed to both EspG and EspG2 (Matsuzawa et al., 2004; Shaw et al., 
2005b).  
Another LEE-encoded effector is EspH; our knowledge about this effector is largely 
based upon empirical studies that investigated how EspH modulated actin dynamics of the host. 
Deletion of EspH caused prolonged filopodia formation concomitant with delayed pedestal 
formation. However, over-expressing of EspH lead to actin polymerization and pedestal 
elongation (Tu et al., 2003). EspH acts synergistically with Tir to modulate the actin pedestals 
through recruiting N-WASP activity and the Arp2/3 complex (explained below) (Wong et al., 
2012). 
EspZ is the smallest LEE encoded effector (98 amino acid). Previous research has 
indicated that EspZ is involved in virulence during rabbit EPEC  infection (Wilbur et al., 2015). 
EspZ has also been shown to promote host cell survival by interaction with the transmembrane 
protein CD98, thus stimulating ß1-integrin/FAK mediated host survival signals (Shames et al., 
2010). EspZ plays an important role in limiting cell death through inhibition of the apoptotic 
pathway (Roxas et al., 2012). It also interacts with the mitochondrial membrane translocase 
Tim17b, thus avoiding the release of cytochrome c and stabilising the mitochondrial membrane 
potential (Shames et al., 2010; Roxas et al., 2012). In order to regulate effector protein 
translocation into host cells by T3SS, EspZ interacts with EspD in the membrane pore and 
regulates the balance of pro- and anti-apoptotic effectors, consequently promoting host cell 
survival (Berger et al., 2012).  
EPEC also possesses additional effectors encoded outside the LEE region known as 
non-LEE (Nle) effectors, although some of these proteins retain the ‘Esp’ nomenclature. Up to 
seventeen known Nle effector proteins are encoded on prophages (PP) and integrative elements 
(IE) (Figure 5). Previous research has demonstrated that LEE and Nle effector proteins work 
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Figure 5. Schematic of the non-LEE effector encoding pathogenicity islands. EPEC possesses seventeen known 
effectors encoded outside the LEE region known as non-LEE (Nle), although some of these proteins retain the 
‘Esp’ nomenclature. These effector proteins are encoded on three integrative elements (IE2, IE5 & IE6) and four 
prophages (PP2, PP3, PP4 & PP6). The direction of the strand and genes are indicated using distinct arrows. (A) 
Demonstrating the fourteen effector proteins (Blue) encoded by the pathogenicity islands IE3, IE5, IE6, PP2, PP4 
and PP6 pathogenicity islands; moreover effectors LifA (IE6; Green) and EspC (IE4; Green). Taken from Dean 
and Kenny (Dean and Kenny, 2009). (B) Diagram demonstrating the prophage, PP3, encoding the NleJ effector 
(Red). Taken from Deng et al., (Deng et al., 2012).  
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antagonistically or synergistically to subvert several host cellular activities. For example LEE 
encoded Tir as well as NleB, NleC and NleE are associated with disrupting the inflammatory 
signalling pathway NF-κB (Nadler et al., 2010; Newton et al., 2010; Pearson et al., 2011; 
Ruchaud-Sparagano et al., 2011; Wong et al., 2011). In addition, a number of Nle effectors 
including NleD delay host cell apoptosis by targeting c-Jun N-terminal kinase (JNK) and MAP 
kinase which subsequently inactivate the transcription factor AP-1, involved in inflammation, 
apoptosis and cell differentiation (Baruch et al., 2011). Both NleH1 and NleH2 delay host cell 
apoptosis through targeting the anti-apoptosis protein Bax-inhibitor1 (Hemrajani et al., 2010). 
NleF also has anti-apoptotic effects as it inhibits caspase activity (Blasche et al., 2013). 
Additionally, the EPEC Nle effector protein EspJ was found to inhibit opsonic phagocytosis 
including both IgG and iC3b pathways. This is likely mediated through its capacity to inhibit 
Src family kinases (SFK), which block actin-driven opsono-phagocytosis (Marchès et al., 2008; 
Young et al., 2014). 
1.1.4 Chaperones 
The delivery of most LEE and Nle effectors through T3SS depends on chaperones encoded in 
the LEE region such as CesF and CesT (Elliott et al., 1999; Elliott et al., 2002; Thomas et al., 
2005). The main functions of the chaperones are (I) to stabilise the effector proteins within the 
bacterial cytosol, (II) to assist in trafficking/docking with the T3SS at the inner membrane and 
(III) to regulate gene expression. In addition, the chaperones are critical for efficient secretion 
of virulence proteins (Elliott et al., 1999; Elliott et al., 2002; Creasey et al., 2003; Thomas et 
al., 2005). It has been demonstrated that CesF is essential for only EspF intra-bacterial stability 
and T3SS delivery (Elliott et al., 2002). In contrast, CesT is essential for the delivery of most 
LEE effectors (Tir, Map, EspH, EspZ). Indeed, Nle are either fully dependent (NleB2, NleG, 
EspJ, NleH1, NleH2) or only partially dependent (NleB1; NleC) on the chaperone CesT. 
However, some effectors such as EspG, NleD and NleF have no CesF/CesT dependence 
(Thomas et al., 2005; Mills et al., 2013). 
 
1.3.5 EPEC pathogenicity 
The transmission of EPEC mainly occurs via the fecal-oral contact with contaminated drink or 
foods (Julian, 2016). When bacteria reach the small digestive system, the pathogenicity of 
EPEC infection is characterised by four stages: The first stage of infection involves EPEC 
binding to epithelia via the Bundle Forming Pilus (BFP) (Giron et al., 1991), which is encoded 
on the EPEC plasmid known as EPEC adherent factor (EAF) (Levine et al., 1985; Jarvis et al., 
1995). It has been demonstrated that BFP retraction promotes EPEC aggregation to form 
microcolonies and promotes efficient translocation of bacterial effector proteins into host cells 
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(Giron et al., 1991; Zahavi et al., 2011). The formation of the BFP allows interaction with other 
EPEC bacteria, forming characteristic EPEC micro-colonies, which are termed ‘localised 
adherence pattern’ (Baldini et al., 1983; Knutton et al., 1987; Frankel et al., 1998). Noticeably, 
the expression of BFP is coordinated by a collection of regulatory genes, encoded by EAF, 
known as plasmid encoded regulator genes A, B and C (perA, perB & perC). Plasmid encoded 
regulators have also been shown to influence other critical virulence factors including the T3SS 
via the LEE encoded regulator (LER) (Mellies et al., 1999). Nevertheless, some EPEC strains 
known as atypical EPEC strains do not display a localised adherence pattern as they lack the 
EAF plasmid. Atypical EPEC strains still have the ability to form A/E lesions, though with 
significantly delayed lesion formation; consequently these strains are less likely to cause human 
diarrheal disease (Levine et al., 1985; Chen and Frankel, 2005; Bueris et al., 2015). The second 
stage of infection involves T3SS mediated delivery of effector proteins into host cells, which 
cause activation of cell signalling pathways, actin polymerisation and cytoskeletal 
rearrangement (Figure 6)(Hodges and Gill, 2010; Croxen et al., 2013). The defining features of 
the last two stages of infection are the diarrhoea-associated events of losing absorptive 
microvilli and the formation of actin-rich pedestal-like structures beneath the adherent bacteria 
(Clarke et al., 2003; Kaper et al., 2004; Hodges and Gill, 2010). Additional diarrhoeal-
associated events include altering the function of apical transporters before the effacement 
process and disrupting barrier function by altering tight junction associated cell-cell interactions 
(Hodges and Gill, 2010; Singh and Aijaz, 2015).  
 
1.4. Phagocytosis  
There are several strategies that cells utilize to internalise molecules: phagocytosis, 
micropinocytosis and endocytosis (Rosales, 2005; Bohdanowicz and Grinstein, 2013). 
Phagocytosis is an important biological process, a key mechanism of innate immunity, that 
involves ingestion and destruction of large particles (≥0.5-µm). The main characteristic of 
phagocytosis is phagosome formation that is independent of clathrin but dependent on actin 
polymerization as well as phosphoinositide 3-kinase (PI-3 kinase) activity (Aderem and 
Underhill, 1999; Bohdanowicz and Grinstein, 2013; Naik and Harrison, 2013). PI-3 kinase is 
crucial for phagocytosis but also plays key roles in regulating membrane trafficking and cell 
growth (Araki et al., 1996; Bohdanowicz and Grinstein, 2013). PI-3 kinase in mammalian cells 
are composed of two subunits, a catalytic (p110) and a regulatory (p85) subunit (Araki et al., 
1996; Naik and Harrison, 2013). PI-3 kinase phosphorylates hydroxyl groups of inositol to  
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Figure 6. The four distinct stages of EPEC infection. The first stage of infection involves EPEC binding to the 
apical surface of enterocytes via the Bundle Forming Pilus (BFP), the formation of the BFP allows the interaction 
with other EPEC bacteria, forming characteristic EPEC micro-colonies which are termed ‘localised adherence 
pattern’. The second stage involves T3SS mediated delivery of a plethora effector proteins into host cells, which 
cause activation of cell signalling pathways, actin polymerisation and cytoskeletal rearrangement. The disruption 
of the host cytoskeleton is caused by the cooperative action of LEE effectors which are encoded on the 
pathogenicity island termed the locus of enterocyte effacement (LEE). These include seven identified effector 
proteins of which one (EspB) is part of the translocon as well as Nle effector proteins with some also named Esp 
(e.g. EspG2, EspL and EspJ). As a consequence, the absorptive microvilli on the apical surface of enterocytes is 
lost extensively which is known as effacement. The defining features of the final stage is the formation of actin 
rich pedestals. Pedestals formation is a very active process which includes the binding of the T3SS delivered 
translocated intimin receptor (Tir) effector, which is inserted into the host cell membrane and the outer membrane 
protein Intimin.  
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produce phosphatidylinositol 3-phosphate, phosphatidylinositol (3,4)-bisphosphate, or 
phosphatidylinositol (3,4,5)-trisphosphate (De Camilli et al., 1996; Naik and Harrison, 2013).  
In contrast, endocytosis uses two ways to form endosomes; caveolar endocytosis 
depends on caveolin and cavins to form a coat (Figure 7; (Krauss and Haucke, 2011; 
Bohdanowicz and Grinstein, 2013). Clathrin-mediated endocytosis uses the GTPase motor 
protein dynamin and the coat protein clathrin (Krauss and Haucke, 2011; Bohdanowicz and 
Grinstein, 2013). PI-3 kinase also plays multiple roles in the regulation of endocytosis, for 
example in intracellular membrane trafficking that follows internalisation (Araki et al., 1996; 
Krauss and Haucke, 2011). By inhibition of post endocytic trafficking it affects the rates of 
fluid-phase endocytosis versus receptor-mediated endocytosis (Krauss and Haucke, 2011; Elkin 
et al., 2016). 
The cells that are capable of phagocytosis include neutrophils, macrophages and 
dendritic cells (Flannagan et al., 2012). Macrophages are derived from monocytes which 
differentiate into macrophages or dendritic cells after leaving the circulation (Murray and 
Wynn, 2011).  
Monocytes can be considered as professional phagocytic cells since they express surface 
receptors which recognise the conserved microbial structures of bacteria and viruses (Murray 
and Wynn, 2011). The most abundant type (40 to 75%) of white blood cells are neutrophils, 
also known as neutrocytes. Although the neutrophils are short-lived, they are essential 
components of the innate immune system as they have the ability to enter any tissue and directly 
target and destroy microbes (Witko-Sarsat et al., 2000). In contrast, dendritic cells (antigen-
presenting cells) capture the antigen, process it and then present it to other immune cells (Hivroz 
et al., 2012).   
There are a number of features that are shared between different phagocytic 
mechanisms: Firstly, ligands on the surface of the microorganism interact with receptors on the 
surface of the phagocyte, thus triggering internalisation, which in turn depends on the 
polymerization of actin at the site of interaction (Araki et al., 1996; Aderem and Underhill, 
1999; Flannagan et al., 2012). Following actin-mediated internalisation, actin is lost from the 
phagosome which then matures, through a series of vesicle fusion and fission events, to a 
microorganism-destructive phagolysosomal compartment (Figure 8) (Aderem and Underhill, 
1999; Flannagan et al., 2012). 
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Figure 7. Pathways of entry into cells. There are several mechanisms of internalisation depending on the size of 
the particles. Large solid particles of >0.5 µm can be internalised by phagocytosis, while fluid is taken up by 
micropinocytosis. Both mechanisms are dependent on actin-mediated remodelling of the plasma membrane. The 
main characteristic of phagocytosis is phagosome formation that is independent of clathrin but dependent on actin 
polymerization as well as phosphoinositide 3-kinase (PI-3 kinase) activity. In contrast, endocytosis uses two ways 
to form endosomes; caveolar endocytosis depends on caveolin and cavins to form a coat. Clathrin-mediated 
endocytosis uses the GTPase motor protein dynamin and the coat protein clathrin. Whereas the caveolin-mediated 
endocytosis depends on intermediate compartments, such as the caveosome that is enriched early endosome. Taken 
from Liu and Roche, (Liu and Roche, 2015).  
 
 
 
 
 
Figure 8. Schematic representation of phagocytosis stages. Taken from https://www.score95.com/blog/wp-
content/uploads/2011/11/USMLE-step-2-ck2.jpg 
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1.4.1 Receptor mediated phagocytosis  
One of the fundamental features of phagocytosis is the clearance the foreign bodies, for instance 
microbes which cause infection, a task that is mediated by a variety of specific surface 
receptors. Dependent on the type of receptors involved, phagocytosis can be divided into two 
main types: opsonized phagocytosis and non-opsonized (Figure 9).  
 
1.4.1.1 Opsonic phagocytosis  
The receptor-mediated opsonic phagocytosis can be categorised into two major groups 
according to the receptor involved: the immunoglobulin IgG protein and complement protein 
antibody. Both recognise effectively the foreign particles which circulate within the blood and 
interstitial fluids.  
 
1.4.1.1.1 The immunoglobulin IgG protein 
The IgG molecule consists of two portions, one known as Fab (variable) region that recognize 
and bind to the epitopes on foreign antigens, while the Fc domain of IgG attaches to Fcγ 
receptors  (FcγRs; Figure 10) (Anderson et al., 1990; Rosales and Uribe-Querol, 2017). The 
FcγRs in human macrophages are divided into two groups: The activating FcγRs such as FcγRI, 
FcγRIIA and FcγRIII receptors, activate effector functions and phagocytosis signalling to 
induce internalisation of the particles (Figure 11). The second type of FcγRs are the inhibitory 
receptors and include FcγRIIB that regulate effector functions negatively (Naik and Harrison, 
2013; Rosales and Uribe-Querol, 2017) .  
Opsonic phagocytosis includes three steps: (I) attachment of ligand-coated particles to 
receptors. (II) Assembly of the FcγR complex which activates a signalling cascade. (III) Uptake 
of molecules dependent on actin polymerisation that form membrane extensions known as 
pseudopods (Griffin et al., 1975; Flannagan et al., 2012; Naik and Harrison, 2013; Rosales and 
Uribe-Querol, 2017). Importantly, iterative activation of FcγR leads to ‘zippering’ the 
membrane around the foreign particle; this includes interaction between receptors and available 
ligands on the host membrane prior to the internalisation process (Griffin et al., 1975; Naik and 
Harrison, 2013; Rosales and Uribe-Querol, 2017).  
Despite similar extracellular domains in all types of FcγRs, the position of their 
immune-receptor tyrosine-based activation motif (ITAM) differs which is important for FcγRs 
clustering (Flannagan et al., 2012; Naik and Harrison, 2013; Rosales and Uribe-Querol, 2017). 
The ITAM of FcγRIIA is located in the cytoplasmic domains (Muta et al., 1994; Naik and 
Harrison, 2013). In contrast, the ITAM of FcγRI and FcγRIII is found in separate  
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Figure 9. Schematic representation of the opsonic and non-opsonic receptors that initiate phagocytosis in 
macrophages. Macrophages possess both opsonic and non-opsonic receptors that interact with the microbes. They 
target coated particles “opsonized” with either C3bi or IgG to the FcγR or CR3 receptors, respectively. The 
scavenger receptors recognise bacterial ligands such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA). In 
contrast, to the Toll-like receptors which recognise the bacterial lipopolysaccharide (LPS) and peptidoglycan 
(PGN), while, the integrines recognise with the bacterial extracellular matrix (ECM) including fibronectin and 
vitronectin. Taken from Naik and Harrison, 2013 (Naik and Harrison, 2013). 
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Figure 10. Simplified schematic of the IgG. The immunoglobulin G (IgG) is the most abundant type of antibody 
in blood. It contains two portions, one known as Fab (variable) region that recognize and attach to the epitopes on 
pathogens, while the Fc domain of IgG attaches to Fcγ receptors (FcγRs). The complement protein responsible for 
opsonising bacteria for phagocytosis is C3b that attach to its receptor on macrophages. Adapted from 
https://es.slideshare.net/munevarjuan/sistema-inmune-curso / picture 17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Different types of FcγRs receptors in phagocytic cells. The FcγRI in human macrophages possess Ig-
like domains so that it has high affinity to bind with IgG. Activation of the FcγRI receptors is achieved by binding 
with their γ dimers which have a stimulatory ITAM motif within their cytosolic tails. While the ITAM motif is 
located in the cytoplasmic domains of the FcγRIIA. FcγRIIB possess an immune-receptor tyrosine-based inhibition 
motif (ITIM) within its transmembrane tail. Adapted from Naik and Harrison, 2013 (Naik and Harrison, 2013).  
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γ-dimers, which associate non-covalently with the ligand binding subunit of the receptors 
(Figure 11) (Hibbs et al., 1989; Ernst et al., 1993). Importantly, the ITAM has a conserved 
tyrosine residue in a YXXL sequence motif which is critical for competent phagocytic 
signalling through FcγRs, which is phosphorylated by tyrosine kinases of the Src family 
(Mitchell et al., 1994; Naik and Harrison, 2013).  
Src tyrosine kinases consist of five conserved components: The N-terminal domain   
(enables it to bind to the plasma membrane), SH2 domains, SH3 domains, the functional 
catalytic domain and the C- terminal with the tyrosine residue (Y527). Phosphorylation of  
Y527 lead to binds to the SH2 domain and induces a closed conformation that inactivates the 
enzyme.  
Following the phosphorylation of the ITAM, spleen tyrosine kinase (Syk) is recruited 
by Src tyrosine kinase via binding to the SH2 domains of Syk kinase (Kimura et al., 1996; Naik 
and Harrison, 2013; Rosales and Uribe-Querol, 2017). Activation of Syk kinase triggers 
different pathways which lead to cytoskeletal rearrangement as well as the release of 
inflammatory mediators (Latour et al., 1996; Naik and Harrison, 2013; Rosales and Uribe-
Querol, 2017). Previous research has found that Syc participates in the recruitment of 
downstream effectors such as PI-3 kinase via the phosphorylation of its p85 subunit (Crowley 
et al., 1997). For pseudopod elongation PI-3 kinase catalyses the phosphorylation of (PI(4,5)P2) 
to (PI(3,4,5) P3) at the plasma membrane during FcγR-mediated phagocytosis (Crowley et al., 
1997; Cox and Greenberg, 2001). The production of the PI-3 kinase is essential for recruiting 
proteins which are important for F-actin remodelling in the phagocytic cup (Naik and Harrison, 
2013; Rosales and Uribe-Querol, 2017).    
Interestingly, FcγR activation stimulates F-actin polymerisation beneath the attached 
particles and consequently promotes membrane protrusions (pseudopods, Figure 12) (Griffin et 
al., 1975). The key factors in the regulation of actin dynamics in eukaryotic cells are GTPases 
of the Rho family such as RhoA, Rac and Cdc42, that switch between the GTP-bound, active 
form and the GDP-bound inactive form (Hall, 1998). It has been shown that Src and Syc 
tyrosine kinases participate in F-actin regulation by activating Rac 1 and Cdc42 (Deckert et al., 
1996). Indeed, Rho family activated by nucleotide exchange, for instance the guanine 
nucleotide exchange factor (GEF), catalyses the exchange of GDP for GTP for activation. GTP-
bound Rac 1 and Cdc42 regulate the F- actin binding protein to assist the formation of the 
membrane protrusions filopodia and lamellipodia (Hoppe and Swanson, 2004). Cdc42 GTPase 
is an important component in FcγR-mediated phagocytosis in macrophages as it plays a key 
role for activation and recruitment of the downstream effector Wiskott - Aldrich syndrome  
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Figure 12. Activation of Fcγ receptor signalling leads to actin rearrangement and pseudopod formation. Following 
the activation of the Src and Syk, the small GTPases Cdc42 and Rac1 are recruited and activated by the guanine 
nucleotide exchange factor Vav. Activation of Rac1 and Cdc42 regulates F-actin binding proteins to facilitate F-
actin cup formation and membrane pseudopod extension around the target particle. Taken from Naik and Harrison, 
2013 (Naik and Harrison, 2013).  
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protein (N-WASP). N-WASP activates the seven-protein nucleator complex (Arp2/3), which 
stimulates the formation of actin filaments that drive the engulfment of particles (Machesky 
and Insall, 1998; May et al., 2000). In addition, activation of Cdc42 by FcγR stimulates PI-3 
kinase, the resulting increase of 3’ PIs in cup membranes leads to inactivation of Cdc42 to 
permit actin recycling necessary for phagosome formation (Beemiller et al., 2010).   
However, not all FcγR stimulate phagocytosis: the FcγRIIB has an immune-receptor 
tyrosine-based inhibition motif (ITIM) which recruits the phosphatase Src homology 2 domain 
containing inositol 5-phosphatase (SHIP). SHIP inhibits phagocytosis through 
dephosphorylation of PI (3,4,5) P3 to PI(4,5)P2 which terminates the PI-3 kinase signalling 
(Cox et al., 2001; Nakamura et al., 2002; Rosales and Uribe-Querol, 2017).  
 
1.4.1.1.2 Complement protein antibody 
The complement protein responsible for opsonising bacteria for phagocytosis that is present in 
serum is C3b, also called Mac-1, CD11b/CD18 or integrin αmβ2. The latter refers to an integrin 
present in macrophages which consists of two conserved α and β chains (Ross et al., 1992). 
There are two pathways that activate the complement system: the classical pathway includes 
indirect attachment to immunoglobulin molecules present on microbes, particularly IgM/IgG-
opsonized pathogens (Hartung and Hadding, 1983; Naik and Harrison, 2013). The second and 
rapid response is the alternative pathway, in which the carbohydrate motifs on the surface of 
the pathogen are recognized directly by complement without relying on the production of 
antibodies (Carroll, 1998; Naik and Harrison, 2013). 
Briefly, the signalling pathway of integrin includes two routes: inside out signalling which 
is important in activating the complement receptor CR3 and causing membrane ruffling in order 
to capture C3Bi- opsonised particles in macrophages (Patel and Harrison, 2008; Naik and 
Harrison, 2013; Rosales and Uribe-Querol, 2017). This process is followed by an outside-in 
signalling process that stimulates F-actin remodelling. Contrasting with the FcγR-mediated 
phagocytosis, the role of Syk tyrosine kinase is not well understood (Kiefer et al., 1998; Naik 
and Harrison, 2013; Rosales and Uribe-Querol, 2017) but it appears that Syk is also 
phosphorylated during CR3-mediated phagocytosis (Shi et al., 2006). While F-actin 
polymerisation is regulated by Cdc42 in FcγR-mediated phagocytosis, it is regulated by RhoA 
GTPase in CR3-mediated phagocytosis (Wiedemann et al., 2006). The regulation of F-actin by 
RhoA GTPase involves two signalling pathways: In first pathway RhoA activates Rho kinase 
(ROCK) and phosphorylates myosin II which stimulates F-actin polymerisation through the 
Arp2/3 complex (Olazabal et al., 2002). The second direct pathway includes the activation of 
mammalian diaphanous-related formin (mDia) by RhoA. mDia in turn stimulates F-actin 
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assembly which is recruited by a microtubule associated protein (Lewkowicz et al., 2008; Naik 
and Harrison, 2013; Rosales and Uribe-Querol, 2017).  
 
1.4.1.2 Non-opsonic phagocytosis  
Microorganisms such as bacteria, fungi and parasites expose various types of conserved 
molecules which are never observed in the higher organisms, known as pathogens-associated 
molecular patterns (PAMPs). Non-opsonic phagocytosis, also known as cis-phagocytosis, is 
activated directly through the recognition of PAMPs by receptors of phagocytic cells (Janeway, 
1992). For example, the polysaccharides mannan and β-glucan which are displayed on the 
surface of certain yeast cells are recognised by mannose- and dectin-1 receptors, respectively 
(Ezekowitz et al., 1990; Brown and Gordon, 2001; Herre et al., 2004; Naik and Harrison, 2013). 
Both belong to the lectin receptor family (Figure 9). The cytosolic domain of the dectin-1 
receptor contains an immune-receptor tyrosine-based activation motif (ITAM) which recruits 
kinases via interaction with SH2 domains (Herre et al., 2004; Flannagan et al., 2012). 
Researchers have found that the macrophage dectin-1 mediated phagocytosis of zymosan, one 
of the components of the Saccharomyces cerevisiae cell wall, was less dependent on Syk, Src, 
PI-3 kinase and Rho GTPases (Herre et al., 2004). 
Other receptors, such as Toll-like receptors (TLRs) and Scavenger receptors SR-A are 
expressed in macrophages and recognise lipopolysaccharides (LPS) on the surface of bacteria 
(Poltorak et al., 1998; Rock et al., 1998; Hoebe et al., 2005; Flannagan et al., 2012). In addition, 
they work co-ordinately to recognise peptidoglycans, lipoteichoic acid and flagellin molecules 
on the cell wall of gram-positive bacteria (Underhill et al., 1999). Research into SR-A 
demonstrated that the receptor is critical for efficient binding and uptake of bacteria by non-
opsonic phagocytosis. The experiments used inhibiters to block SR-A receptors and 
consequently decreased internalisation was observed. Moreover, SR-A was shown to recognise 
not only LPS but also lipoteichoic acid of bacteria (Poltorak et al., 1998; Peiser et al., 2000). 
The signalling pathways triggered by SR-A-mediated non-opsonic phagocytosis include a 
number of molecules such as protein kinase C, Src, MARKS as well as PI-3 kinase (Nikolic et 
al., 2007; Sulahian et al., 2008). In contrast, integrin receptors recognise and attach to 
extracellular matrix proteins including fibronectin and vitronectin (Figure 9) (Freeman and 
Grinstein, 2014).  
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1.4.2 Strategies used by pathogens to inhibit phagocytosis  
There are several ways for bacterial pathogens to avoid both opsonic and non-opsonic 
phagocytosis. These include interfering with opsonin-binding which is considered to be the 
most common strategy against opsonic phagocytosis. One of the bacterial virulence factors is 
the capsule which consists of polysaccharides and is used by bacterial and fungal species such 
as EPEC, Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae as a 
shield to prevent the deposition of opsonin (Flannagan et al., 2012). Another way to avoid being 
internalised, is the synthesis of protein A and M-protein by Staphylococcus aureus and 
Streptococcus pyogenes respectively. Protein A binds to the Fc portion of IgG thereby 
preventing its interaction with Fc receptors (Foster, 2005). On the other hand, the M-protein 
recruits an inhibitor of complement activation called C2b-binding protein. Likewise the YadA 
of Yersinia enterocolitica prevents deposition of the complement component iC3b (China et 
al., 1993). 
To survive in the presence of non-opsonic phagocytosis, bacteria must be able to inhibit 
signalling pathways required for the effective uptake. Some microbes such as EPEC (see below) 
and Pseudomonas aeruginosa use their T3SS to inject effector proteins into phagocytic cells 
(Flannagan et al., 2012). Delivering these effectors inhibits Rho-family GTPases or antagonize 
tyrosine phosphorylation and PI-3-dependent signalling by imitating the function of inhibitory 
host proteins (Flannagan et al., 2012). For example, the Yersinia inhibitory mechanism has been 
linked to the subversive activity of YopH and YopE delivered by T3SS. YepE inhibits uptake 
of Yersinia by acting as a GTPase‐activating protein (GAP), negatively regulates the switch by 
enhancing the intrinsic GTPase activity, for RhoA, Rac1 or Cdc42, which are responsible for 
regulating actin cytoskeleton dynamics (Black and Bliska, 2000; Pawel‐Rammingen et al., 
2000). YopH inhibits bacterial uptake by inducing the de-phosphorylation of the focal adhesion 
kinase in both professional and non-professional phagocytes (Fallman et al., 2002; de la Puerta 
et al., 2009). 
However, some pathogens such as HIV and Haemophilus ducreyi do not have an 
injection system, thus, they use a different mechanism to inhibit phagocytosis, named Trojan 
horse-like strategy. In this strategy, the microbes engulf normally and once they are internalised 
their effectors block the phagocytic capacity of the host cells preventing further uptake of 
additional microbes (Wood et al., 2001; Mazzolini et al., 2010).   
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1.4.2.1 EPEC anti-phagocytosis activity  
EPEC has a T3SS-dependent capacity to inhibit its uptake by J774.A1 macrophages via 
phosphoinositide 3 (PI-3 kinase) dependent pathways (Goosney et al., 1999; Celli et al., 2001; 
Quitard et al., 2006). However, many EPEC bacteria (~40%) are still internalised via PI-3 
kinase independent pathways (Goosney et al., 1999; Celli et al., 2001; Quitard et al., 2006). 
While EPEC uptake occurs through both pathways in macrophages, in the M-cell model system 
(microfold; antigen-sampling cells in gut) it is mainly through PI-3 kinase dependent pathways 
(Martinez‐Argudo et al., 2007). It is speculated that delaying EPEC exposure to immune cells 
provides an advantage to the bacteria’s life cycle (Quitard et al., 2006). The PI-3 kinase 
inhibitory mechanism has been linked to the subversive activity of EspB, EspH, EspG and EspF 
proteins (Quitard et al., 2006; Iizumi et al., 2007; Dong et al., 2010; Humphreys et al., 2016). 
Studies using M-cells have revealed that the inhibition of EPEC translocation is EspF dependent 
(Martinez‐Argudo et al., 2007). However, in bovine M-cells model, EspF-dependent inhibition 
of uptake is less effective than EHEC, in contrast with murine macrophages (Tahoun et al., 
2011). However, the mechanism of EspF inhibition remains undefined (Quitard et al., 2006). 
In addition, studies in the macrophage model have ruled out roles for several other effectors 
(Tir, Map) and Intimin in the EspF-dependent inhibitory process (Celli et al., 2001; Quitard et 
al., 2006). Studies with EspF variants found that its mitochondrial targeting and SNX9 binding 
motifs were non-essential for its inhibitory activity (Quitard et al., 2006; Weflen et al., 2010; 
Young, 2013). However, a fusion protein in which the first 101 amino acids were replaced with 
those of Tir (provides a T3SS targeting signal) failed to complement the EspF mutant anti-
phagocytosis defect (Quitard et al., 2006). The latter indicates a key role for features within the 
N-terminal 101 amino acids, though the presence of the Tir domain may simply be hindering 
EspF’s anti-phagocytic activity; for example by preventing EspF from adopting a functional 
conformation or targeting it away from a binding partner.  
Additionally, EspB can also inhibit phagocytosis; as discussed earlier EspB is not only 
an effector protein but also one of the components of the EPEC translocon that links the T3SS 
to host cells (Iizumi et al., 2007). EspB can disrupt myosin interaction with actin filaments 
through binding to the myosin motor domains of myosin family proteins (myosin-1c, -2, -5, -6 
and -10). This interaction interrupts actin dynamics, consequently preventing pseudopod 
extension of the membrane around the invading bacterium and loss of myosin dependent 
closure of the phagocytic cup (Iizumi et al., 2007).  
In contrast, EspH inhibits uptake of EPEC by counteracting both opsonic and non-
opsonic phagocytosis through inhibiting the activity of RhoGEFs (Dong et al., 2010). EspH has 
the ability to target the DH-PH domain of RhoGEFs, which disrupts the interaction between the 
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GEF and their Rho GTPase target. Blocking this interaction inhibits host GTPase activation and 
downstream signalling, consequently, prevents actin remodelling and phagosome formation 
(Dong et al., 2010). 
Interestingly, EspG has recently been identified as an inhibitor of non-opsonic 
phagocytosis through inhibition of the WAVE regulatory complex (WRC; a five-subunit 
protein complex in the Wiskott-Aldrich syndrome protein (WASP)) which interferes with 
phagocytosis and enables EPEC to evade phagocytic cells (Humphreys et al., 2016). Inhibition 
of WRC is achieved by binding to the small GTPase Arf1, thereby either preventing the 
signalling to ARNO (Arf1 activator) or blocking the interaction with the small GTPases-Rac1, 
which blocks WRC recruitment and activation (Humphreys et al., 2016).  
 
1.5 Summary and project aims  
Bacterial pathogens such as EPEC employ a wide range of strategies to colonise, survive and 
cause diarrhoeal disease. Through T3SS, EPEC delivers many effector proteins directly into 
host cells and subverts a number of host cell functions and signalling pathways including 
inhibition of phosphoinositide PI-3 kinase dependent uptake by macrophages. EPEC’s ability 
to inhibit PI-3 kinase dependent pathways has been linked to the subversive activity of the LEE-
encoded EspB, EspH, EspG and EspF effectors. EspB inhibits bacterial uptake by targeting 
myosin motor proteins which promote pseudopod extension. In contrast, EspH inhibits the 
activity of RhoGEF which is responsible for regulating actin cytoskeleton dynamics. EspG 
inhibits the activity of the WAVE regulatory complex which is responsible for actin 
polymerisation through targeting the small GTPases Arf6 and Arf1. However, the mechanism 
by which EspF inhibits phagocytosis remains undefined. Understanding how EPEC inhibits its 
uptake by macrophages would provide greater understanding of the EPEC infection strategy 
and provide critical insights into the anti-phagocytic mechanism. Thus, the project aims are to 
examine if EspF alone could inhibit phagocytosis and investigate the mechanism by which 
EPEC inhibit its uptake by macrophages. 
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2.1 Cell culture  
2.1.1 Culturing of bacterial strains 
Bacterial strains used in this study are listed in Table 2. Bacteria were streaked from frozen 
cultures (-80 °C) onto Luria-Bertani (LB) agar plates and incubated at 37 °C or 26 °C for E. 
coli and Yersinia strains, respectively. Agar plates were supplemented, when appropriate, with 
the antibiotic(s) Nalidixic acid [Nal], Carbencillin [Cb], Chloramphenicol [Cm] and 
Kanamycin [Km] at 50, 100, 25 and 25 μg/ml final concentration, respectively. LB broth 
containing appropriate antibiotics was inoculated with a single bacterial colony picked from an 
LB agar plate for overnight (16-18 h) incubation at 37 °C (or at 26 °C Yersinia) with, or for 
infection studies, without shaking at the required temperature. Bacteria were usually diluted 
1:10 into serum free Dulbecco’s minimal Eagles medium (DMEM; Sigma D5796), containing 
appropriate antibiotic(s), for 3 h to pre-induce T3SS expression (Rosenshine et al., 1996a). 
When needed, overnight LB broth cultures (post-shaking) were used to make frozen stocks (-
80 °C) by adding 10% glycerol (final concentration) prior to freezing.  
 
2.1.2 Mammalian cell culture  
Mammalian cell culturing was implemented under sterilised conditions in a Class 2 laminar 
flow hood (BioMat 2) with studies using HeLa (human cervix-derived epithelial-like; 
ATCC_CCL2) and J774.A1 (mouse macrophage-like; ATCC_TIB-67) cells. Mammalian cells 
were grown in Dulbecco’s minimal Eagles medium (DMEM), supplemented with 10% foetal 
calf serum (FCS; GIBCO) in a 5% CO2/37°C incubator (LEEC; Research CO2 Incubator). Cells 
were routinely maintained in 25 cm2, 75 cm2 or 175 cm2 (Corning; 430639, 430641, 431080; 
respectively) culture flasks at 37 ˚C in a 5% CO2 atmosphere. Every 2-3 days the cell media 
was replaced with fresh media. When the cells reached 80-90% confluence they were washed 
twice with Phosphate Buffered Saline pH 7.4 (PBS; 137 mM sodium chloride [NaCl], 2.7 mM 
potassium chloride [KCl], 10 mM disodium phosphate and 1.8 mM monopotassium phosphate; 
pH 7.4) and detached, for macrophages, into DMEM using a scraper (TC Cell Scraper 25 cm; 
Sarstedt 83.183) and, for HeLa cells, by adding 1x trypsin solution (Trypsin-EDTA 
[ethylenediamine acetic acid]; Sigma; T4174) for 10-15 min prior to adding DMEM. A sample 
was removed to determine cell viability - percentage of cells that exclude trypan blue (Sigma; 
T8154) - and cell concentration, using a haemocytometer following the manufacturer’s 
instructions (Hawksley; AC1000). The cells were seeded into a new flask [routinely 1:6 
dilution] or into wells of a 24 well plate (NunclonTMΔ Surface, Nunc), 60mm dishes (SPL Life 
Sciences) or onto sterile 13 mm glass coverslips (VWR, 631-1578) within wells of a 24 well
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plate to obtain 70-80 confluency for the day of the experiment. The cell passage number was 
recorded and cells replaced following 20 (J774.A1) and 30 (HeLa cells) passages. Frozen 
culture stocks were generated by placing cells (106/ml) in DMEM containing 10% DMSO 
(Sigma; D2650)/10% FCS into a -80 °C freezer overnight inside a closed polystyrene box (after 
wrapping within paper towels) before transferring to liquid nitrogen storage. 
 
2.2 Molecular biology 
2.2.1 DNA Isolation 
LB shaking cultures of strains carrying appropriate plasmids (Table 3), routinely 5 ml, were 
used to harvest the appropriate bacterial strain by centrifugation (13,000 xg, 5 min, room 
temperature [RT]) with plasmid DNA isolated using the AccuPrep plasmid miniprep kit 
(Bioneer; K-3030) according to manufacturer’s instructions. Concentration and purity of 
isolated plasmids were determined using a NanoDrop 100 spectrophotometer (Thermo 
Scientific) following manufacturer’s instructions. 
 
2.2.2 Polymerase chain reaction (PCR) of EPEC genes and agarose gel electrophoresis 
Genes were amplified using purified plasmids or DNA released from bacteria following lysis 
in dH2O (100°C, 5 min) using oligonucleotide primers (Table 4) specific to the target gene. 
These primers were designed using the Serial Cloner 2.6.1 software (Scientific and Educational 
Software; Franck Perez, Serial basics) and PCR reactions undertaken using a Veriti 96 well 
thermocycler (Applied Biosystems). PCR reactions were routinely in a total volume of 25 μl 
containing DNA, 1x Taq reaction buffer (New England Biolabs; B9014S), dNTPs (200 μM 
final concentration; New England Biolabs; N0447S), Taq DNA Polymerase (1.25 units/50 μl 
final concentration; New England Biolabs M0273L) and each primer (0.2 μM final 
concentration) using conditions given in Table 5. 
The PCR products were assessed by adding 10x ficoll loading dye (to 1x final 
concentration) and loading, alongside 2-log DNA ladder (New England Biolabs; N3200L), on 
agarose gels  (0.7-1% w/v agarose in TAE [40 mM Tris-acetate, 1mM EDTA] buffer) 
containing the fluorescent nucleic acid stain GelRedTM (Biotium; BT4100 at 1:30,000 
dilution). Samples were run at 100 volts for an appropriate time with DNA visualised using a 
UV transilluminator (Biorad) for image capture. 
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2.2.2.1 Sequence analysis  
The target gene (or region thereof) was PCR amplified using Q5 high-fidelity DNA polymerase 
(New England Bio-labs), the product isolated using the GenElute™ PCR Clean-Up Kit (Sigma; 
NA1020) prior to sending for sequencing (Source Bioscience, Cambridge, UK). The resulting 
sequences were analysed using the Serial Cloner 2.6.1 software. 
 
2.2.3 Preparation of electro-competent bacteria and transformation with DNA  
LB shaking cultures, routinely 5 ml, were diluted 1:100 in 100 ml LB broth (supplemented with 
appropriate antibiotics) for growth at 37°C or, for Yersinia strains, 28°C with shaking (225-250 
rpm) until reached optical density (OD600; 1 OD = 109 bacteria) of 0.4-0.6 as assessed using a 
UV 1101 Biotech photometer (WPA). Bacterial cultures were rapidly cooled (on ice with 
shaking) and then pelleted (12,000 x g, 15 min, 4°C) and re-suspended in 50 ml ice-cold sterile 
H2O. This washing step was repeated twice with the bacterial pellet re-suspended in 20 ml 
sterile, ice cold, 10% glycerol before pelleting as before. The resulting pellet was re-suspended 
in 500 μl ice-cold sterile 10% glycerol with 40 μl aliquots placed into ice cold 0.5 ml Eppendorf 
tubes (Sarstedt; 72.690.001) for immediate use or snap freezing (in liquid nitrogen) for long 
term storage (-80°C).  
For electroporation, 25-50 ng/μl of plasmid DNA (see Table 3) was added to an aliquot 
of (thawed) cells and transferred into an ice-cold electroporation cuvette (2mm-gap; GenPulser 
II; Bio-Rad) on ice for 5-10 min prior to electroporation using setting 2.5 KV, 200 Ω, 25 mF, 
4.5μs. The transformed cells were immediately resuspended in 1 ml pre-warmed, 37°C, super 
optimal broth with catabolite repression (SOC; 0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 & 20 mM Glucose) media and incubated 1 h at 
37°C (28°C for Yersinia strains) with 50-1000 μl plated onto LB agar plates containing 
appropriate antibiotic(s). Colonies evident after 16-20 incubation at 37°C (28°C for Yersinia 
strains) were screened for presence of electroporation-introduced gene by PCR and/or, see 
below, western blot analysis. 
 
2.2.4 Disrupting EPEC mutants by allelic exchange 
EPEC genes were inactivated using available suicide vectors (Table 6) introduced via 
conjugation (using SM10 λpir strain carrying the suicide vector) as previously described 
(Kenny et al., 1997b; Philippe et al., 2004). Briefly, the donor SM10 and recipient EPEC strains 
were grown separately in LB broth cultures (supplemented with appropriate antibiotics) at 37°C 
shaking, then, mixed together and plated onto LB agar plates at 37°C to allow conjugation 
between recipient and donor strains. Bacteria (from the resulting bacterial growth) were 
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inoculated into 3 ml of LB broth containing antibiotics to select for the trans-conjugant (EPEC 
with suicide vector inserted into chromosome via single cross-over event) and incubated with 
shaking for 4-6 h at 37°C. The next day, the resulting culture was serially diluted onto LB agar 
plates supplemented with appropriate antibiotic(s) and incubated at 37°C overnight. Following 
incubation, single colonies were streaked out on four LB agar plates at 37°C overnight 
(supplemented with Nal, Cb or Km antibiotics) to identify putative trans-conjugants. To enable 
the excision of inserted suicide plasmid, candidate trans-conjugant was grown, with shaking, in 
LB broth (supplemented with appropriate antibiotic(s) beyond plating on LB agar plates 
containing 5% sucrose with appropriate antibiotic(s) and incubated 24-42 h at 30°C. To test for 
suicide vector loss, single colonies were streaked out on four LB agar plates (supplement with 
Nal, Cb or Km antibiotic(s)) and incubated at 37°C overnight. Finally, the potential gene 
disrupted strains colonies were screened for loss of target gene by PCR analysis. 
 
2.3 Mammalian cells infection  
2.3.1. Standard phagocytosis assay 
Studies used a previously described protocol (Goosney et al., 1999) with minor modifications. 
Briefly, J774.A1 cells were seeded (~1.1x105) on glass coverslips 2 days prior to infection to 
obtain 60-70% confluence on the infection day. LB standing E. coli cultures (Yersinia strains 
grown with aeration at 28°C) were diluted (1:10) into DMEM (with antibiotic when appropriate) 
for 3 h (30 min for Yersinia strains) prior to determining the OD600 value and calculating the 
volume for a Multiplicity of Infection (MOI) of 100:1 (bacteria to J774.A1 macrophage). Thirty 
minutes prior to infection, the macrophages were washed (37°C PBS) and incubated in DMEM. 
Following an hour infection, the cells were washed (37°C PBS) and incubated in DMEM 
containing chloramphenicol (bacterial protein synthesis inhibitor; 25 μg/ml final concentration) 
for 1 h to promote uptake of adherent bacteria unable to inhibit phagocytosis. Finally, the cells 
were washed twice (ice cold PBS) and fixed by incubating 20 min with PBS containing 2.5% 
para-formaldehyde (PFA; Santa Cruz Biotechnology ; sc-281692) and storing (4°C; short term).  
The percentage of bacterial internalisation was determined as previously described 
(Quitard et al., 2006). Briefly, extracellular bacteria were labelled by incubating 30 min (at RT) 
with anti-EPEC 0127 rabbit or anti-E. coli all serotypes antibodies (Table 7) diluted in PBS. 
Following three washes (PBS), the cells were incubated 30 min with goat anti-rabbit Alexa-555 
(fluoresces Red) conjugated secondary antibodies (Table 7). The cells were then washed again 
(3 x with PBS) with all cell-associated bacteria labelled by incubating with the same primary 
antibody (diluted in PBS containing 1% Triton X-100 [makes macrophage membrane 
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permeable to antibodies]) followed by goat anti-rabbit Alexa-488 (fluoresces Green) 
conjugated secondary antibodies (Figure 13; Table 7). The dye 4’6-diamidino-2-phenylinodole 
(DAPI - fluoresces blue) was routinely added in final antibody incubations to detect bacterial 
and host DNA. Coverslips were placed onto FluorSave reagent (Calbiochem; 345789) on glass 
slides (Thermo Scientific) for phase contrast/fluorescent microscopy examination (Zeiss 
Axioskop Epifluorescence microscope) (Figure 13). Fifty macrophages with 20-50 cell-
associated bacteria (identified in phase/contrast or ‘blue’ channel) were randomly selected to 
count the number of extracellular (fluoresce Red) and total-cell associated (fluoresce Green) 
bacteria enabling the percentage internalisation to be calculated as: (number of Green bacteria 
minus number of Red bacteria) divided by number of Green bacteria) multiplied by 100. These 
studies were undertaken in a semi-blind manner i.e. samples were placed (usually by Prof 
Kenny) in a withheld order until all counting and the percentage of internalisation calculation 
were made. A range of multiplicity of infections (MOIs) were examined with 100:1 (bacteria: 
macrophages) found to be the best to obtain 70-80% of the macrophages (each 
strain) having 20-50 cell-associated bacteria. Higher MOIs (200:1) lead to 70-80% of the 
macrophages having more than 50 cell-associated bacteria which were too many to reliably 
count. Lower MOIs (50:1) lead to 70-80% of the macrophages having less than 20 cell-
associated bacteria which was considered too few to reliably detect differences between strains. 
  
2.3.2 Alternative (two-wave infection) phagocytosis assay 
J774.A1 macrophages were prepared and infected for 1 h as described (2.3.1) prior to washing 
(37°C 1 x PBS) and incubating 1 h in DMEM containing gentamicin (bactericidal antibiotic; 
100 μg/ml final concentration). The macrophages were then washed (37°C PBS) and incubated 
in DMEM supplemented with 10% FCS for 1 h before replacing with serum free DMEM (30 
min) and infecting (MOI 100:1) with the EPEC T3SS mutant (carries Green fluorescent protein-
expressing plasmid) for 1 h. The cells were then washed three times (37°C PBS), incubated 1 
h in DMEM containing chloramphenicol (25 μg/ml final concentration) and processes as 
described earlier (2.3.1.1). As the total number of cell-associated second-wave bacteria are 
revealed by their expression of GFP (fluoresces Green), the antibody labelling procedure was 
only needed to identify the extracellular bacteria (fluoresce Red). The percentage internalisation 
of second-wave infecting bacteria was calculated using data of extracellular (fluoresce Green 
& Red) and total cell-associated (only fluoresce Green) bacteria as described above. 
 
2.3.3. Infection for immunoblot analysis 
J774.A1 cells or HeLa cells were seeded (~5x105) into 6 well plates 2 days prior to infection to  
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Figure 13. Standard phagocytic assay. J774.A1 macrophages were infected for 1 h (MOI 100:1) with the indicated 
strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria using differential 
antibody staining to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages 
with 20-50 cell-associated bacteria were randomly chosen to count the number of ‘Red’ and ‘Green’ bacteria. 
Strains used were EPEC and strains lacking a functional T3SS (T3SS) or four LEE proteins: Intimin, Tir, Map and 
EspF (etmf). Images are representative of at least three independent experiments taken by epifluorescence 
microscope with an 100x oil objective. Scale bar 5.5 μm.  
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obtain 80-90% confluence on the infection day. Following infection - using previously 
described conditions/MOI - the cells were washed twice (ice cold PBS) and incubated 5 min in 
100 μl ice cold PBS (Sigma)/Triton X-100 lysis buffer (1% Triton, 1mM  
phenylmethylsulphonyl fluoride [PMSF; Sigma P7626], 0.5 mM sodium fluoride [NaF], 1mM 
sodium orthvanadate [NaVO4]; protease inhibitor cocktail (Sigma; P8340 [1/100 dilution]). 
The cells were detached using a cell scraper, and transferred to 1.5 ml centrifuge tubes (Sarstedt; 
72.690.001) for centrifugation (13,000 xg, 4 min, 4°C). The resulting ‘soluble’ fraction 
(contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) was 
transferred to a new tube where 5x Laemmli sample buffer (Laemmli, 1970) was added to a 
final 1x concentration. The remaining Triton X-100 ‘insoluble’ pellet (contains host nuclei and 
cytoskeleton plus adherent bacteria) was washed with cold PBS and re-suspended in 1x 
Laemmli sample buffer. The samples were heated (100°C, 5 min), vortexed and used 
immediately (for western blot analysis; see below) or stored (-20°C). 
 
2.4 Immunoblot analysis 
Protein samples derived from 5x105 mammalian cells were loaded into separating wells for 
SDS gel electrophoresis as described (Laemmli, 1970). Protein samples were separated using a 
15% and 12% polyacrylamide resolving gel and 5% polyacrylamide stacking gel (0.125 M Tris-
HCl pH 6.8, 0.1% w/v SDS, 0.1% w/v ammonium persulfate & 0.1% v/v TEMED); all gels 
were prepared in dH2O (Laemmli, 1970). Polyacrylamide gels were loaded into a vertical 
electrophoresis cell (Mini Trans-Blot Cell (Bio-Rad)) system, with electrophoresis performed 
using 1X SDS running buffer (25 mM Tris-HCl, 192 mM glycine and 0.1 % w/v SDS; pH 8.3) 
at 200 volts for 1 h. Proteins were then transferred onto polyvinylidene fluoride (PVDF) 
membrane (GE Healthcare) in 1X transfer buffer (25 mM Tris & 192 mM glycine; pH 8.3) 
using the Bio-Rad transfer system at 110 volts for 60 min (Kenny and Finlay, 1995). Protein 
transfer efficacy was assessed by Ponsceau Red staining (Sigma bP7170; prior to washing away 
with PBS). The membranes were blocked overnight at 4 °C with gentle agitation in 5% 
skimmed milk powder (Marvel) i) PBS solution if probing for alkaline phosphatase (AP) or ii) 
Tris-buffered saline with Tween-20 (TBS-T, 150 mM NaCl and 10 mM Tris-Hcl; VWR 
Scientific, 0.1% Tween-20 pH 7.5; Sigma-Aldrich) if probing for horseradish peroxidase 
(HRP). The next day, the membrane was washed 5 min with PBS (x 3) and then incubated 1 h 
in PBS containing anti -Tir, anti -EspF or anti -EspB antibodies (Table 7). Post-incubation and 
washing (5 min with PBS x 3 for AP or TBSTx3 for HRP) the membrane was incubated with 
appropriate AP-conjugated antibodies or HRP-conjugated antibody (Table 7). Blots were 
developed using NBT/BCIP reagent diluted in developing buffer (Promega; 2 M Tris, 5 M 
37 
 
NaCl, 1 M MgCl2, pH 9.5) for AP. For HRP, PVDF membranes were exposed to ECL 
chemiluminesence western blotting substrate (Thermo Fisher Scientific, 1:1 ratio) for 5 min. 
The membrane then was exposed to Hyperfilm ECL (Amersham Biosciences) and developed. 
2.5 Immunofluorescent microscopy analysis 
Studies used a previously described protocol (Nougayrède and Donnenberg, 2004; Dean et al., 
2010b). Briefly, cells were seeded (~1.1x105 per well) onto glass coverslips 2 days prior to 
infection for 70-90% confluency on the infection day. The cells were washed (37°C PBS) and 
DMEM - containing antibiotics when appropriate - added prior to a 3 h infection (MOI 100:1) 
with bacteria pre-grown in DMEM. The cells were washed three times (ice cold PBS), fixed 
(2.5% PFA, 20 min) and, post PBS washing, incubated (30 min; RT) with anti-EspF antibody 
(Table 7) in PBS alone or PBS containing 1% Triton X-100. Following three washes (PBS), the 
cells were incubated 30 min with goat anti-rabbit Alexa-488 (fluoresces green) conjugated 
secondary antibodies and DAPI (stains mammalian/bacterial DNA; fluoresces blue). Coverslips 
were mounted in FluorSave reagent on glass slides for analysis (Zeiss Axioskop 
Epifluorescence microscope with an 100x oil objective and/or Leica TCS SP2 UV confocal 
laser-scanning microscope [Leica Microsystems GMBH Heidelberg]) with an 63x 1.32 NA oil-
immersion objective; housed within the Bio-Imaging Unit, Newcastle University. The captured 
images were processed using Image-J software.   
 
2.6 Detecting T3S secreted proteins  
Studies used a previously described protocol (Kenny and Finlay, 1995). Following infection in 
DMEM- using previously described conditions/MOI (see above 2.5), the media was collected 
and centrifuged for 10 min to remove the bacteria. Trichloroacetic acid (TCA; 10% v/v final 
concentration) was added to the resulting supernatant which contains secreted proteins then left 
for 1 h at 4°C before pelleting the precipitated proteins and re-suspended in Laemmli sample 
buffer before resolution by SDS/PAGE 12%. 
 
2.7 Statistical analysis  
Statistical analysis was performed using GraphPad Prism V6.0 (GraphPad software) to analyse 
data sets using a one-way (ANOVA) analysis of variance with additional Dunnett’s test (*) 
compared with control positive (EPEC) or (*) compared with control negative (T3SS) or 
Tukey's test for multiple comparisons between strains. P-values of p<0.05 were considered 
significant. 
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EPEC Strain  Description  Selection Reference  
EPEC E2348/69 Prototypical (O127:H6) strain. NalR (Levine et al., 1985) 
T3SS (cfm-14) 
Lacks functional type 3 secretion 
system. 
NalR, KmR (Jarvis et al., 1995) 
map Lacks Map effector. NalR (Kenny and Jepson, 2000) 
tir  
Lacks residues 50-320 of Tir 
effector. 
NalR (Kenny et al., 1997b) 
tirfull  Lacks all Tir residues.  NalR This study 
eae 
Lacks Intimin outer membrane 
protein.  
NalR (Donnenberg and Kaper, 
1991) 
espH::Km Lacks EspH effector. KmR (Tu et al., 2003) 
espH Lacks EspH effector. NalR, KmR Unpublished, Kenny lab 
espHfull  Lacks EspH effector. NalR (Dong et al., 2010) 
espF Lacks EspF effector. NalR (Warawa et al., 1999) 
espB (eaeB) Lacks EspB translocator protein.  NalR (Foubister et al., 1994) 
espZ (81) Lacks EspZ effector.  NalR Unpublished, Kenny lab 
espGorf3core* Lacks EspG, EspG2/Orf3, EspH, 
Tir Map, Intimin and 2 chaperones 
(CesT, CesF).  
NalR (Ruchaud‐Sparagano et al., 
2007) 
espGorf3coreΔespZ(81) As above but also lacks EspZ. NalR This study 
me Lacks Map & Intimin. NalR Unpublished, Kenny lab 
tm Lacks Tir & Map. NalR (Jepson et al., 2003) 
et 
Lacks Intimin & Tir. NalR (Ruchaud-Sparagano et al., 
2011) 
etAA Lacks Intimin & Tir. NalR This study 
fh Lacks EspF & EspH. KmR Unpublished, Kenny lab 
fhAA Lacks EspF & EspH. KmR This study 
fe Lacks EspF & Intimin.  NalR Unpublished, Kenny lab 
feAA Lacks EspF & Intimin. NalR This study 
ft Lacks EspF & Tir. NalR Unpublished, Kenny lab 
ftAA Lacks EspF & Tir. NalR This study 
th Lacks Tir & EspH. KmR Unpublished, Kenny lab 
mh Lacks Map & EspH.  KmR Unpublished, Kenny lab 
fm Lacks EspF & Map.  NalR (Dean and Kenny, 2004) 
fmAA Lacks EspF & Map.  NalR This study 
eh Lacks Intimin & EspH. KmR Unpublished, Kenny lab 
feh Lacks EspF, Intimin & EspH.  KmR Unpublished, Kenny lab 
fth Lacks EspF, Tir & EspH.  KmR Unpublished, Kenny lab 
tmf  Lacks Tir, Map & EspF. NalR Unpublished, Kenny lab 
fet Lacks EspF, Intimin & Tir. NalR Unpublished, Kenny lab 
fme Lacks EspF, Map & Intimin.  NalR Unpublished, Kenny lab 
meh Lacks Map, Intimin & EspH. KmR Unpublished, Kenny lab 
fmh  Lacks EspF, Map & EspH. KmR This study 
tmh  Lacks Tir, Map & EspH. KmR This study 
eth  Lacks Intimin, Tir & EspH.  KmR Unpublished, Kenny lab 
etm Lacks Intimin, Tir & Map.  NalR Unpublished, Kenny lab 
etmh Lacks Intimin, Tir, Map & EspH. KmR Unpublished, Kenny lab 
tmfh Lacks Tir, Map, EspF & EspH. KmR Unpublished, Kenny lab 
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fmeh Lacks EspF, Map, Intimin & EspH. KmR Unpublished, Kenny lab 
feth Lacks EspF, Intimin, Tir & EspH. KmR Unpublished, Kenny lab 
etmf  Lacks Intimin, Tir, Map & EspF. NalR (Quitard et al., 2006) 
etmfh (quin)  
Lacks Intimin, Tir, Map EspF & 
EspH. 
KmR This study 
TOEA7  
 
Lacks 14 effectors (on PP2, IE2, 
PP4, IE6, PP6, IE5 gene regions) & 
EspG.  
 (Yen et al., 2010) 
TOEA7/pTet 
As above but carries pACYC184 
plasmid (lacks gene encoding 
CmR). 
TetR Unpublished, Kenny lab 
TOEA7Δcore/pTet  
As above but also lacks EspH, 
CesF, Map, Tir, CesT & Intimin.  
TetR Unpublished, Kenny lab 
 
Bacterial Strain  Description  Selection Reference  
DH10B Non-pathogenic K12 E. coli strain.   (Grant et al., 1990) 
TOB01  
(E. coli K12) 
 
K12 E. coli strain carrying EPEC B171-
8 bfp and perABC operons on pTOK-01 
plasmid. Also has pTOK-02 (no cloned 
inserts). 
KmR, CmR 
 
(Yen et al., 2010) 
TOB02  
(E. coli K12)  
As per TOBO1 but also LEE region 
(from EPEC B171-8) on pTOK-02. 
KmR, CmR  
 
(Yen et al., 2010) 
Yersinia 
enterocolitica 
MRS40 (pIML421) 
Lacks main Yersinia T3SS Yop 
effectors.  
NalR (Iriarte and Cornelis, 1998) 
Table 2. List of EPEC and non-EPEC strains used in this study providing a brief description of key characteristics, 
antibiotic used for selection (NalR, KmR, CbR, CmR, TetR indicates resistance to Nalidixic acid, Kanamycin, 
Carbenicillin, Chloramphenicol and/or Tetracycline) and source of strain. “Km” and “full” indicates that 
associated genes was disrupted by introduction of a gene encoding Kanamycin resistance or removal of sequence 
between start and stop codons, respectively. Note, gene name indicates order of gene disruption, for example, ft 
reveals that the tir gene was disrupted from an espF mutant background though order of espG/espG2 gene 
disruption in indicated (*) strain not known.  
 
 
Plasmid  Encodes Selection  Reference  
pSK-cesF::HA  CesF as a CesF::HA fusion 
protein.  
CbR Provided by Brendan Kenny 
pSK-map Map.  CbR (Kenny and Jepson, 2000) 
pCVD438-eae Intimin. CmR (Donnenberg and Kaper, 1991) 
pACYC-espH::HA EspH as an EspH::HA 
fusion protein.  
CmR Provided by Brendan Kenny 
pGFP  Green Fluorescent Protein.  CbR Provided by Brendan Kenny 
pBR322-espF  EspF.  CbR (Nagai et al., 2005) 
pBR322-espF(A3)  EspF with leucine 104, 151 
and 197 substituted for 
alanine.  
CbR (Dean et al., 2013) 
pSK-Δ101espF  
 
EspF lacking residues 1-101 
(replaced with those from 
Tir).  
CbR (Quitard et al., 2006) 
pACYC-T7-espF  EspF as T7::EspF fusion 
protein.  
CmR (Dean and Kenny, 2004) 
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pBR322-espF (L16E) EspF cannot target 
mitochondria. 
CbR (Nagai et al., 2005) 
pBR322-espF (L16E; ∆100-
183)  
As above but also lacks 
residues 100-183. 
CbR (Holmes et al., 2010) 
pBR322-espF (∆21-183)  EspF lacking residues 21-
183. 
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; ∆51-
168) 
As espF (L16E) but also 
lacks residues 51-168.  
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; ∆5)  As espF (L16E) but also 
lacks five base pairs (499-
503). 
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; ∆51-73) As espF (L16E) but also 
lacks residues 51-73.  
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; P74A)  As espF (L16E) but with 4 
proline residues, 79-82, 
changed to alanine. 
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; ∆62-73)  As espF (L16E) but also 
lacks residues 62-73. 
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; ∆23-52) As espF (L16E) but also 
lacks residues 23-52.  
CbR Provided by Brendan Kenny 
pBR322-espF (∆21-73) EspF lacking residues 21-73.  CbR (Holmes et al., 2010) 
pBR322-espF (L16E; ∆51-73 
and Δ117-162) 
As espF (L16E) but also 
lacks residues 51-73 & 117-
162. 
CbR Provided by Brendan Kenny 
pBR322-espF (L16E; S47A)  As espF (L16E) but also 
with serine 47 changed to 
alanine. 
CbR Provided by Brendan Kenny 
pACYC-tir_cesT Tir and CesT.  CmR (Kenny et al., 2002) 
pACYC-tir R521_cesT CesT and Tir with arginine 
521 substituted for alanine. 
CmR (Kenny et al., 2002) 
pACYC-tir S463A_cesT CesT and Tir unable to be 
phosphorylated on S463. 
CmR Provided by Brendan Kenny 
pACYC-tir Y474F_cesT CesT and Tir unable to be 
phosphorylated on Y474. 
CmR Provided by Brendan Kenny 
pACYC-tir Y474-454F 
S434A-463A_cesT 
CesT and Tir unable to be 
phosphorylated  
CmR Provided by Brendan Kenny 
pACYC-tir polyproline_cesT CesT and Tir cannot form 
pedestal. 
CmR Provided by Brendan Kenny 
pACYC-tir S434A_cesT CesT and Tir unable to be 
phosphorylated on S434. 
CmR Provided by Brendan Kenny 
pACYC-tir S434/463A_cesT CesT and Tir unable to be 
phosphorylated on S434 and 
S463. 
CmR Provided by Brendan Kenny 
Table 3. List of plasmids used in this study providing a brief description of key encoded factor(s), antibiotic used 
for selection (CbR, CmR indicates resistance to Carbenicillin and Chloramphenicol respectively) and source of 
plasmid. 
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Name  Oligonucleotide sequence 5’-3’  
eae Forward Primer  CATTCTAACTCATTGTGGTGG 
eae Reverse Primer  CTAGCTAGAGACTTGATTACC 
map Forward Primer GTGCTGGAGGAAAAGTTCTG 
map Reverse Primer CAGCGCAGTAAGTTTCC 
espH Forward Primer CCCTTTGGCAACCGTAAAGC 
espH Reverse Primer AAATATCGTCCCCAGAACAG 
espF Forward Primer ATGGAATTAGTAACGCTGCTTCTACAC 
espF Reverse Primer TTGGTTACCCTTTCTTCGATTGCTCATAG 
tir Forward Primer CCGCCACTACCTTCACAAAC 
tir Reverse Primer GCGTTGGTGCGGCATTTACAG 
nleF Forward Primer AAGGGGGTTTTGATATGTTACCAACAAGTG  
nleF Reverse Primer CCACGAGGCATTTCATTGCTCGTAG  
nleE1 Forward Primer CCAGTATGTATACCAGCAGTTCATGGTAAG  
nleE1Reverse Primer ATTGGGCGTTTTCCGGATATAACTG  
Table 4. Oligonucleotides used in this study to PCR determine the presence of intact or disrupted EPEC genes. 
 
 
Stage  Temperature  Time  Cycles  
Initial denaturation  95°C  30 sec  1  
Denaturation  
Annealing  
Extension  
95°C  
56-68°C  
68°C  
30 sec  
60 sec  
60 sec  
30  
Final Extension  68°C  5 min  1  
Table 5. Polymerase chain reaction (PCR) Thermocycling conditions used to amplify EPEC’s genes with Taq 
DNA polymerase. 
 
 
Suicide Plasmid To disrupt the  Antibiotic  
Selection  
Reference  
pCVD422-Δtirfull tir gene. CbR Provided by Brendan Kenny 
pCVD422-Δtir tir gene  CbR  (Kenny et al., 1997b) 
pCVD422-ΔespZ (81) espZ gene. CbR Provided by Brendan Kenny 
pCVD422-ΔespF espF gene. CbR (Warawa et al., 1999) 
pCVD422-Δmap map gene. CbR (Kenny and Jepson, 2000) 
pCVD422-Δeae Intimin-encoding gene. CbR (Donnenberg and Kaper, 1991) 
pCVD422-ΔespH::Km espH gene  CbR Provided by Brendan Kenny 
pCVD422-ΔespHfull espH gene. CbR (Dong et al., 2010) 
Table 6. List of suicide vectors used in this study indicating which gene can disrupt, antibiotic used for selection 
(KmR, CbR indicates resistance to Kanamycin and Carbenicillin respectively) and source of plasmid “::Km” 
indicates that associated gene was disrupted by introduction of a gene encoding Kanamycin resistance while “81” 
reveals absence of sequence encoding 81 of 98 EspZ residues. 
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Antibody  Type  Dilution 
(IF)  
Dilution 
(WB)  
Supplier & Catalogue #  
Primary Antibody 
Anti-EPEC 0127  Rabbit (monospecific 
E. coli OK) antiserum 
1/100  NA  Statens Serum Institut; #44305  
Anti-E. coli  Rabbit (polyclonal)  1/100  NA  AMS Biotech; Cat # B65001R  
Anti-Tir  Rabbit (polyclonal) NA  1/5000  Kenny Lab  
Anti-EspF  Rabbit (polyclonal) 1/100 1/2000  Kenny Lab  
Anti-EspB  Rabbit (polyclonal) NA 1/2000 Kenny Lab 
Anti-HA Mouse (monoclonal) NA 1/1000 Sigma; # H3663 
Secondary Antibody 
Anti Rabbit IgG-HRP  Goat  NA  1/5000  Jackson Immuno Research; 
#111-035-003  
Anti Mouse IgG-HRP  Goat  NA  1/5000  Jackson Immuno Research; 
#115-035-003  
Anti-Rabbit IgG-AP  Goat NA 1/5000 Jackson Immuno Research; 
#111-055-144 
Anti-Mouse IgG-AP  
Goat 
 
NA 
 
1/5000 
Jackson Immuno Research; 
#115-055-146 
Anti Rabbit Alexa Fluor 
555  
Goat  1/100  NA  Molecular Probes; #A11008  
Anti Rabbit Alexa Fluor 
488  
Goat  1/100  NA  Molecular Probes; #A21428  
DAPI (DNA staining)  NA  1/1000  NA  Invitrogen; #D1306  
Table 7. List of antibodies used for immunofluorescence (IF) and/or western blot (WB) analyses providing 
information on type, dilution and source.  
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Chapter 3. EspF is not sufficient to inhibit the 
uptake of EPEC by J774.A1 macrophages
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3.1 Introduction  
The T3SS dependent delivery of EspF into host cells has been linked to many subversive events 
such as: microvilli effacement, apoptosis, mitochondrial dysfunction, nucleolus disruption, ion 
transport inactivation, TJ barrier disruption and anti-phagocytosis (Celli et al., 2001; Crane et 
al., 2001; McNamara et al., 2001; Dean and Kenny, 2004; Nougayrède and Donnenberg, 2004; 
Nagai et al., 2005; Shaw et al., 2005a; Dean et al., 2006; Guttman et al., 2006; Quitard et al., 
2006; Alto et al., 2007; Peralta-Ramirez et al., 2008; Dean et al., 2010b). EspF’s capacity to do 
all these subversive events is linked to the presence of EspF in several cellular compartments 
i.e. host cytoplasm, mitochondria, plasma membrane (apical and lateral surfaces) and nucleus 
(Dean and Kenny, 2009; Holmes et al., 2010). 
To carry out all the subversive activity mentioned above, EspF need to be translocated 
efficiently into the host cells. Translocation of the effector EspF into host cells is dependent on 
the LEE encoded chaperone CesF chaperone, which interacts specifically with EspF but not 
with other EPEC effectors (Elliott et al., 2002). CesF is essential for stability and efficient 
translocation of EspF into host cells; however it is not essential for EspF secretion (Elliott et 
al., 2002).  
 It has been well established that EspF plays a key role in inhibiting EPEC uptake by 
phagocytic cells such as macrophage and M-cell models in vitro and in vivo (Quitard et al., 
2006; Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 2011). However, the 
EspF inhibitory mechanism remains undefined. 
To address whether the EspF effector protein, in the absence of other EPEC factors, 
encodes sufficient information to enable EPEC to inhibit its uptake by macrophages, different 
approaches could be used to introduce EspF into mammalian cells. For example, i) introducing 
EspF protein by micro-injection and ii) delivering EspF protein into macrophages via T3SS of 
different pathogen, as used previously to deliver the EPEC Tir effector into host cells (Kenny 
and Warawa, 2001) iii) expressing EspF within the cells by transfection, as used previously to 
transfect HeLa cells and Caco-2 cells (Crane et al., 2001; Dean et al., 2010b; Dean et al., 2013). 
However, it is very difficult to transfect phagocytic cells such as macrophages with the 
limitation of transfection including cytotoxicity and low transfection efficiency (Arkusz et al., 
2006).  
The aim of this chapter was to test whether the EspF effector protein encodes sufficient 
information to enable EPEC to inhibit its uptake by macrophages. This was achieved through 
i) delivering EspF protein into macrophages via T3SS of Yersinia to avoid some of the 
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limitations identified in J774A.1 macrophages transfection ii) testing the anti-phagocytosis 
capacity of an EPEC strains unable to deliver most known effectors except EspF.  
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3.2 Results 
3.2.1 EPEC requires a functional type three secretion system (T3SS) and EspF effector 
protein to inhibit its uptake by J774.A1 macrophages  
EPEC has a T3SS-dependent capacity to inhibit its uptake by J774.A1 macrophages via 
phosphoinositide 3 (PI 3)-kinase dependent pathways (Celli et al., 2001; Quitard et al., 2006). 
However, many EPEC bacteria (~40%) are still internalised via PI 3-kinase independent 
pathways (Celli et al., 2001; Quitard et al., 2006). Prior to investigate whether EspF was 
sufficient to inhibit EPEC uptake by macrophages, it was necessary to re-establish the anti-
phagocytosis assay. To determine the percentage of internalised bacteria a published standard 
anti-phagocytosis protocol (Quitard et al., 2006) was followed with minor changes designed to 
aid re-establishment of a robust assay. Accordingly, J774.A1 macrophages (60-80% confluent) 
were infected for 1 h with pre-induced (to activate the T3SS) bacterial strains that carry a Green 
Fluorescent Protein (GFP)-expressing plasmid (see Materials and Methods). Moreover, after 
infection the cells were washed (to remove non-adherent bacteria) and incubated for 1 h with 
DMEM supplemented with chloramphenicol (stops bacterial protein synthesis) to promote 
uptake of adherent bacteria. An antibody based approach was used to label the extracellular 
bacteria (Red) as described (Goosney et al., 1999; Celli et al., 2001; Quitard et al., 2006) (see 
Materials and Methods). The percentage of phagocytosed bacteria was calculated as: (Total 
cell-associated bacteria [Green] minus extracellular bacteria [Red]/Total cell-associated 
bacteria [Green]) x 100. A range of multiplicity of infections (MOIs) were examined with 100:1 
(bacteria: macrophages) found to be the best and most reproducible to recapitulate previously 
published results (Quitard et al., 2006). Initial infections involved EPEC, T3SS mutant, EspF 
deficient (espF) mutant and DH10B (non-pathogenic E. coli) strains carrying a GFP-expressing 
plasmid (see Materials and Methods). PCR analysis was used to confirm the presence of an 
intact espF gene in only EPEC and T3SS mutant strains (Figure 14A). 
Prior to carrying out the phagocytosis assay, the nature of the T3SS mutant (unable to 
translocate effectors) was interrogated by infecting J774A.1 macrophages (see Materials and 
Methods) which were fractionated into Triton X-100 soluble fractions (contain host 
cytoplasmic and membrane proteins plus T3SS-delivered effectors) and insoluble (contains 
host nuclei and cytoskeleton proteins plus adherent bacteria) fractions for western blot analysis. 
As previously described (Kenny et al., 1997b; Kenny and Finlay, 1997) Tir shifting in the 
soluble fraction was used as a marker of a functional effector delivery system, as it is the first 
and abundant EPEC protein delivered into target cells (Mills et al., 2008) linked to shifts i
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Figure 14. EPEC requires a functional type 3 secretion system (T3SS) and EspF effector protein to inhibit its 
uptake by J774.A1 macrophages. Indicated strains were used for (A) PCR analysis or to infect (B&D) J774.A1 
macrophages or (B&C) HeLa cells. (A) Oligonucleotides specific to espF were used in PCR analyses to determine 
the presence of an intact (618bp) or deleted (~180bp) espF gene with PCR products visualised, alongside molecular 
mass markers 2-log (1000Kb ladder), on a 1% agarose gel. (B&D) Macrophages and HeLa (C&D) cells were left 
uninfected (Uninfect.) or infected MOI of 100:1 with indicated strains for 3 h before isolating Triton X-100 soluble 
(contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and insoluble (contains host 
nuclei and cytoskeleton plus adherent bacteria) fractions. Samples were examined by western blot analysis (12% 
SDS-PAGE) probing with anti-EspF, anti-Tir and anti-EspB antibodies. Arrows indicate the position of Tir 
(unmodified T0 and host kinase modified T’’ forms), EspF and EspB proteins. (D) J774.A1 macrophages were 
infected for 1 h (MOI 100:1) with indicated strains (pre-grown in DMEM for 3 h) prior to determining the 
percentage of internalised bacteria using antibodies to label extracellular bacteria (Red) with total cell-associated 
bacteria detected by plasmid expression of the Green Fluorescent Protein (Green). Fifty macrophages with 20-50 
cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-associated 
bacteria (Green) enabling the percentage internalisation to be calculated. (D) Quantification studies were carried 
out in a semi-blind manner with the percentage of internalised bacteria displayed as the mean value (± standard 
deviation) from at least three independent experiments. * indicates statistically significant differences (Dunnett’s 
post-test) compared to EPEC data (3* p< 0.001 4* p< 0.0001; one-way ANOVA) or by Tukey's test for multiple 
comparisons between strains (1#p<0.05, 2#p<0.01 and ns not significant). Strains used were EPEC, T3SS-
deficient (T3SS) and EspF-deficient (espF) mutants as well as non-pathogenic K12 (DH10B) E. coli, which all 
carried a GFP-expressing plasmid.
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apparent molecular mass from its unmodified form (T0) to modified form (T’’) due to the 
addition of phosphate groups on serine residues by host kinases (Warawa and Kenny, 2001). 
As expected (Kenny et al., 1997b; Kenny and Finlay, 1997), EPEC infection led to the detection 
of the T’’ form in the soluble and, due to its interaction with the EPEC surface protein Intimin, 
insoluble fractions (Figure 14B). Moreover, the EspB and EspF effector proteins were also 
evident in the soluble and insoluble fractions. Unexpectedly, the T3SS mutant infection was 
linked to low levels of Tir (only unmodified form), EspF and EspB proteins in the soluble 
fraction (Figure 14B and data not shown) suggestive of non-specific contamination as Tir would 
be modified to T’’ form if in host cytoplasm. To interrogate whether this background issue 
related to the fractionation procedure or cell type (phagocytic), the infection was repeated using 
non-phagocytic HeLa cells routinely deployed for fractionation studies in the Kenny laboratory. 
As reported (Kenny et al., 1997b; Kenny and Finlay, 1997) both forms of Tir (T0 and T’’) were 
detected in the soluble and insoluble fractions of EPEC-infected cells. By contrast, Tir was only 
evident in the insoluble, not soluble, fraction of T3SS mutant-infected HeLa cells (Figure 14B) 
and only in the unmodified form thereby illustrating T3SS-dependent delivery. These results 
suggest that the standard fractionation protocol with macrophages cannot be used to 
demonstrate T3SS dependent delivery of effectors, possibly due to the internalisation of 
bacteria and their degradation in lysosomes. Therefore, fractionation studies were carried out 
with HeLa cells to test T3SS functionality prior to testing the anti-phagocytic capacity of 
strains. Thus, HeLa cells were infected with EPEC, T3SS mutant, EspF deficient (espF) and 
DH10B (non-pathogenic E. coli) strains. As expected, Tir, EspF or EspB proteins were not 
evident in the soluble fraction of uninfected, T3SS mutant or DH10B infected cells while EspF, 
EspB and Tir (T0 and T’’ forms) were detected in the soluble and insoluble fractions of EPEC-
infected cells (Figure 14C). No band for EspF protein was detected in the soluble and insoluble 
fractions of espF -infected cells which confirm the nature of this mutant strain (Figure 14C). 
Having supported the correct nature of these GFP plasmid-carrying strains, they were 
used to infect macrophages to determine their capacity to inhibit phagocytosis, as outlined 
above. Infection with the T3SS mutant resulted in most (68.5 ± 5.7%) bacteria being 
internalised in contrast to only a minority (37.1 ± 1.7%) of cell-associated EPEC bacteria 
(Figure 14D), consistent with previous studies (Celli et al., 2001; Quitard et al., 2006). 
Noticeably, EPEC’s ability to block PI 3-kinase-dependent phagocytic pathways was 
confirmed by infecting macrophages, which were treated with LY294002 inhibitor (to block 
the PI-3 kinase phagocytic pathways), with T3SS mutant that reduce the internalisation to levels 
indistinguishable from wild type EPEC (data not shown). The internalisation process 
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responsible for the uptake of ~37% of EPEC presumably relates to PI-3 kinase independent 
pathways (Celli et al., 2001; Quitard et al., 2006). Moreover, as reported, the espF mutant 
behaved like the T3SS mutant (no statistical difference) while, interestingly, the K12 strains 
displayed a greater (p<0.01) defect (Figure 14D). The latter finding suggests that EPEC also 
possesses T3SS-independent mechanisms that contribute to EPEC capacity to inhibit its uptake. 
This work confirms that EPEC inhibits its uptake by J774A.1 macrophages in a manner 
dependent on a functional T3SS and the EspF effector protein and also suggests that there may 
be a T3SS-independent inhibitory contribution.   
 
3.2.2 Critical role for LEE, but not 14 Nle effectors in EPEC’s T3SS-dependent anti-
phagocytc activity  
Having confirmed EspF’s critical role in the anti-phagocytosis process, studies were undertaken 
to examine EspF sufficiency. EPEC subversion of host cell functions and signalling pathways 
depends, mostly, on the activity of LEE and/or non-LEE-encoded (Nle) effector proteins (Dean 
and Kenny, 2009). Thus, to explore whether EspF requires functions of non-LEE effectors to 
inhibit PI3-kinase dependent phagocytosis, studies examined phagocytosis of a strain, TOE-
A7, which lacks 14 non-LEE encoded effectors and LEE EspG (Yen et al., 2010). Strain 
genotype was supported by PCR analyses (Amin, 2016). Importantly, western blot analysis of 
soluble fractions obtained after infection of HeLa cells revealed delivery of EspF and Tir (both 
T0 and T’’ forms; not shown; but see Figure 23A). The latter promoted infection studies with 
J774.A1 macrophages to determine their anti-phagocytic capacity compared to a positive 
(EPEC) and negative (etmf) control strains. The latter strain doesn’t express three LEE effectors 
(Tir, Map, EspF) or Intimin surface protein and, like the espF mutant, is unable to inhibit PI-3 
kinase dependent uptake pathways (Quitard et al., 2006). As these strains do not carry a GFP-
expressing plasmid, the percentage internalisation was determined by antibody labelling 
extracellular bacteria (Red) followed by total cell associated bacteria (Green)(Figure 13) 
(Heesemann and Laufs, 1985; Quitard et al., 2006) (see Materials and Methods). 
 As reported, the etmf mutant strain was readily internalised by macrophages with the 
majority (67.7 ± 0.32%) inside the cells (Figure 15). In contrast, only 28.2 ± 3.9% of EPEC 
bacteria were phagocytosed, significantly less than the negative control (etmf mutant; p<0.0001; 
Figure 15). Infection of cells with the TOE-A7 strain resulted in 31.9 ± 3.9% being internalised 
which was statistically indistinguishable from the EPEC data (Figure 15) ruling out critical 
roles, individual or cooperative, for 15 (14 non-LEE plus EspG) effectors in EPEC’s T3SS 
dependent ability to inhibit its uptake by J774.A1 macrophages.  
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Figure 15. Ruling out critical roles for 14 non-LEE effectors and LEE EspG in EPEC’s T3SS dependent ability to 
inhibit phagocytosis. J774.A1 macrophages were infected (MOI 100:1) with indicated strains (pre-grown in 
DMEM for 3 h) for 1 h prior to determining the percentage of bacterial internalisation following differential 
antibody stains labelling extracellular (Red) and total cell-associated (Green) bacteria. Fifty macrophages with 20-
50 cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-associated 
bacteria enabling the percentage internalisation to be calculated. Quantification studies were carried out in a semi-
blind manner with the percentage of internalised bacteria displayed as the mean value (± standard deviation) from 
at least three independent experiments. * indicates statistically significant differences (Dunnett’s post-test) 
compared to EPEC data (4* p< 0.0001 and ns not significant; one-way ANOVA) or by Tukey's test for multiple 
comparisons between strains (4# p<0.0001). Strains used were EPEC, etmf (lacks LEE-encoded Intimin [eae gene 
product] plus Tir, Map and EspF effectors) and TOE-A7 (lacks 14 non-LEE-encoded effectors plus LEE EspG).  
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As EPEC encodes at least three additional non-LEE-encoded effectors -EspC (Guignot et al., 
2015), NleJ and Lif A (Deng et al., 2012) and probably other cryptic effectors- studies 
interrogated whether the LEE region encodes sufficient information to enable E. coli to inhibit 
its uptake. These studied used available (Yen et al., 2010) non-pathogenic E. coli strains that 
carry two plasmids; one encodes EPEC’s major adhesin (the bundle forming BFP) and positive 
regulator of LEE region expression (Per) (Giron et al., 1991; Mellies et al., 1999; Mellies et al., 
2007) with the second plasmid either encoding no new functions (TOB01 strain) or EPEC LEE 
region (TOB02 strains). PCR analysis supported strain genotype by confirming the presence of 
several nle genes in EPEC but not TOB01 or TOB02 strains (Figure 16A). Additionally, the 
EspF and Tir (T0 and T’’ forms) proteins were detected in the soluble fraction of EPEC and 
TOB02, but not etmf or TOB01, -infected HeLa cells (Figure 16B). Infection of J774A.1 
macrophages to determine strain anti-phagocytosis activity revealed TOB02 (25.9 ± 3.3% 
internalised) to behave like EPEC (30.02 ± 4.1 internalised) while TOB01 (81.1 ± 5.3% 
internalised) behaved like the negative, etmf mutant, control (74.8 ± 1.2 internalised; Figure 
16C). Thus, these results reveal that the EPEC BFP and Per gene operons do not bestow onto 
E. coli the capacity to inhibit phagocytosis, unless the LEE region is also introduced thereby 
illustrating that the LEE region encodes sufficient information to enable E. coli (carrying 
BPF/Per operons) to inhibit its uptake by J774.A1 macrophages to a similar extent as EPEC 
presumably by providing the capacity to block PI 3-kinase dependent uptake pathways. 
 
3.2.3. Yersinia can delivers EspF into host cells with efficient delivery dependent on co-
expression of its chaperone, CesF 
Having ruled out roles for 14 Nle effectors, demonstrated LEE sufficiency and confirmed that 
EspF is essential for E. coli to inhibit their uptake by J774.A1 macrophages, studies were 
undertaken to determine if EspF alone could inhibit phagocytosis. Yersinia pseudotuberculosis 
has been shown to deliver, via its T3SS, the EPEC Tir effector into host cells with efficient 
delivery dependent on co-expressing the Tir chaperone, CesT (Warawa and Kenny, 2001). 
These studies employed a mutant lacking the main Yersinia encoded (Yop) effectors (Warawa 
and Kenny, 2001). Thus, studies examined if Yersinia could also delivery EspF into host cells 
in a manner dependent, or not, on its chaperone (CesF) and, if so, the impact of this delivered 
effector on PI3K-dependent phagocytosis. 
As the previously used Yersinia strain is resistant to many antibiotics – introduced when 
engineering yop gene loss – this hindered the introduction of antibiotic selectable plasmids, 
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Figure 16. The EPEC LEE region encodes sufficient functions to enable non-pathogenic E. coli (carrying EPEC 
BFP and Per operons) to inhibit its uptake by J774.A1 macrophages. PCR probing for nleF and nleE1 genes was 
used to support strain genotype (A) before infecting HeLa cells for western blot analysis (B) and J774A.1 
macrophages for anti-phagocytosis assay (C). (A) PCR products were visualised, alongside molecular mass 
markers 2-log (1000Kb ladder), on a 1% agarose gel to determine the presence of intact nleF (390 bp) or nleE1 
(403 bp) genes. (B) HeLa cells were left uninfected or infected for 3 h (MOI 100:1) with indicated strains before 
isolating Triton X-100 soluble (contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) 
and insoluble (contains host nuclei and cytoskeleton plus adherent bacteria) fractions for western blot analysis 
(12% SDS-PAGE) probing for EspF and Tir proteins. Arrows indicate the position of Tir (unmodified T0 and host 
kinase modified T’’ forms) and EspF proteins. (C) J774.A1 macrophages were infected for 1 h (MOI 100:1) with 
the indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria 
using differential antibody staining to label extracellular (Red) and then total cell-associated (Green) bacteria. Fifty 
macrophages with 20-50 cell-associated bacteria were randomly chosen to count the number of extracellular and 
total cell-associated bacteria enabling the percentage internalisation to be calculated. Quantification studies were 
carried out in a semi-blind manner with the percentage internalised bacteria displayed as the mean value (± 
standard deviation) from at least three independent experiments. * indicates statistically significant differences 
(Dunnett’s post-test) compared to EPEC data (4* p< 0.0001; one-way ANOVA) or by Tukey's test for multiple 
comparisons between strains (4# p< 0.0001; ns not significant). Strains used were EPEC, etmf (lacks LEE-encoded 
Intimin [eae gene product] plus Tir, Map and EspF effectors) and non-pathogenic E. coli strains TOB01 (carries 
plasmid encoding EPEC BFP adhesion and Per regulator plus ‘empty’ plasmid) and TOB02 (as TOB01 but with 
EPEC LEE region on an ‘empty’ plasmid).  
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and thus studies examined the utility of an antibiotic-sensitive Yop-deficient Yersinia 
enterocolitica strain (Iriarte and Cornelis, 1998). As the available cesF carrying plasmid 
encodes CesF as a CesF::HA fusion (Kenny; unpublished) shared the same antibiotic resistance 
(Chloramphenicol) as available EspF-expressing plasmids, studies used a carbenicillin-
selectable plasmid that encodes EspF as a T7-EspF fusion protein (Dean and Kenny, 2004). 
Thus, initial studies were undertaken to determine if the N-terminal tag interfered with EspF’s 
anti-phagocytic activity following introduction of the T7-EspF encoding plasmid into the EspF-
deficient etmf quadruple mutant. First, infections were carried out on HeLa cells for western 
blot comparison of EspF and T7-EspF delivery levels. This analysis revealed similar EspF and, 
as evidenced by the slower migration (due to T7 tag), T7-EspF protein expression and delivery 
levels (Figure 17A). Importantly, these EspF and T7-EspF complemented strains were just as 
capable as EPEC, unlike the etmf control strain, at inhibiting their uptake by J774.A1 
macrophages (Figure 17B) illustrating that the N-terminal T7 epitope tag does not affect EspF’s 
ability to inhibit phagocytosis as reported (Quitard et al., 2006).  
Having confirmed that T7-EspF can be used as a substitute for EspF, studies examined 
the ability of Yersinia to express and deliver EspF into HeLa cells in a CesF-dependent or -
independent manner. Thus, the T7-EspF plasmid was introduced into Yersinia, with or without 
the CesF-encoding plasmid, for a 3 h infection of HeLa cells at standard (100:1) MOI but with 
an additional centrifugation step to promote Yersinia-host cell interaction (Ruchaud-Sparagano 
et al., 2011). Western blot examination of isolated soluble and insoluble fractions revealed EspF 
in the insoluble fractions of EPEC-infected cells, with T7-EspF evident in the insoluble 
fractions of cells infected with Yersinia strains carrying the pT7-espF plasmids in the presence 
or absence of pcesF plasmids (Figure 18). Linkage of the CesF-expressing plasmid with 
increased EspF signal is consistent with its published role in promoting EspF stability (Elliott 
et al., 2002). Significantly, EspF related proteins were only detected in the soluble fractions of 
cells infected with EPEC or Yersinia carrying both, not single, pcesF and pT7-espF plasmids 
(Figure 18). CesF::HA and/or T7-EspF protein expression in the appropriate Yersinia strains 
was confirmed by probing with anti-T7 and anti-HA antibodies (not shown). In summary, these 
results demonstrate that Yersinia can express and deliver the EPEC EspF effector into HeLa 
cells in a manner promoted by co-expressing its chaperone, CesF. 
 
3.2.4. Yersinia- delivered EspF does not inhibit the capacity of J774A.1 macrophages to 
internalise EPEC  
Having demonstrated that Yersinia can deliver the EspF effector into cells in a manner  
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Figure 17. EspF and T7-EspF variants rescue the etmf mutant anti-phagocytosis defect. Indicated strains were used 
to infect (A) HeLa cells and (B) J774.A1 macrophages. (A) HeLa cells were infected for 3 h (MOI 100:1) with the 
indicated strains before isolating Triton X-100 soluble (contains host cytoplasmic and membrane proteins plus 
T3SS-delivered effectors) and insoluble (contains host nuclei and cytoskeleton plus adherent bacteria) fractions 
for western blot analysis (12% SDS-PAGE) probing for EspF. Arrows indicate the position of EspF and T7-EspF 
proteins. (A) * indicates cross-contamination of well. (B) J774.A1 macrophages were infected (MOI 100:1) with 
indicated strains (pre-grown in DMEM for 3 h) for 1 h prior to determining the percentage of internalised bacteria 
using differential antibody stains to label extracellular bacteria (Red) and then total cell-associated bacteria 
(Green). Fifty macrophages with 20-50 cell-associated bacteria were randomly chosen to count the number of 
extracellular and total cell-associated bacteria enabling the percentage internalisation to be calculated. (B) 
Quantification studies were carried out in a semi-blind manner with the percentage internalised bacteria displayed 
as the mean value (± standard deviation) from at least three independent experiments. * indicates statistically 
significant differences (Dunnett’s post-test) compared to EPEC data (4* p<0.0001; one-way ANOVA) or by 
Tukey's test for multiple comparisons between strains (4# p<0.0001 and ns not significant). Strains used were 
EPEC, etmf (lacks LEE-encoded Intimin [eae gene product] plus Tir, Map and EspF effectors) and etmf carrying 
plasmids expressing EspF (pespF) or T7-EspF (pT7-espF).    
 
 
 
 
 
 
 
 
 
 
Figure 18. Yersinia delivers EspF into HeLa cells in a manner promoted by co-expressing its chaperone CesF. 
HeLa cells were left uninfected or infected (MOI 100:1) with indicated strains for 3 h before isolating Triton X-
100 soluble (contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and insoluble 
(contains host nuclei and cytoskeleton plus adherent bacteria) fractions for western blot analysis (12% SDS-PAGE) 
probing for EspF. Arrows indicate the position of EspF and T7-EspF proteins. The blot is representative of those 
obtained from three independent experiments. Strains used were EPEC, Yersinia carrying no plasmid (-) or 
plasmids encoding CesF (as a CesF::fusion protein) and/or T7-EspF proteins.  
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dependent on co-expressing its chaperone CesF, studies were undertaken to determine the best 
MOI to deliver T7-EspF to a similar extent as EPEC. Thus, HeLa cells were infected with 
Yersinia over a range of MOIs prior to isolating samples for western blot analysis which 
revealed an MOI of 80:1 to give T7-EspF signals comparable to the EspF signal of EPEC-
infected cells (Figure 19). Yersinia uptake by macrophages is through PI-3 kinase independent 
pathways (Celli et al., 2001), and thus assessing whether EspF delivery by this strain could 
inhibit PI-3 kinase independent pathways required the development of a two-wave infection 
protocol. For example determine if cells pre-infected with Yersinia would inhibit uptake of an 
EPEC T3SS (GFP-expressing) mutant. Thus, J774A.1 macrophages were infected with EPEC 
(MOI 100:1) and Yersinia (range of MOI’s) strains for 1 h. The infections were stopped by 
adding fresh DMEM supplemented with antibiotic to kill extracellular bacteria for 1 h, followed 
by an hour recovery period (in DMEM +FCS). Post recovery, macrophages were infected for 
an hour with GFP-expressing EPEC T3SS mutant (second wave infection; MOI 100:1). Of 
note, the non-adherent bacteria were collected after the infection and retained for western blot 
analysis to support strains genotype (Figure 20A). Western blot analysis of the non-adherent 
bacterial samples revealed EspF and Tir expression in EPEC, but not Yersinia strains, with T7-
EspF only evident in Yersinia strains carrying the pT7-espF and pcesF plasmids (Figure 20A) 
with signal strength increasing with MOI. 
Following the second-wave infection, antibody staining was used to label the 
extracellular T3SS mutant bacteria (Red) with total cell-associated T3SS mutant bacteria 
revealed by their GFP-positive nature (see Materials and Methods). Calculating the percentage 
uptake of second-wave T3SS mutant bacteria revealed that only cells pre-infected with EPEC, 
not Yersinia or Yersinia carrying pT7-espF and pcesF plasmids, inhibited T3SS mutant uptake 
(~20% internalised compared to ~80% for Yersinia pre-infected cells; Figure 20B). The data is 
supported by additional experiments where the uptake was assessed, in a semi-blind manner, 
whether or not inhibit without quantification (not shown). These findings suggest that delivery 
of EspF into macrophages is not sufficient to inhibit their ability to internalise EPEC. However, 
an alternative unlikely possibility is that Yersinia can deliver EspF into HeLa but not J774A.1 
macrophages. Therefore, imaging studies were undertaken to probe for Yersinia delivery of T7-
EspF into macrophages. 
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Figure 19. An MOI of 80:1 is best for Yersinia to deliver T7-EspF into HeLa cells to a similar extent as EPEC. 
HeLa cells were infected with EPEC (MOI of 100:1) and Yersinia (indicated MOI; using gentle centrifugation 
[500 xg, 5 minutes] to initiate macrophage-bacteria interaction) carrying plasmids encoding the EspF-specific 
chaperone CesF (as a CesF::Ha fusion protein) and/or T7-EspF protein. Following a 3 h infection the Triton X-
100 soluble (contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and insoluble 
(contains host nuclei and cytoskeleton plus adherent bacteria) fractions were isolated for western blot analysis 
(12% SDS-PAGE) to probe for EspF, Tir and HA-tagged proteins. Arrows indicate position of Tir, EspF, T7-EspF 
and CesF:HA proteins. The blot is representative of those obtained from three independent experiments. 
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Figure 20. EspF is not sufficient to inhibit the uptake of EPEC by macrophages. J774.A1 macrophages were 
infected with indicated strains (pre-grown in DMEM for 3 h) using gentle centrifugation - 500 xg, 5 minutes- for 
1 h prior to (A) isolating non-adherent bacteria for western blot analysis and (B) antibiotic killing extracellular 
bacteria prior to a 1 h infection with the T3SS mutant carrying a GFP-expressing plasmid (second wave of 
infection). Yersinia was added at the indicated MOI with EPEC and the T3SS mutant at 100:1. The extracellular 
bacteria were labelled ‘Red’ with total T3SS mutant evident by GFP ‘Green’ expression. Fifty macrophages with 
20-50 cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-associated 
bacteria. A two-wave infected T3SS/GFP bacteria were only counted which expresses both ‘Green’ (GFP) and 
‘Red’, but not Red only (EPEC; first wave infection) (see Materials and Methods). Quantification studies were 
carried out in a semi-blind manner with the percentage of internalised bacteria revealed no difference between the 
different MOIs and, thus, only the highest was quantified. The data shown is representative of three independent 
experiments revealed similar results for each, thus, only one experiment was quantified. (A) Arrows indicate the 
position of Tir, EspF and T7-EspF proteins. Strains used were EPEC, T3SS/GFP, Yersinia carrying no plasmid or 
plasmids expressing T7-EspF and the EspF specific chaperone CesF::HA. 
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3.2.5. Immuno-detection of EspF, but not T7-EspF delivery into macrophages  
EspF targets mitochondria where its accumulation can be detected by immunofluorescence 
microscopy (Nougayrède and Donnenberg, 2004; Dean et al., 2010b). As previous studies used 
non-phagocytic cells, initial work involved HeLa cells infected for 3 h (MOI 100:1) with EPEC 
strains that can or cannot express or deliver EspF into cells. Post-infection, cells were washed 
and fixed before adding anti-EspF antibody in the presence and absence of detergent (1% 
Triton; enables antibodies to cross host membranes) for detection by secondary Alexa 488 
conjugated (Green) antibodies. However, immunofluorescent imaging analysis revealed a high 
anti-EspF background signal with both uninfected and EPEC-infected cells when no detergent 
was present. Punctate aggregate signals in EPEC infected, not uninfected, cells when detergent 
was added (not shown) characteristic of EspF accumulation in mitochondria (Nougayrède and 
Donnenberg, 2004; Dean et al., 2010b).  
Repeat studies with J774.A1 macrophages provided similar results with high anti-EspF 
background for all cells that had not been exposed to detergent but also detergent-treated cells 
which were uninfected or infected with the effector delivery defective (espB) and EspF-
deficient (espF) strains (Figure 21). Although more difficult to detect in macrophages, there 
was an obvious punctate EspF signal in EPEC infected cells that had been detergent-treated 
(Figure 21) that presumably reflects EspF accumulation in mitochondria. By contrast, no signal 
difference was evident for cells infected with strains (etmf mutant or Yersinia) expressing the 
T7-EspF variant when examined following addition or absence of detergent (data not shown). 
The latter data suggests that either T7-EspF is not delivered into macrophages or, more likely, 
that the N-terminal T7 tag prevents EspF targeting to mitochondria with accumulation in the 
cytoplasm obscured by the high background signal. To test the latter possibility, macrophages 
were infected with the EPEC and the etmf/pT7-EspF mutant strains to deliver EspF and pT7-
EspF respectively with antibody probing revealing accumulation of only EspF in mitochondria 
(data not shown) supporting the idea that the T7 tag compromises the functionality of EspF’s 
mitochondrial targeting sequence. Several approaches were undertaken to decrease the high 
anti-EspF background, for example by adding blocking agents, but none were successful.  
Thus, another strategy was undertaken to negate the need to use the T7-EspF variant i.e. 
clone espF onto pACYC184 (chloramphenicol resistant) for introduction into Yersinia carrying 
pcesF::HA (carbenicillin resistant). Unexpectedly, introduction of pACYC-espF into this strain 
did not lead to high levels of EspF expression (sequencing confirmed the absence of unwanted 
PCR-introduced mutations) and/or EspF delivery into infected cells suggestive of plasmid 
incompatibility issues.  
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Figure 21. Immuno-detecting T3SS-dependent delivery of EspF. J774.A1 macrophages were infected for 3 h (MOI 
100:1) with indicated strains prior to fixing cells and incubating with anti-EspF antibodies in PBS alone (-) or PBS 
containing 1% Triton (+) to make the host membrane permeable to the antibodies. The bound EspF antibodies 
were labelled with Alexa 488-conjugated (Green) secondary antibodies for immunofluorescent detection. DAPI 
was also added to detect DNA (host and bacterial; blue channel) see Materials and Methods. Strains used were 
EPEC, EspF-deficient (espF) and effector-delivery deficient (espB) mutants. The data shown is representative of 
three independent experiments. Images are representative of at least three independent experiments taken by 
epifluorescence microscope with an 100x oil objective. Scale bar 5.5 μm.  
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Despite the failure to demonstrate T7-EspF delivery into macrophages by Yersinia, the data 
collectively support the idea that EspF does not encode sufficient information to inhibit uptake 
of EPEC (T3SS mutant). To support this conclusion, another strategy was undertaken. 
 
3.2.6. EspF requires the function of other effectors to inhibit EPEC’s uptake by J774.A1 
macrophages 
To further explore EspF sufficiency to inhibit EPEC uptake by macrophages, studies 
interrogated the dependence of the subversive process on other effectors. Initial work focused 
on the available espGorf3core mutant strain which lack genes for Intimin, four LEE effectors 
(EspG, EspH, Tir, Map), a Nle (EspG2/Orf3) effector and the two effector-specific chaperones, 
CesF/CesT. While CesF is essential for EspF intra-bacterial stability and T3SS delivery (Elliott 
et al., 2002), CesT is essential for the delivery of most LEE effectors (Tir, Map, EspH, EspZ). 
Indeed, Nle are either fully dependent (NleB2; NleG; EspJ; NleH1; NleH2) or only partially 
dependent (NleB1; NleC) on the chaperone CesT but, some effectors (eg EspG; NleD; NleF) 
have no CesF/CesT dependence (Thomas et al., 2005; Mills et al., 2013). Thus, this strain is, 
theoretically, unable to express and/or deliver many Nle and most LEE (including EspF) 
effectors. Thus, the pcesF::HA plasmid was introduced, generating espGorf3core/pcesF::HA, 
to restore EspF delivery prior to examining if the anti-phagocytosis mechanism depends on the 
activity of effectors not expressed or delivered by this strain.  
Prior to investigating the strain’s anti-phagocytosis capacity, HeLa cells were infected 
for western blot confirmation of restored EspF delivery. Examining the insoluble fractions 
illustrated that only one strain, espGorf3core/pcesF::HA, expressed a HA-tagged protein and 
that this was linked to restoring the EspF signal to the level found in the insoluble fraction of 
EPEC-infected cells (Figure 22A). As predicted, introducing pcesF::HA also restored the level 
of EspF found in the soluble fraction to that found in EPEC-infected cells (Figure 22A).  
Having confirmed strain genotype, macrophages were infected to determine their ability 
to inhibit phagocytosis. As expected, the positive control, EPEC, inhibited uptake (only 30.1 ± 
6.4% internalised) in contrast to the negative, etmf mutant, control (71.6 ± 7.6% internalised; 
Figure 22B). Crucially, the espGorf3core mutant behaved like the negative control whether it 
carried the pcesF::HA plasmid or not (Figure 22B) indicating roles for other effectors. Similar 
results (Figure 23A & 23B) were obtained with a more complex ‘core’ mutant, TOE-A7Δcore 
(Table 2; Materials & Methods), which differs from espGorf3core by the additional absence of  
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Figure 22. EspF requires the activity of other effectors to inhibit EPEC uptake by macrophages. Indicated strains 
were used to infect (A) HeLa cells for western blot analysis and (B) J774.A1 macrophages for the phagocytosis 
assay. (A) HeLa cells were left uninfected or infected for 3 h (MOI of 100:1) with indicated strains before isolating 
Triton X-100 soluble (contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and 
insoluble (contains host nuclei and cytoskeleton plus adherent bacteria) fractions for western blot analysis (12% 
SDS-PAGE) probing for EspF, Tir and HA-tagged proteins. Arrows indicate the position of Tir (unmodified T0 
and host kinase modified T’’ form), EspF and CesF::HA proteins. The blot is representative of those obtained from 
three independent experiments. (B) J774.A1 macrophages were infected 1 h (MOI 100:1) with indicated strains 
(pre-grown in DMEM 3 h) prior to determining the percentage bacterial internalisation using differential antibody 
stains distinguish extracellular bacteria (Red) from total cell-associated (Green) bacteria. Fifty macrophages, with 
20-50 cell-associated bacteria, were randomly chosen to count the number of extracellular and total cell-associated 
bacteria enabling the percentage internalisation to be calculated. (B) Quantification studies were carried out in a 
semi-blind manner with percentage internalisation displayed as the mean value (± standard deviation) from at least 
three independent experiments. * indicates statistically significant differences (Dunnett’s post-test) compared to 
EPEC data (4* p< 0.0001; one-way ANOVA) or by Tukey's test for multiple comparisons between strains (ns not 
significant). Strains used were EPEC, etmf (lacks LEE-encoded Intimin [eae gene product] plus Tir, Map and EspF 
effectors), espGorf3Δcore strain (lacks espG, orf3, espH, tir, map, eae, cesF and cesT genes) carrying no plasmid 
(-) or a plasmid encoding the EspF-specific chaperone CesF [as a CesF::HA fusion protein].  
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Figure 23. EspF requires the activity other effectors to inhibit EPEC uptake by macrophages. Indicated strains 
were used to infect (A) HeLa cells for western blot analysis and (B) J774.A1 macrophages for the phagocytosis 
assay. (A) HeLa cells were left uninfected or infected for 3 h (MOI of 100:1) with indicated strains before isolating 
Triton X-100 soluble (contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and 
insoluble (contains host nuclei and cytoskeleton plus adherent bacteria) fractions for western blot analysis (12% 
SDS-PAGE) probing for EspF, Tir and HA-tagged proteins. Arrows indicate the position of Tir (unmodified T0 
and host kinase modified T’’ form), EspF and CesF::HA proteins. The blot is representative of that obtained from 
three independent experiments. (B) J774.A1 macrophages were infected 1 h (MOI 100:1) with indicated strains 
(pre-grown in DMEM 3 h) prior to determining the percentage bacterial internalisation using differential antibody 
stains distinguish extracellular bacteria (Red) from total cell-associated (Green) bacteria. Fifty macrophages, with 
20-50 cell-associated bacteria, were randomly chosen to count the number of extracellular and total cell-associated 
bacteria enabling the percentage internalisation to be calculated. (B) Quantification studies were carried out in a 
semi-blind manner with percentage internalisation displayed as the mean value (± standard deviation) from at least 
three independent experiments. * indicates statistically significant differences (Dunnett’s post-test) compared to 
EPEC data (4* p< 0.0001; one-way ANOVA) or by Tukey's test for multiple comparisons between strains (4# 
p<0.0001 and ns not significant). Strains used were EPEC, etmf (lacks LEE-encoded Intimin [eae gene product] 
plus Tir, Map and EspF effectors), TOE-A7 (lacks 14 non-LEE encoded plus LEE EspG effectors) and TOE-
A7Δcore strain (as TOE-A7 but also lacks espH, tir, map, eae, cesF and cesT genes) carrying no plasmid or a 
plasmid encoding the EspF-specific chaperone CesF [as a CesF::HA fusion protein]. 
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thirteen Nle effector-encoding genes. Of note, similar western blot and phagocytosis data was 
obtained for EPEC and TOE-A7 (lacks 14 nle genes) strains reaffirming no detectable roles for 
14 Nle effectors in delivering EspF and Tir as well as the anti-phagocytosis mechanism. By 
contrast, the ‘core’ variants, with reduced (TOE-A7core) or EPEC-like (TOE-
A7core/pCesF::HA) EspF expression/delivery levels (Figure 23A) could not inhibit 
phagocytosis (Figure 23B) supporting a requirement for other effectors in the anti-phagocytosis 
process. 
 
3.2.7. Confirmation of T3SS/CesF-dependent EspF delivery into macrophages  
The implied dependence of EPEC’s EspF-driven anti-phagocytic activity on other effectors 
rests on the, western blot supported, assumption that introducing the pcesF::HA plasmid 
rescued the EspF delivery defect of espGorf3core and TOE-A7Δcore mutants. To provide 
further support for EspF delivery, J774A.1 macrophages were infected and fixed before 
antibody probing for EspF accumulation in mitochondria as before (see Materials and 
Methods). Immunofluorescent microscopy analysis revealed that adding antibodies in the 
absence of detergent led to, as before, a background EspF signal with detergent addition having 
no impact on the signal for espB (can’t deliver effectors) infected cells (Figure 24). 
Interestingly, there was evidence of some EspF delivery (punctate staining) in espGorf3core 
and TOE-A7Δcore-infected cells consistent with the observed low level of EspF 
expression/delivery (Figure 22 and 23). By contrast, a much more dramatic punctate staining 
pattern was evident in detergent-treated cells that had been infected with EPEC, the 
espGorf3core/pcesF::HA or TOE-A7Δcore/pcesF::HA mutants (Figure 24). This work, 
together with the western blot data, illustrates that the EspF delivery-defect of CesF-deficient 
(core mutant) strains was completely rescued by introducing the CesF::HA encoding plasmid. 
Moreover, the failure of the CesF-complemented espGorf3core and TOE-A7Δcore strains to 
inhibit their uptake by J774A.1 macrophages supports the idea that EspF does not encode 
sufficient information to inhibit phagocytic pathways but depends on the activity of co-
delivered effectors. As our studies also ruled out a role for the 14 Nle effectors and core-deleted 
LEE effectors, the findings implicate roles for other (CesT-dependent) effectors.  
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Figure 24. Rescuing EspF delivery defect of core mutants by introducing CesF::HA encoding plasmid. J774.A1 
cells were infected for 3 h (MOI 100:1) with indicated strains prior to fixing cells and adding anti-EspF antibodies 
in PBS alone (-) or PBS containing 1% Triton (+) to enable antibody to cross host membranes. Bound antibodies 
were detected using Alexa 488-conjugated antibodies (green channel). Cells were also incubated with DAPI to 
stain DNA (host and bacterial; blue channel) see Materials and Methods. Strains used were EPEC, espB (can 
secrete EspF but cannot deliver EspF into cells), espGorf3core (lacks espG, orf3, espH, tir, map, eae, cesF and 
cesT genes) and TOE-A7Δcore (lacks 14 nle genes plus espG, espH, tir, map, eae, cesF and cesT genes). Indicated 
strains carried a plasmid (pcesF) encoding the EspF-specific chaperone CesF as a CesF::HA fusion protein. Images 
are representative of three independent experiments taken by confocal laser-scanning microscope at 63x 1.32 NA 
oil-immersion objective. Scale bar 7.5 μm.  
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3.3 Discussion 
The T3SS-delivery of the EPEC EspF effector protein into host cells is essential for EPEC to 
inhibit their uptake through PI-3 kinase dependent pathways (Quitard et al., 2006; Martinez‐
Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 2011). The aim of this chapter was to 
test whether the EspF effector protein encodes sufficient information to enable EPEC to inhibit 
its uptake by macrophages. Here we clearly confirmed that EPEC has the ability to inhibit its 
uptake by J774A.1 macrophages in a manner dependent on a functional T3SS and EspF effector 
protein, and also suggest a T3SS-independent inhibitory contribution. Furthermore, we show 
that the LEE region encodes sufficient information to enable E. coli to inhibit its uptake by 
J774.A1 macrophages and, crucially, demonstrate that EspF is not sufficient to inhibit EPEC 
uptake.  
The anti-phagocytic data generated in this study is consistent with others (Goosney et 
al., 1999; Celli et al., 2001; Quitard et al., 2006; Marchès et al., 2008) and confirms that EPEC 
has a T3SS-dependent capacity to inhibit its uptake by J774.A1 macrophages. Interestingly, 
studies with non-pathogenic K12 E. coli strains (DH10B and TOB01) suggested a T3SS-
independent inhibitory contribution, which may implicate roles for other EPEC-specific T3SS-
independent factors such as EspC protein (autotransporter link to cell cytotoxicity), T2SS-
dependent substrate(s) required for EPEC virulence, surface components such as pili, 
membrane proteins or capsule (Giron et al., 1991; Stein et al., 1996; Whitfield, 2006; Baldi et 
al., 2012; Guignot et al., 2015). Further work is required to define the EPEC factors and 
mechanisms mediating this T3SS-independent inhibitory mechanism.  
While anti-phagocytosis depends on LEE functions (Quitard et al., 2006; Iizumi et al., 
2007; Dong et al., 2010), it was unclear whether the LEE region encodes sufficient information 
to enable E. coli K12 to inhibit its uptake by macrophages. Here we show that the LEE region 
encodes sufficient information to enable E. coli K12 to inhibit its uptake to a similar level as 
EPEC. This finding was supported by subsequent work of another PhD student (Amin, 2016). 
The E. coli K12 strain also carries plasmids encoding an EPEC adhesin (BFP, facilitates the 
initial attachment of the microbe to its host cell surface) and Per (promotes LEE gene 
expression) but these factors are not responsible as present in the negative control strain which 
did not inhibit phagocytosis. However, these factors may be required (or promote) the LEE-
mediated inhibitory event but previous studies discounted a role for BFP (Goosney et al., 1999). 
Thus, it is likely that anti-phagocytosis is due to LEE-encoded effectors previously linked to 
this event i.e. EspF (Quitard et al., 2006), EspB (Iizumi et al., 2007), EspH (Dong et al., 2010) 
and/or EspG (Humphreys et al., 2016).  
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It is important to note that the EPEC factors in the E. coli K12 experiments came from EPEC 
B171-8; another prototypic typical EPEC strain (Yen et al., 2010) with significant differences 
between LEE-encoded effectors, for example, only 66%, 66% and 77% identity between EspB, 
Tir and EspF protein respectively (McDaniel and Kaper, 1997; Simonovic et al., 2000; Yen et 
al., 2010). Nevertheless, we predict that the EPEC E2348/69 LEE region also encodes all the 
factors required to enable K12 E. coli (carrying per and/or bfp operons) to inhibit phagocytosis. 
Support from this suggestion comes from the finding that an EPEC E2348/69 strain lacking 
most (14 of 17) proven non-LEE-encoded effectors inhibited its uptake similar to the parental 
EPEC strain. However, as this strain lacks EspG (and its Nle homologue EspG2) our finding 
contrasts to a recent publication which suggested that the EPEC EspG effector inhibits 
phagocytosis (Humphreys et al., 2016). A possible reason for the conflicting results may be use 
the different cell models; RAW264.7 (ATCC-TIB71) versus, in this study, J774A.1 (ATCC 
TIB-67) mouse macrophage-like cells, protocols and/or reagents.   
The critical role of EspF has been supported by previous studies using macrophage 
models (Quitard et al., 2006; Marchès et al., 2008) M-cell, in vitro and in vivo, model 
(Martinez‐Argudo et al., 2007; Tahoun et al., 2011), however, the EspF inhibitory mechanism 
remains undefined. One question arising from earlier studies is whether EspF encodes sufficient 
information to inhibit EPEC uptake by macrophages, or whether it requires additional EPEC 
factors in the anti-phagocytosis process. To address this, the EspF effector was delivered, via 
T3SSs, into host cells in the absence of all or most known EPEC effectors. The former involved 
a Yersinia strain -lacking genes encoding the key Yersinia encoded (Yop) effectors, as this 
strategy was used to deliver the EPEC Tir effector into HeLa cells in a manner greatly promoted 
by co-expressing the Tir chaperone CesT (Kenny and Warawa, 2001). Our studies revealed for 
the first time, that Yersinia can deliver EspF into HeLa cells in a manner dependent on co-
expressing its chaperone CesF. While EspF delivery into HeLa cells was evident by western 
blot analysis of isolated (Triton X-100 soluble and insoluble) fractions, similar studies with 
macrophages were not able to illustrate T3SS-dependent effector delivery. The latter is 
probably due to the phagocytic nature of macrophages leading to non-specific internalisation 
(endocytosis) or T3SS-secreted proteins, perhaps, released during degradation of internalised 
bacteria within phago-lysosomes. Thus, a well-established protocol, using HeLa cells, was used 
in this study to support the T3SS dependent delivery of effectors (Kenny and Warawa, 2001; 
Grosdent et al., 2002). It should be noted that these studies used a plasmid encoding a CesF::HA 
tagged protein which illustrates that adding a short C-terminal extension does not interfere with 
two of its chaperone functions: promoting intracellular stability of EspF and T3SS delivery.     
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The inability to detect T3SS-delivery into macrophages led to the development of a fluorescent 
microscopy approach (Nougayrède and Donnenberg, 2004; Dean et al., 2010b), which could 
clearly illustrate T3SS-dependent delivery of EspF into HeLa cells and J774A.1 macrophages. 
However, this approach did not work with the T7-EspF varaint as the T7 tag, apparently, stops 
EspF from targeting mitochondria, the basis of the assay, with the cytoplasmic accumulation 
not evident due to high background signals. It should be noted that we confirmed that, as 
reported (Quitard et al., 2006), T7 EspF could substitute for EspF to rescue the anti-
phagocytosis defect of EspF deficient etmf mutant. As attempts to reduce the high background 
antibody signal were unsuccessful, attempts were made to generate a plasmid expressing EspF 
(un-tagged version) compatible with a plasmid expressing its chaperone CesF. However, 
unfortunately, introducing the new generated EspF into pcesF- carrying Yersinia did not 
increase EspF delivery level. As the sequencing analysis confirmed the absence of PCR-
introduced mutations, possible explanations for this finding include incompatibility issues. In 
support of this hypothesis another PhD student (A. Madkour) has recently found that Yersinia’s 
ability to deliver Tir was abolished by the presence of a second plasmid CesT. Nevertheless, 
our data are consistent with Yersinia being able to deliver EspF (T7-EspF), in a CesF dependent 
manner, into HeLa cells, and presumably J774.A1 macrophages, to a similar level as EPEC but 
this fail to interfere with the phagocytic activity of J774.A1 macrophages towards EPEC. It 
should be noted that Yersinia’s ability to inhibit phagocytosis was assessed through a two-wave 
approach i.e. first-wave EPEC or Yersinia/pT7-espF/pcesF::HA (to pre-deliver EspF) infection 
before infecting with an EPEC T3SS mutant (GFP expressing) and determining the percentage 
of internalisation of the second wave T3SS/GPF mutant bacteria. Collectively, while this work 
failed to illustrate Yersinia delivery of T7-EspF into macrophages, unlike HeLa cells, the 
finding make it highly likely that it was delivered but failed to inhibit phagocytosis implicating 
crucial role(s) for other EPEC encoded factor(s). 
Support for the above hypothesis came from a second strategy i.e studies with an EPEC 
strains unable to deliver most known effector except EspF. Firstly, we confirmed the 
expectation that an espGorf3core (and later TOE-A7Δcore) mutant, which lacks CesF, 
delivered little EspF into HeLa cells or (via fluorescent microscopy studies) macrophages and 
could not inhibit phagocytosis. Importantly, plasmid introducing CesF (as a CesF-HA fusion 
protein) rescued the EspF delivery, but not anti-phagocytosis, defect supporting the idea that 
EspF does not encode sufficient information to inhibit EPEC uptake by macrophages. 
Moreover, the finding implicates key role for factors encoded within the core region i.e. Intimin 
three effectors (EspH, Map, Tir).  
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In summary, this study not only confirms a dependence of EPEC’s anti-phagocytosis activity 
on a functional T3SS and EspF effector protein, but discounted a key role of  fifteen (fourteen 
Nle and EspG) effectors and argues that all required factors are encoded on the LEE region. 
Furthermore, this work demonstrates that delivering EspF into macrophages is not sufficient to 
inhibit EPEC uptake and implicates a critical role for one or more of the gene products encoded 
on the LEE core region i.e. Intimin, EspH, Map and/or Tir. 
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Chapter 4. Investigating roles for LEE core region 
proteins in EPEC’s capacity to inhibit its uptake by 
J774.A1 macrophages 
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4.1 Introduction  
In the previous chapter we have demonstrated that EspF requires the function of other effector 
proteins to inhibit EPEC’s uptake, probably one or more of the LEE core region proteins EspH, 
Map, Tir and Intimin.   
Tir (translocated Intimin receptor) is the first LEE effector delivered into the host cells 
by the T3SS. Tir is inserted into the host membrane where it acts as a receptor for Intimin to 
mediate intimate host-pathogen interactions (Kenny et al., 1997a; Campellone et al., 2004a). 
As previously discussed, phosphorylation of two serine residues, S434 and S463, is linked to 
shifts in apparent molecular mass and membrane insertion as well as efficient pedestal 
formation (Warawa and Kenny, 2001). Phosphorylation on two tyrosine residues, Y454 and 
Y474, is linked to actin nucleation by inefficient and efficient mechanisms respectively. Most 
is known about the latter process, as phosphorylation of residue Y474 recruits an adaptor 
protein, Nck, which in turn recruits N-WASP to sequester the Arp2/3 actin nucleating 
machinery inducing pedestal formation (Kenny, 1999; Gruenheid et al., 2001; Campellone et 
al., 2002). Previous research has examined the anti-phagocytosis capacity of tir and eae mutant 
strains revealed an intermediate anti-phagocytosis activity compared to EPEC (Goosney et al., 
1999). However, other studies could not confirm a role in the phagocytosis inhibition for either 
of them (Celli et al., 2001; Quitard et al., 2006) .  
The other two LEE effector molecules, Map (mitochondrial-associated protein) and 
EspF, target mitochondria and decrease mitochondrial membrane potential during EPEC 
infection leading to cell death (Kenny and Jepson, 2000; Nougayrède and Donnenberg, 2004; 
Nagai et al., 2005). Importantly, it has been shown that EPEC has the ability to inhibit its uptake 
which is dependent on a functional T3SS and the EspF effector protein (Quitard et al., 2006; 
Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 2011), but no essential role 
for Map was revealed (Quitard et al., 2006). However, the mechanism of EspF inhibition 
remains undefined (Quitard et al., 2006). 
Current knowledge of the effector EspH showed that its loss leads to prolonged 
filopodia formation concomitant with delayed pedestal formation. However, the over-
expression of EspH led to actin polymerization and pedestal elongation (Tu et al., 2003). 
Indeed, EspH inhibits uptake of EPEC by inhibiting the activity of RhoGEF which is 
responsible for regulating actin cytoskeleton dynamics (Dong et al., 2010). 
The core region also includes two chaperones, CesF and CesT, which are encoded on the LEE 
region. The main chaperone’s functions are regulating gene expression, supporting the effectors 
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trafficking with the T3SS at the inner membrane and stabilisation of the effector proteins within 
the bacterial cytosol (Cornelis et al., 1998; Elliott et al., 1999; Creasey et al., 2003). It has been 
demonstrated that CesF  binds only to the EspF effector protein (Elliott et al., 2002). In contrast, 
CesT binds and regulates the efficient translocation of at least twelve effector proteins, either 
fully (Tir, EspZ, EspH, Map, EspJ, NleG, NleH1 & NleH2) or partially (NleB1, NleB2, NleC 
& NleA) (Thomas et al., 2005; Mills et al., 2013).  
Previous research has demonstrated that LEE effectors have overlapping functions 
(redundancy) and can work cooperatively and/or antagonistically in subverting host cell 
activities (Dean and Kenny, 2009; Schmidt, 2010; Santos and Finlay, 2015). For example, the 
three effectors (Tir, Map and EspF) and the outer membrane protein Intimin act cooperatively 
to efface absorptive microvilli of enterocytes (Dean et al., 2006). This not only reflects the 
complexity of host pathogen interactions but also reveals the difficulty in determining the 
contribution of specific stimuli to subvert host cellular pathways such as inhibiting 
phagocytosis.  
The aim of this chapter was to examine the role of the core-encoded factors in inhibiting 
EPEC uptake by macrophages through screening a bank of available mutants in which 
implicated core region genes (encode Map, EspH, Tir, Intimin), plus the EspF-encoding gene, 
were inactivated in all combinations.  
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4.2 Results 
4.2.1 Unexpected role for Tir but not EspF or EspH in EPEC’s anti-phagocytic activity in 
the J774.A1 macrophage model 
The data presented in chapter 3 suggested that the LEE region encodes sufficient information 
to enable EPEC to inhibit its uptake by J774.A1 macrophages and discounted major roles for 
14 Nle effectors in phagocytosis inhibition. By contrast, studies with the espGorf3core/pcesF 
mutant implied that EspF capacity to inhibit phagocytosis depended on one or more factors 
encoded on the core LEE region i.e. three effectors (EspH, Map, Tir), Intimin or CesT; required 
for delivery of most LEE and many Nle effectors (Thomas et al., 2005; Mills et al., 2013). As 
CesT is required for the T3SS-dependent delivery of EspH, Map and Tir, studies were re-
focused to study the roles of the core-encoded effectors and Intimin protein by examining a 
bank of available mutants in which the genes encoding these proteins, as well as the EspF 
effector, were inactivated in all combinations (See Table 2; Materials and Methods).   
The usual anti-phagocytosis assay was carried out on each strain in at least three 
independent experiments, with many strains included in additional experiments while the 
control (EPEC and T3SS mutant) strains were assessed in over 20 experiments. The percentage 
internalisation for each experiment was recorded in a single file with the resulting mean (± SD) 
used to generated individual graphs for the single, doubles, triples and quadruple/quintuplet 
mutants alongside EPEC and T3SS mutant data. Examining the data from the single mutants- 
genotypes supported by PCR analysis (Figure 25A)- reveals, that as before, most T3SS mutant 
were internalised (78.2 ± 7.8%) in contrast to EPEC where only a minority (29 ± 5.8%) of 
bacteria were phagocytosed (Figure 25B). No significant difference in the percentage of uptake 
was identified for cells infected with EPEC and the map or eae mutant strains (Figure 25B). 
These results confirmed that the individual Map or Intimin proteins do not play critical roles in 
inhibiting EPEC phagocytosis by J774.A1 macrophages (Quitard et al., 2006). By contrast, 
infection of cells with the tir mutant resulted in   a small but significant (p< 0.001) anti-
phagocytic defect (42.9 ± 6.8% versus 29 ± 5.8% EPEC internalised) indicating a minor role in 
EPEC’s anti-phagocytosis activity, consistent with a previous study (Goosney et al., 1999).  
As the tir mutant is missing residues 50-320 (followed by a stop codon) of this 550 
residue protein, it was possible that the short N-terminal polypeptide, that carries a T3SS signal 
sequence and host kinase-recruitment motif (Crawford and Kaper, 2002; Bommarius et al., 
2007), is delivered into cells and could interfere with the phagocytic process. Thus, a tirfull 
mutant was generated in which the entire gene (from start to stop codons) was deleted (see 
Materials and Methods) as supported by PCR analysis (Figure 26A). 
73 
 
 
 
Figure 25. Individual role for Tir but not Map, EspF, EspH or Intimin proteins in EPEC’s anti-phagocytic activity 
in the J774.A1 macrophage model. Indicated strains were used for (A) PCR analysis or to infect (B) J774.A1 
macrophages. (A) Oligonucleotides specific to the eae, map, espH, tir and espF gene were used in PCR analyses 
to determine the presence of an intact or deleted genes with PCR products visualised, alongside molecular mass 
markers 2-log (1000Kb ladder), on a 1% agarose gel. (B) J774.A1 macrophages were infected for 1 h (MOI 100:1) 
with indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria 
using antibodies to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages 
with 20-50 cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-
associated bacteria (Green) enabling the percentage internalisation to be calculated. (B) Quantification studies 
were carried out in a semi-blind manner with the percentage internalised bacteria displayed as the mean value (± 
standard deviation) from at least three independent experiments. * indicates statistically significant differences 
(one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* p< 0.0001, 3* p< 0.001). Strains 
used were EPEC and strains lacking a functional EspF (espF), EspH (espH), Map (map), Tir (tir), Intimin (eae) 
protein or T3SS (T3SS).
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Figure 26. Minor role for the Tir effector in EPEC’s anti-phagocytic activity in the J774.A1 macrophage model. 
Indicated strains were used for (A) PCR analysis or to infect (B) J774.A1 macrophages. (A) Oligonucleotides 
specific to the tir gene were used in PCR reaction to determine absence of intact tir gene with PCR products 
visualised, alongside molecular mass markers 2-log (1000Kb ladder), on a 1% agarose gel. (B) J774.A1 
macrophages were infected for 1 h (MOI 100:1) with indicated strains (pre-grown in DMEM for 3 h) prior to 
determining the percentage of internalised bacteria using antibodies to label extracellular bacteria (Red) and total 
cell-associated bacteria (Green). Fifty macrophages with 20-50 cell-associated bacteria were randomly chosen to 
count the number of extracellular and total cell-associated bacteria (Green) enabling the percentage internalisation 
to be calculated. Quantification studies were carried out in a semi-blind manner with the percentage of internalised 
bacteria displayed as the mean value (± standard deviation) from at least three independent experiments. * indicates 
statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* 
p< 0.0001, 3* p< 0.001, 2* p< 0.01). Strains used were EPEC, tir (tir partially deleted), tirfull (tir fully deleted) 
and T3SS (T3SS-deficient).
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Similar to the tir strain, infecting J774.A1 macrophages with the tirfull mutant again led to 
similar,  intermediate, anti-phagocytosis activity (43.8 ± 6.5% of bacteria internalised; Figure 
26B).  
Surprisingly, studies with the espF mutant revealed that this strain behaved in a manner 
indistinguishable to the wildtype, EPEC, strain (Figure 25B) in contrast to its published critical 
role in EPEC’s anti-phagocytic activity (Quitard et al., 2006; Martinez‐Argudo et al., 2007; 
Marchès et al., 2008; Tahoun et al., 2011) and earlier demonstration of an espF/pGFP strain 
failing to inhibits its uptake by J774.A1 macrophages (Figure 14, Chapter 3). The EPEC-like 
phenotype with this espF mutant was predicted to reflect an acquisition of mutations that 
restored its anti-phagocytic activity. Thus, studies examined the anti-phagocytic activity of 
espF mutant strains (espF1-3) available in frozen culture stocks of previous laboratory members. 
PCR analysis confirmed that each strain lacked an intact espF gene (Figure 27A) with 
phagocytic assays revealing EPEC-like phenotypes for each (Figure 27B). Thus, this finding 
contrasts to earlier studies (Figure 14, Chapter 3) and work with espF-deficient mutants 
(generated in this and/or other laboratories) using cultured macrophages; M-cell model and/or 
in vivo studies (Quitard et al., 2006; Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun 
et al., 2011).  
Surprisingly, the examined espH::Km mutant displayed no significant defect in the anti-
phagocytic assay (Figure 25A) in contrast to its reported inability to inhibit phagocytosis (Dong 
et al., 2010). Thus, studies examined another available (NalS) espH::Km mutant (Tu et al., 
2003) which was found to behave in a near identical manner (Figure 28). To support these 
findings, the espH mutant used in the study illustrating EspH’s anti-phagocytic activity (Dong 
et al., 2010) was requested but unfortunately it displayed binding issues leading to, a kindly 
provided suicide vector (Dong et al., 2010), being used to generate a new (NalR) espHAA mutant 
(see Materials and Methods). This espHAA mutant lacking a functional espH gene was 
supported by PCR analyses (Figure 29A) and found to behave in a statistically indistinguishable 
manner to the wild type, EPEC, strain (Figure 29A).  
In conclusion, these results unexpectedly failed to support essential roles for EspF and 
EspH effectors for EPEC to inhibit its uptake by J774A.1 macrophages but revealed a minor 
role for Tir while confiming no roles for Map or Intimin. 
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Figure 27. No detectable roles for the EspF effector in EPEC’s capacity to inhibit its uptake by J774.A1 
macrophages. Indicated strains were used for (A) PCR analysis or to infect (B) J774.A1 macrophages. (A) 
Oligonucleotides specific to espF gene were used in a PCR reaction to determine the presence of an intact 
(~500bp) or deleted espF gene with PCR products visualised, alongside 2-log molecular mass markers on 
a 1% agarose gel. (B) J774.A1 macrophages were infected for 1 h (MOI 100:1) with indicated strains (pre-
grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria using antibodies to 
label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages with 20-50 
cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-associated 
bacteria (Green) enabling the percentage internalisation to be calculated. (B) Quantification studies were 
carried out in a semi-blind manner. Strains used were EPEC, T3SS-deficient (T3SS) mutant, previously 
used EspF-deficient mutant (espF) plus espF mutants taken from frozen culture stocks of former laboratory 
workers (espF1-3).  
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Figure 28. EPEC does not require an intact espH gene to inhibit its uptake by J774.A1 macrophages. Indicated 
strains were used for investigations to support their genotype by (A) confirming expected antibiotic resistance 
profile and (B) PCR analysis prior to use for infection of (C) J774.A1 macrophages. (A) The genotypes of the two 
espH mutants (espH NalR/KmR and espH NalS/KmR) were confirmed with antibiotic selective plates. (B) 
Oligonucleotides specific to espF and espH genes were used in PCR analyses to determine the presence of an 
intact or deleted genes with PCR products visualised, alongside 100bp and 1Kb molecular mass markers, on a 1% 
agarose gel. The oligonucleotides were specific to regions within the espH gene and, thus, absent from espH::Km 
variants. (C) J774.A1 macrophages were infected for 1 h (MOI 100:1) with indicated strains (pre-grown in DMEM 
for 3 h) prior to determining the percentage of internalised bacteria using antibodies to label extracellular bacteria 
(Red) and total cell-associated bacteria (Green). Fifty macrophages with 20-50 cell-associated bacteria were 
randomly chosen to count the number of extracellular and total cell-associated bacteria (Green) enabling the 
percentage internalisation to be calculated. (C) Quantification studies were carried out in a semi-blind manner with 
the percentage of internalised bacteria displayed as the mean value (± standard deviation) from at least three 
independent experiments. * indicates statistically significant differences (one-way ANOVA with Dunnett’s post-
hoc test) compared to EPEC data (4* p< 0.0001) or by Tukey's test for multiple comparisons between strains (ns 
not significant). Strains used were EPEC, T3SS-deficient (T3SS), espH NalR/KmR and espH NalS/KmR (EspH 
deficient) mutants. 
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Figure 29. Confirming that EspH dose not play critical role in inhibiting phagocytosis. Indicated strains were used 
for (A) PCR analysis or to infect (B) J774.A1 macrophages. (A) Oligonucleotides specific to espH gene were used 
in a PCR reaction to determine the presence of an intact (~600bp) or deleted espH gene with PCR products 
visualised, alongside 2-log molecular mass markers on a 1% agarose gel. (B) J774.A1 macrophages were infected 
for 1 h (MOI 100:1) with indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of 
internalised bacteria using antibodies to label extracellular bacteria (Red) and total cell-associated bacteria (Green). 
Fifty macrophages with 20-50 cell-associated bacteria were randomly chosen to count the number of extracellular 
and total cell-associated bacteria (Green) enabling the percentage internalisation to be calculated. Quantification 
studies were carried out in a semi-blind manner with the percentage of internalised bacteria displayed as the mean 
value (± standard deviation) from at least three independent experiments. * indicates statistically significant 
differences (one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* p< 0.0001, ns not 
significant). Strains used were EPEC and strains lacking a functional EspF (espF), espHAA (espH), Map (map), 
Tir (tir), Intimin (eae) protein or T3SS (T3SS).
A B 
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4.2.2 Double mutant data uncovers cooperative relationships enabling EPEC to inhibit its 
uptake by J774.A1 macrophages  
Examining the double mutant (10 strains) data revealed some strains to be linked to a much 
higher level of outlier data (i.e. mean of an experiment distinctly different to other repeats which 
cluster together; Table 8, Figure 30A). Thus, while there was only one outlier per 28 (3.5%) 
EPEC and 17 (5.9%) T3SS mutant experiments there was one in four (25%) for the eh, tm 
mutants and one in six (16.6%) for th mutant (Figure 30A) leading to removal of the outlier 
with the resulting data (Figure 30B) used for statistical analysis. Remarkably, one double (ft) 
mutant behaved very unusually as 3 (of 6) data points clustered to provide an EPEC-like 
phenotype (37.7 ± 3.7% versus 29 ± 6%) while the remaining three in a T3SS mutant-like 
clustering (67.9 ± 2.5% versus 78.2 ± 7.9%; Figure 30B). The latter results indicates that 
deleting both EspF and Tir may cause some sort of instability in the anti-phagocytic assay. It 
should be noted that the genotype of each double mutant was supported by PCR analyses 
(Figure 30C).  
Interestingly, the data of only three double mutants was statistically indistinguishable 
(mh, fm) or very close (me; p<0.05) to the positive (EPEC) control data (Figure 30B), consistent 
with the single (m, f, h, e) mutant data (Figure 25B). By contrast, the remaining (7) double 
mutants displayed major, statistically significant (p<0.0001; Figure 30B), defects with one (fh) 
as defective as the T3SS mutant while a slightly reduced, but significant, defect was evident for 
the other double mutants except et and ft; the latter due to two distinct data clusters (Figure 
30B). This data is suggestive of EspF/Tir; Intimin/Tir; Tir/EspH; Intimin/EspH; EspF/Intimin; 
Tir/Map and EspF/EspH cooperatively promotes EPEC’s ability to inhibit its uptake by 
J774A.1 macrophages. 
A concern for the four espF-related double mutants stemmed from the fact that they 
were generated (Kenny Unpublished) from an espF mutant which inhibited phagocytosis 
(Quitard et al., 2006; Martinez‐Argudo et al., 2007) but not in this study. Therefore, these 
double mutants were re-made using the espF mutant assayed in this study, producing fmAA, ftAA, 
feAA and fhAA (See Materials and Methods). PCR analysis supported the correct genotype of 
these newly-generated double mutants (Figure 31A). It should be noted that strain name reflects 
the order genes were disrupted; for example, fh reveals espH gene inactivated from the espF 
mutant background. 
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Figure 30. Examining double mutant reveals cooperative relationships in EPEC’s ability to inhibit its uptake by 
J774.A1 macrophages. Indicated strains were used to infect (A&B) J774.A1 macrophages with, post-infection, 
non-adherent bacteria isolated for (C) PCR analysis. (A&B) J774.A1 macrophages were infected for 1 h (MOI 
100:1) with indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised 
bacteria using antibodies to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty 
macrophages with 20-50 cell-associated bacteria were randomly chosen to count the number of extracellular and 
total cell-associated bacteria (Green) enabling the percentage internalisation to be calculated. (A&B) 
Quantification studies were carried out in a semi-blind manner with the percentage of internalised bacteria 
displayed as the mean value (± standard deviation) from at least three independent experiments. The data from 
each independent experiment is shown (◊) with outliers (  ) removed providing data (B) used for statistical analysis. 
* indicating statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to 
EPEC data (1* p< 0.05, 4* p< 0.0001, ns not significant; B).* indicates statistically significant differences (one-
way ANOVA with Dunnett’s post-hoc test) compared to T3SS data (1* p< 0.05, 2* p< 0.01, 4* p< 0.0001, ns not 
significant). (C) Oligonucleotides specific to eae, map, espH, tir and espF genes were used in PCR analyses to 
determine the presence of an intact or deleted genes with PCR products visualised, alongside molecular mass 
markers 2-log (1000Kb ladder), on a 1% agarose gel. Studies used EPEC and strains lacking a functional T3SS 
(T3SS) or two LEE proteins: EspF and EspH (fh; #1 in C), EspF and Intimin (fe; #2 in C), EspF and Map (fm; #3 
in C), EspF and Tir (ft; #4 in C), Tir and EspH (th; #5 in C), Tir and Map (tm; #6 in C), Map and EspH (mh; #7 in 
C),Map and Intimin (me; #8 in C), Intimin and EspH (eh; #9 in C). It should be noted that PCR supporting et 
mutant genotype was not demonstrated here but see Figure 33A.  
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Table 8. Percentage internalised data for indicated double, triple, quadruple and quintuplet mutant bacteria with 
data in red considered to be an outlier. The mean (Av) and standard deviation (SD) data is given for data including 
or excluding the indicated outliers with columns indicating the number of independent experiments (# of n) and 
outliers in the data sets.  
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Figure 31. Examining newly generate espF-related double mutants. Indicated strains were used for (A) PCR 
analysis or to infect (B) J774.A1 macrophages. (A) Oligonucleotides specific to eae, map, espH, tir and espF genes 
were used in PCR analyses to determine the presence of an intact or deleted genes with PCR products visualised, 
alongside molecular mass markers 2-log (1000Kb ladder), on a 1% agarose gel. (B) J774.A1 macrophages were 
infected for 1 h (MOI 100:1) with indicated strains (pre-grown in DMEM for 3 h) prior to determining the 
percentage of internalised bacteria using antibodies to label extracellular bacteria (Red) and total cell-associated 
bacteria (Green). Fifty macrophages with 20-50 cell-associated bacteria were randomly chosen to count the 
number of extracellular and total cell-associated bacteria (Green) enabling the percentage internalisation to be 
calculated. (B) Quantification studies were carried out in a semi-blind manner with the percentage internalised 
bacteria displayed as the mean value (± standard deviation) from at least three independent experiments (except 
fmAA and ftAA where only from two independent experiments) with data from each independent experiment shown 
(◊).* indicates statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to 
EPEC data (4* p< 0.0001, ns not significant; B). Studies used EPEC and strains lacking functional proteins EspF 
and Intimin (fe, feAA), EspF and EspH (fh, fhAA), EspF and Map (fm, fmAA), EspF and Tir (ft, ftAA) plus T3SS-
deficient (T3SS) mutants. Strains labelled ‘AA’ are newly generated with data for other strains taken from Figure 
31B. 
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Assessing these new double mutants revealed (Figure 31B) similar findings for the new fmAA 
mutant (37.1 [n=2] versus 37.6 ± 5.5% [n=3]), while the new ftAA mutant displayed an T3SS 
mutant like phenotype (62 [n=2]) that contrasts to the ‘dual’ phenotype of the original mutant 
(37.7 ± 3.7% [n=3 of 6] and 67.9 ± 2.5% [n=3 of 6]; Figure 31B). By contrast, the new fhAA 
mutant displayed an intermediate defect (45.5 ± 7.5% [n=3]) contrasting with 76 ± 8% [n=5] 
for the fh mutant (Table 8) whereas the newly generated feAA mutant produced variable data 
(48.8 ± 17.7% [n=3; ~45, 68, 34%]) in contrast to original fe mutant (66.8 ± 7.3% [n=3]). 
Despite this variability, the data supports the idea that EspF functions together with either 
Intimin, Tir or EspH (but not Map) proteins to promote EPEC’s capacity to inhibit its uptake 
by J774.A1 macrophages.  
Moreover, a potentially important role for Tir and Intimin cooperativity functions in 
EPEC’s anti-phagocytic activity as supported by finding that the newly generated et double 
mutant (etAA)- genotype supported by PCR analysis (Figure 32A)- had a similar defect to the 
original double mutant (56.2 ± 8 [n=3] versus 59 ± 6.6% [n=5]; Figure 32B). Support for the 
phagocytic-defective of the remaining double mutants (fe, th, eh, tm, et) was obtained, due to 
time constraints, using a different strategy i.e. assessing if plasmid re-introducing a missing 
gene led to an EPEC-like phenotype by visual observations of the ‘Red’ (extracellular) and 
‘Green’ (total cell-associated) bacterial signals with findings only used if the identify of control 
(EPEC and T3SS mutant) strains were, in semi-blind studies, correctly defined. This work 
confirmed the expectation that introducing Intimin or Tir expressing plasmids into the et mutant 
led to an EPEC-like phenotype. Similarly, introducing a plasmid-expressing Intimin in the fe 
double mutant and Tir or Map into the tm double mutants resulted in EPEC-like phenotype in 
contrast to the T3SS mutant-like signal for the negative controls (T3SS and double mutants). 
While plasmid-expressing Tir in the th double mutant resulted in EPEC-like phenotype, 
plasmid-expressing EspH in the same double mutant resulted in an intermediate phenotype in 
contrast to the T3SS mutant. It should be re-iterated that strain identify was only revealed after 
the assessment was completed. Due to the time constraint, no data was generated with the fe 
mutant carrying an EspF expressing plasmid, thus, further work is needed to complement the 
fe double mutant with plasmid-expressing EspF and other possible complementation of the 
combinations.  
Collectively, this work argues for important cooperative, but redundant, roles for 
Intimin and EspH (eh mutant), EspF and Tir (ft mutant), Tir and Map (tm mutant), Intimin and 
Tir (et mutant), EspF and EspH (fh mutant), EspF and Intimin (fe mutant), Tir and EspH (th 
mutant) but not Map and Intimin (me mutant), Map and EspH (mh mutant) or EspF and Map 
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Figure 32. Confirming critical cooperative roles for Intimin and Tir proteins in promoting EPEC’s capacity to 
inhibit its uptake in the J774.A1 model. Indicated strains were used for (A) PCR analysis or to infect (B) J774.A1 
macrophages. (A) Oligonucleotides specific to eae, map, espH, tir and espF genes were used in PCR analyses to 
determine the presence of an intact or deleted genes with PCR products visualised, alongside molecular mass 
markers 2-log (1000Kb ladder), on a 1% agarose gel. (B) J774.A1 macrophages were infected for 1 h (MOI 100:1) 
with indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria 
using antibodies to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages 
with 20-50 cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-
associated bacteria (Green) enabling the percentage internalisation to be calculated. (B) Quantification studies 
were carried out in a semi-blind manner with the percentage of internalised bacteria displayed as the mean value 
(± standard deviation) with data from each independent experiment shown (◊).* indicates statistically significant 
differences (one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* p< 0.0001, 3* p< 0.001 
and ns not significant) or by Tukey's test for multiple comparisons between strains (ns not significant; B). Studies 
used EPEC and strains lacking functional proteins Intimin and Tir (et and etAA), Tir (tir), Intimin (eae) and T3SS 
(T3SS). Strains labelled ‘AA’ are newly generated with data for other strains taken from Figure 30.
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(fm mutant) for EPEC to inhibits its uptake in this J774A.1 model. However, the finding that 
the phagocytosis defect associated with most double mutants was not as great as the T3SS 
mutant (1* p< 0.05, 2* p< 0.01, 4* p< 0.0001, ns not significant; Figure 30B) is suggestive of 
contributions of other factors. 
4.2.3 Additional complexity in EPEC’s anti-phagocytic activity  
 Examination of the ten triple mutant data, from three to six independent experiments, revealed 
outlier data with four (20% rate for feh, fth and eth mutants with 30% for the fme triple mutant; 
Table 8, Figure 33A) with the data also presented lacking the outliers (Figure 33B). As before, 
strain genotype was supported by PCR analysis of bacteria obtained from post macrophage 
infection (Figure 33C). Examining the triple mutant (include outlier) data revealed only one 
triple (fmh) mutant was statistically indistinguishable or very close (feh and fme; p<0.05) to the 
positive (EPEC) control data (Figure 33A). By contrast, the remaining (5) triple mutants 
displayed major, statistically significant (p<0.0001; Figure 33B), defects with a slightly 
reduced, but significant, defect was evident for two triple mutants (meh and tmh) (Figure 33B). 
Statistical analysis (after outlier data deletion) revealed only one triple (feh) mutant to behave 
like EPEC which is in contrast to prominent defects for the related double (fe, fh, eh) mutant 
strains (Figure 30B). One triple mutant (fme) had small, but statistically significant (Figure 
33B), defects similar to two, of three, of the corresponding double (fm/me; Figure 30B, Table 
8) but contrasts to prominent defects of the other double (fe; Figure 30B, Table 8) mutant. The 
remaining triple mutants had large defects, similar to the quintuplet (etmfh) mutant (Table 8), 
but significantly less than the T3SS mutant Figure 33B, Table 8).  The triple mutant data could 
be placed into three distinct classes: first class contain fet, fth and eth which share a similar 
phenotype to the corresponding double mutants (Figure 34). For example, the fet triple mutant 
(66.3 ± 4.5% internalisation) behaves like the et (59 ± 6.6%), fe (66.8 ± 7.3%) and half of the 
ft (58.2 ± 14.5%) double mutants. It should be noted that we used the T3SS-like ft (n=3), not 
EPEC-like (n=3), data and that this phenotype ‘instability’ was not evident with the fet triple 
mutant suggesting that it relates to Intimin protein expression in the ft genetic background. 
The second class contains the tmf, etm and tmh triple mutants which had similar defects 
to two of their related double mutants while the remaining double mutant had significant anti-
phagocytic activity (Figure 35, Table 8). For instance, the tmf mutant (68.4 ± 5.4% 
internalisation) behaved like the tm (67.5 ± 2.5%) and ft (58.2 ± 14.5%) mutants but not fm 
(36.7 ± 5.5%) mutant. Again, specific to this example, we used the T3SS-like ft (n=3), not 
EPEC-like (n=3), data with phenotype ‘instability’ for the tmf triple mutant suggesting that it 
may also relate to Map protein expression in the ft genetic background.  Moreover, the data  
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Figure 33. Additional complexity behind EPEC’s ability to inhibit phagocytosis demonstrated by triple data. 
Indicated strains were used to infect (A&B) J774.A1 macrophages with, post-infection, non-adherent bacteria 
isolated for (C) PCR analysis. (A&B) J774.A1 macrophages were infected for 1 h (MOI 100:1) with indicated 
strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria using antibodies 
to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages with 20-50 cell-
associated bacteria were randomly chosen to count the number of extracellular and total cell-associated bacteria 
(Green) enabling the percentage internalisation to be calculated. (A&B) Quantification studies were carried out in 
a semi-blind manner with the percentage of internalised bacteria displayed as the mean value (± standard deviation) 
from at least three independent experiments. The data is also shown lacking outliers   (B) and used for statistical 
analysis with * indicating statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) 
compared to EPEC data (1* p< 0.05, 2* p< 0.01, 3* p< 0.001, 4* p< 0.0001 and ns not significant; A&B). * 
indicates statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to T3SS 
data (1* p< 0.05, 2* p< 0.01, 4* p< 0.0001; B). (C) Oligonucleotides specific to eae, map, espH, tir and espF 
genes were used in PCR analyses to determine the presence of an intact or deleted genes with PCR products 
visualised, alongside molecular mass markers 2-log (1000Kb ladder), on a 1% agarose gel. Studies used EPEC 
and strains lacking a functional T3SS (T3SS) or three LEE proteins: EspF, Map and Intimin (fme; #1 in C), EspF, 
Tir and EspH (fth; #2 in C), EspF, Intimin and EspH (feh; #3 in C), EspF, Map and EspH (fmh; #4 in C), Map, 
Intimin and EspH (meh; #5 in C), Tir, Map and EspF (tmf; #6 in C), EspF, Intimin and Tir (fet; #7 in C), Tir, Map 
and EspH (tmh; #8 in C), Intimin, Tir and EspH (eth; #9 in C), Intimin, Tir and Map (etm; #10 in C).  
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Figure 34. Class 1 mutant strains have T3SS mutant-like phenotypes similar to related double mutants. Shown 
data is mean data with SD in brackets and number of independent experiments indicated (underlined). It should be 
noted that we used the T3SS-like ft (n=3), not EPEC-like (n=3) for comparison with triple mutant. 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                     
Figure 35. Class 2 mutant strains have T3SS mutant-like phenotypes that contrasts to one of the three 
corresponding double mutants. Shown data is mean data with SD in brackets and number of independent 
experiments indicated (underlined). 
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suggests that the phagocytic activity of the fm, me and mh double mutants depends on Tir 
activities.  
The final class only contains the meh triple mutant (51.4 ± 3.3%) which shared a similar 
defect to only one of the double mutants (eh [64.6 ± 7.7%]) with the others (mh [36.3 ± 10.7%], 
me [39.6 ± 8.4%]) displaying an EPEC-like phagocytic phenotype (Figure 36, Table 8).   
The eh mutant defect contrasts to the significant phagocytic activity of the meh triple 
mutant suggesting the Map suppresses the anti-phagocytic activity of other EPEC proteins, 
presumably Tir or EspF (as eh mutant defect similar to that of the etmfh mutant; Table 8) present 
in meh triple mutant contrasts to prominent defects of the other double (fe and fh respectively; 
Figure 30B, Table 8) mutants.   
Interestingly, all but one (tmfh [n=5]) of the more complex multi-mutants 
(quadruple/quintuple) was not associated with outlier data with a 20% rate for the etmfh (n=5), 
~17% for etmh (n=5) and feth (n=5) with only 5% for etmf (n=19) mutants (Figure 37A, Table 
8) with the data also present lacking these outliers and used for statistical analysis (Figure 37B).   
As usual, strain genotype was supported by PCR analysis of bacteria (Figure 37C) 
obtained, at the end of an experiment, from infected wells. While each multi-mutants displayed 
a significant defect, relative to EPEC, two strains (fmeh, etmh) appeared to retain significantly 
anti-phagocytic activity compared to the feth and etmf mutants which behaved like the 
quintuplet, etmfh (63.9 ± 8.9% internalised), strain (Figure 37B). The latter findings suggest 
that the fmeh and tmfh mutant’s anti-phagocytic activity depends on the remaining proteins (Tir 
and Intimin respectively). However, interpretation of the final quadruple mutant (tmfh) is 
hindered by phenotype instability; 3 data points cluster around ~38% and two ~70% (Figure 
37B). Interestingly, each multi-mutant was significantly more phagocytic than the T3SS mutant 
indicating the presence of additional, T3SS-dependent, factors that can inhibit EPEC uptake 
(Figure 37B).  
The multi-mutants also fell into three distinct classes with the first (Figure 38) 
containing only one member (fmeh; 39.1± 10% internalisation) which retains significant levels 
of anti-phagocytic activity similar to each of the four related triple mutants - fmh (42.4 ± 6.1%), 
fme (39.7 ± 5.5%), feh (34.7 ± 4.8 %), meh (47.1 ± 9.0 %) – and thus does not identify any extra 
inter-relationships. This work suggests, as mentioned above, that the fmeh mutant’s phagocytic 
activity is Tir dependent. 
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Figure 36. Class 3 mutant strains have T3SS mutant-like phenotypes similar to only one of the three corresponding 
double mutants. Shown data is mean data with SD in brackets and number of independent experiments indicated 
(underlined). 
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Figure 37. Additional complexity in EPEC’s capacity to inhibit its uptake by J774.A1 macrophages. Indicated 
strains were used to infect (A&B) J774.A1 macrophages with, post-infection, non-adherent bacteria isolated for 
(C) PCR analysis. (A&B) J774.A1 macrophages were infected for 1 h (MOI 100:1) with the indicated strains (pre-
grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria using differential antibody 
staining to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages with 20-
50 cell-associated bacteria were randomly chosen to count the number of ‘Red’ and ‘Green’ bacteria. 
Quantification studies were carried out in a semi-blind manner with the percentage internalised bacteria displayed 
as the mean value (± standard deviation) with data from each independent experiment shown (◊) with outliers (  ) 
removed providing data (B) used for statistical. * indicates statistically significant differences (one-way ANOVA 
with Dunnett’s post-hoc test) compared to EPEC data (2* p< 0.01, 4* p< 0.0001; B). * indicates statistically 
significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to T3SS data (4* p< 0.0001; 
B). (C) Oligonucleotides specific to eae, map, espH, tir and espF genes were used in PCR reactions to determine 
the presence or absence of intact genes. The PCR products were visualised, alongside 2-log molecular mass 
markers on a 1% agarose gel. Studies used EPEC and strains lacking a functional T3SS (T3SS) or four or five of 
the LEE proteins Map (m), Intimin (e), EspH (h), Tir (t), and/or EspF (f). Note strain name indicates order genes 
were inactivated, for example, etmfh reveals gene encoding Intimin was disrupted first, then Tir, then Map, then 
EspF and finally EspH. 
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Figure 38. Class 1 mutant strain has significant anti-phagocytic activity similar to related triple mutants. Shown 
data is mean data with SD in brackets and number of independent experiments indicated (underlined).  
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The second class (Figure 39) contains the feth (58.1 ± 6.5%) and etmf (68.5 ± 4.4%) mutants as 
sharing a similar defect with three triple mutants with the fourth displaying significantly more 
phagocytic activity i.e. feh (34.7 ± 4.8%) and fme (39.7 ± 5.5%) respectively. The latter 
differences suggest that the feh and fme mutant’s anti-phagocytic activity depends on Tir.   
The final group (Figure 40) contains the etmh (48.4 ± 6.1% internalisation) and tmfh 
(50.5 ± 17.6%) mutants which apparently have significantly more anti-phagocytic activity than 
several corresponding triple mutants (etm [61.8 ± 8.3%]/eth [60.4 ± 7.4%] and tmf [68.4 ± 
5.4%]/fth [62.1 ± 8.7%] respectively) and the quintuple (etmfh [63.9 ± 8.9%]) mutant. The latter 
implies that the anti-phagocytic activity of the etmh and tmfh mutants depends on the remaining 
proteins (EspF and Intimin respectively) whose contributions are suppressed by Map and/or 
EspH.   
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Figure 39. Class 2 mutant strains have T3SS mutant-like phenotypes that contrasts to one of the four corresponding 
triple mutants. Shown data is mean data with SD in brackets and number of independent experiments indicated 
(underlined).  
 
 
 
 
 
 
 
 
 
Figure 40. Class 3 mutant strains have significant anti-phagocytic activity in contrast to several related triple 
mutants which display T3SS mutant-like phenotypes. Shown data is mean data with SD in brackets and number 
of independent experiments indicated (underlined).
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4.3 Discussion 
EPEC’s ability to inhibit PI 3-kinase dependent phagocytosis has been linked to the subversive 
activity of the LEE-encoded EspF, EspH EspB and EspG effector proteins (Quitard et al., 2006; 
Iizumi et al., 2007; Dong et al., 2010; Humphreys et al., 2016). Previous data (Chapter 3) 
suggests that EspF alone is not sufficient to inhibit EPEC uptake and this may require the LEE 
core region-encoded effectors (Tir, Map, EspH) and/or the Intimin surface protein to aid in the 
process. Screening of mutants in which genes encoding these five proteins were inactivated in 
all combinations, linked disruption of some genes with phenotype instability and, surprisingly, 
failed to support critical roles for EspF or EspH effectors. Indeed, this work suggests that EspF 
and EspH have indirect roles in EPEC’s anti-phagocytic activity and phenotype instability. 
Crucially, the work in this thesis shows EPEC’s anti-phagocytic activity (in the J774A.1 model) 
is dependent either on the function of Tir or Intimin (redundant roles) and reveals unknown 
complexity behind EPEC’s ability to inhibit its uptake by macrophages. 
The critical role of EspF in inhibiting EPEC uptake by macrophages or M-cells has been 
demonstrated in many studies (Quitard et al., 2006; Martinez‐Argudo et al., 2007; Marchès et 
al., 2008; Tahoun et al., 2011). Indeed, while this idea was supported by my initial studies using 
an espF mutant (carrying a GFP expressing plasmid; chapter 3 Figure15), the screening studies 
conducted with the espF mutant (no GFP plasmid) revealed the mutant to behave like EPEC. 
A possible explanation for the these findings include the deleterious effects of GFP expression 
as previously reported in in vivo (Krestel et al., 2004; Agbulut et al., 2007) and in vitro 
(Hanazono et al., 1997; Liu et al., 1999), that may affect espF mutant’s ability to inhibit 
phagocytosis. This unexpected finding was supported by studies with espF clones obtained 
from frozen stock collections of former lab members thereby arguing against the difference 
stemming from acquisition of genetic alterations. Indeed, a high level of stability has been found 
in the EPEC genome (Donnenberg et al., 2015) and clones came from the same ‘founder’ stock. 
Crucially, EspF’s anti-phagocytic activity has been demonstrated in other laboratories (Quitard 
et al., 2006; Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 2011), using the 
espF mutant obtained from our group (Quitard et al., 2006; Martinez‐Argudo et al., 2007), 
while others initially failed to define a phagocytic defect (Celli et al., 2001).  
This phenotype instability is possibly due to alterations in the infection model, for 
example, macrophage passaging-induced alterations (genetic or epigenetic incorporated into 
new frozen stocks) and/or reagent variability (especially cytokine-rich Foetal Calf Serum as 
known batch-to-batch variability) (Bhatt et al., 2011; Baker, 2016). However, we predict that 
the phenotype instability relates to EPEC, as inactivating multiple genes was linked to 
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increasing number of outlier data. Thus, while outlier data was relatively rare for EPEC, for 
T3SS and single mutants (0-6% rate) there was a 20-30% rate for some multi-mutants. Whereas 
one double mutant (ft) displayed an 50% outlier rate i.e strain acting like the T3SS mutant in 
half the experiments and like EPEC in the others. The fact that these strains sometimes 
displayed wild type phenotype (although it is not consist), implies they do possess inhibitory 
activity(ies) but cannot always deploy them. This could be due to experimental/environmental 
differences impacting on the expression and/or activity of key factors (T3SS, LEE effectors, 
Intimin) and/or the delivery of all, or specific effectors. Indeed, LEE protein expression is 
known to be regulated not only at the transcriptional level but also post-transcriptional and post-
translational levels (Bhatt et al., 2011). Interestingly, phenotypic instability seemed to be under 
the influence of Map and EspH activities as there was a 50% outlier rate for the ft (n=6) double 
mutant decreasing to 20% for the fth (n=5) triple and 0% for tmfh (n=5) quadruple mutant. 
Further studies are needed to investigate this further and to determine where their impact is on 
EPEC (e.g. influencing protein expression/delivery) or the host cells (e.g. altering cellular 
process with direct/indirect impact on PI-3 kinase uptake pathway). A role for genetic 
alterations introduced during allelic exchange mediated gene knockout in some of the 
unexpected findings is possible as re-generating some multiple mutants, from original single 
mutants, did not always produce similar results.  For example ft instability was not evident with 
the ftAA (strain name indicates the order genes were inactivated) which now mimicked the T3SS 
mutant while a T3SS mutant phenotype of the original fh (n=5) double mutant was not 
reproduced by fhAA (n=3; 45.5 ± 7.5% internalisation versus 76 ± 8%). The genomes of the 
latter two strains have been sequenced but data reassembly and comparison analyses have not 
been completed. 
This study suggests that anti-phagocytosis, at least in the J774A.1 model, is a more 
complex process than recognised. As EspF, EspH and Map activities are not required for the 
process, unless under specific infection conditions or when EPEC lacks specific gene products 
- but is driven by the remaining interrogated factors; Intimin and Tir (via redundant and, 
possibly, cooperative mechanisms).  
While tir mutant, consistently displayed a higher level of internalisation than wild type, 
statistically significant, both et and etAA mutant strains consistently displaying a more 
prominent defect. In contrast, the eae mutant behaves like EPEC phenotype, suggests a more 
prominent role for Tir in the inhibitory processes consistent with a previous report (Goosney et 
al., 1999). The validity of our data is supported by the findings that: (i) a tm mutant strain is the 
only Map-deficient double mutant that failed to inhibit its uptake compared with T3SS, as Map 
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was excluded from inhibition process, supporting that EPEC dependent on Tir to inhibit its 
internalisation, (ii) the deletion of Tir from double and triple mutant strains (fm, mh, me, fme, 
feh) resulted in loss of the ability to inhibit phagocytosis (iii) the mutant strain which only 
expresses Tir (fmeh) demonstrated a greater level of anti-phagocytosis than the T3SS mutant, 
which indicates implicates an ability of Tir to inhibit EPEC uptake.  
Interestingly, while the quadruple etmf mutant consistently displayed the reported major 
defect in inhibiting phagocytosis (Quitard et al., 2006), this was mirrored by the newly-
generated et and quintuple etmfh mutants. None of these strains were as defective as the T3SS 
mutant, arguing for the existence of additional factors can also influence the macrophage uptake 
process. 
The complex data set raises many predictions for interrogation. For example, the work 
predicts that Tir or Intimin can drive anti-phagocytosis in the absence of the other three 
interrogated proteins and that Map, EspF and EspH activity can influence the Tir and/or 
Intimin-dependent anti-phagocytic processes. Moreover, the finding that the etmf anti-
phagocytic defect can be effectively  rescued by re-introducing espF (Quitard et al., 2006)(and 
this study), is surprising as the corresponding etm mutant behaves like the etmf mutant. The 
latter suggests that the EspF copy number is responsible for this difference with associated 
higher EspF delivery levels. Possibly, altering macrophage processes in a manner that makes 
the PI3 kinase-dependent phagocytic pathway more sensitive to inhibition by other delivered 
effectors i.e. the remaining interrogated gene product, EspH, and/or other effectors. Indeed, 
other data argues for Map, EspF and EspH being able to suppress EPEC’s anti-phagocytic 
activity. For example, the T3SS mutant phenotype of the eh double mutant contrasts with 
EPEC-like phenotype of the feh triple suggesting that the EspF, in this genetic background, 
suppresses the phagocytic activity of Map or, more likely, Tir. Indeed, Map suppresses the anti-
phagocytic activity of other effector molecules, as it presence in fe, fh and eth, allow mutant 
strains to demonstrate low anti-phagocytosis activity. In contrast, the absence of Map from 
mutant strains (fme, fmh and etmh) increased the anti-phagocytosis activity to a far greater 
extent than when expressed. There is also evidence for Intimin and EspH possessing 
suppressive roles, in specific genetic background.  
In summary, our studies argue that EPEC’s anti-phagocytic activity depends on the 
activity (redundant) of Tir or Intimin proteins with Map, EspF, EspH and, possibly, other 
effectors having activities that can impact on the anti-phagocytic process in manner influenced 
by environmental factors.
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Chapter 5. Preliminary investigations on EspF, 
Tir and Intimin’s roles in enabling EPEC to 
inhibit their uptake by J774.A1 macrophages 
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5.1 Introduction  
Work in the previous chapter implied that EspF has an indirect role in EPEC’s anti-
phagocytic activity while Tir or Intimin activities may drive the inhibitory process and 
thus the focus was on these three proteins.   
5.1.1 EspF  
EspF is a small (206 amino-acids) protein with the N-terminal 73 amino-acids containing 
three targeting signals: for T3S secretion (residues 1-20), targeting to mitochondria 
(MTS; residues 1-101) and the host nucleolus (residues 21-74) (Charpentier and Oswald, 
2004; Nagai et al., 2005; Dean et al., 2010b). Substitution of leucine 16 to glutamic acid 
(L16E) prevents EspF targeting the mitochondria (Nagai et al., 2005). By contrast, the 
rest of EspF is composed of three highly similar polyproline-rich repeat regions (PPR) 
(Figure 41A) (McNamara and Donnenberg, 1998). Each PPR has binding sites for sorting 
nexin 9 (SNX9) and N-WASP leading to a complex that remodels the host plasma 
membrane (Marchès et al., 2006; Alto et al., 2007). EspF has been reported to interact 
with at least 12 host proteins in several cellular compartments i.e. host cytoplasm, 
mitochondria, plasma membrane (apical and lateral surfaces) and nucleus (Dean and 
Kenny, 2009; Holmes et al., 2010). EspF is multifunctional linked to many subversive 
activites (Dean and Kenny, 2009). For instance, EspF targeting mitochondria is linked to 
permeabilise the mitochondrial membrane, which releases cytochrome c into the 
cytoplasm. The latter in turn activates caspases and triggers apoptosis as evidenced by 
phosphatidylserine on the cell surface, internucleosomal DNA cleavage and caspase 
cleavage of cytokeratins (Crane et al., 2001; Nagai et al., 2005). In vivo studies (mouse 
model with mouse-specific strain), linked cell death with EspF targeting mitochondria 
(Nagai et al., 2005). EspF activity is also linked to disease-associated processes such as 
(i) disrupting enterocyte-enterocyte interactions i.e. tight junctions thereby compromising 
barrier function, (ii) the elongation-associated loss/effacement of absorptive microvilli, 
(iii) altering activity of ion/nutrient/fluid transporters and (iv) inhibiting EPEC uptake by 
phagocytic Microfold (M-cells) (Dean et al., 2006; Guttman et al., 2006; Quitard et al., 
2006; Martinez‐Argudo et al., 2007; Hodges et al., 2008; Marchès et al., 2008; Peralta-
Ramirez et al., 2008; Dean and Kenny, 2009; Tahoun et al., 2011). Importantly, EspF can 
act with other effectors to subvert cellular processes, for example with Tir, Map and 
Intimin activities to disrupt intestinal barrier function and efface microvilli (Dean and 
Kenny, 2004; Dean et al., 2006).   
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Figure 41. Schematic representation of EspF and Tir effector proteins. (A) EspF is a 206 amino acid protein 
with its N-terminus (residues 1-20) required for secretion; while the mitochondrial targeting sequence 
(MTS, residues 1-24) is required for mitochondrial targeting with an essential leucine 16 residue; and a 
nucleolus targeting signal (residues 21-74). The remainder of the protein (C-terminus) is composed of three 
polyproline-rich repeat regions (PPR). Each PPR possess a number of eukaryote-like binding domains 
(sorting nexin 9 (SNX9) and N-WASP, respectively) that are thought to enable the recruitment of various 
host proteins. (B) Tir is a 550 amino acid protein with an extracellular domain (residues 254-363) that binds 
the EPEC surface protein intimin. The remaining residues of Tir are at the N-terminus (residues 1-233) and 
the C-terminus (residues 383-550), the latter located in the cytoplasm of the host and are the target of 
numerous kinases. Two serine residues, S434 and S463, are phosphorylated by protein kinase A, while 
Y474 phosphorylation is critical for Nck recruitment and N-WASP activation. This leads to Arp2/3-
dependent actin nucleation and consequently, pedestal formation. Moreover, Y454 phosphorylation leads 
to the recruitment of PI3-kinase (phosphatidylinositide 3-kinase). Recruitment of the latter kinase is 
associated with an increase of phosphatidylinositol (3, 4, 5)-trisphosphate, which is believed to cause 
pedestal elongation, aid bacterial attachment and inhibit cell death. Adapted from Dean and Kenny et 
al.,(Dean and Kenny, 2009).
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Key to EspF’s subversive activity is its efficient translocation into host cells which 
depends on the chaperone CesF (Elliott et al., 2002). CesF promotes EspF stability within 
EPEC and its efficient translocation into cells but is not needed for T3SS-dependent 
secretion of EspF into the extracellular milieu (Elliott et al., 2002). While previous studies 
have demonstrated a key role for EspF to enable EPEC to inhibit its uptake in cultured 
macrophages and M-cells (in vitro and in vivo) models (Quitard et al., 2006; Martinez‐
Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 2011), studies argue against a 
need for EspF to target mitochondria or binding the SNX9 or N-WASP proteins in the 
anti-phagocytosis process (Quitard et al., 2006; Weflen et al., 2010; Young, 2013). By 
contrast, one study implicated a critical role for the N-terminal 101 residues: swapping 
this region for the first 101  residue of Tir led to a fusion protein, TirΔMTSEspF, that did 
not rescue the anti-phagocytic defect of an EspF-deficient strain (Quitard et al., 2006). 
The N-terminal 101 residues of Tir encode signals required for direct T3SS and binding 
to the Tir chaperone, CesT, as well as features linked to recruiting host kinases and 
cytoskeletal proteins (see below).  
 
5.1.2 Tir  
Tir delivery into cells leads to its insertion into the host plasma membrane to act as a 
receptor for Intimin linked to mediating intimate host-pathogen interactions and inducing 
subversive signalling leading to alterations including polymerisation of actin beneath 
adherent EPEC i.e. pedestal formation (Kenny et al., 1997a; Campellone et al., 2004a). 
Tir is a 550 amino acid protein with N- (residues 1-233) and C- (residues 383-550) 
terminal regions exposed to the host cytoplasm with an extracellular Intimin binding 
domain (residues 254-363) linked by two transmembrane domains (De Grado et al., 1999; 
Hartland et al., 1999; Kenny, 1999). 
As mentioned, the N-terminus contains a feature (polyproline-rich region) that 
recruits tyrosine kinases to phosphorylate a C-terminal-located tyrosine residue, Y474 
(Kenny, 2001a; Phillips et al., 2004; Swimm et al., 2004; Bommarius et al., 2007). The 
N-terminal domain is also linked to the recruitment of many cytoskeletal-related proteins 
(Bommarius et al., 2007). By contrast, the C-terminus has several known substrates for 
phosphorylation by host kinases, including protein kinase A (PKA) and tyrosine kinases. 
Phosphorylation on two serine residues, S434 and S463 (Figure 41B), is linked, as 
previously discussed, to shifts in apparent molecular mass and the membrane insertion 
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process as well as efficient pedestal formation (Warawa and Kenny, 2001). 
Phosphorylation on two tyrosine residues, Y454 and Y474, is linked to actin nucleation 
by inefficient and efficient mechanisms respectively. Most is known about the latter 
process where Y474 phosphorylation recruits an adaptor protein, Nck, which recruits N-
WASP to sequester the Arp2/3 actin nucleating machinery to induce pedestal formation 
(Kenny, 1999; Gruenheid et al., 2001; Campellone et al., 2002). Y454-associated actin 
nucleation occurs independently of  Nck (Campellone and Leong, 2005) but, leads to the 
recruitment of phosphatidylinositide 3-kinase (PI-3 kinase) and SHP2 (Selbach et al., 
2009). PI-3 kinase recruitment is linked to an increase of phosphatidylinositol (3, 4, 5)-
trisphosphate levels linked to promoting pedestal elongation, phagocytosis and inhibiting 
cell death (Franke et al., 1997; Selbach et al., 2009; Rosales and Uribe-Querol, 2017). Tir 
is also phosphorylated on Y484 and Y511 (ITIM-like motifs) linked to recruitment of 
SHIP-2 (SH2 domain-containing inositol 5-phosphatase) which suppresses signalling that 
induces anti-microbial responses (Yan et al., 2013). 
Importantly, most of Tir’s activities depend on the interaction with Intimin 
inducing intimate pathogen-host cell interaction, pedestal formation, microvilli 
effacement, disruption of enterocyte-enterocyte interactions and downregulation of Map 
activity, i.e. filopodia formation (Dean et al., 2006; Dean et al., 2013) and barrier 
disruption (Dean and Kenny, 2004; Dean et al., 2006; Dean et al., 2013). The latter event 
depends on an arginine finger-like motif linked to down-regulation of small GTPase 
activity with Map activating GTPases including Cdc42 and, indirectly, Rho (Kenny et al., 
2002; Berger et al., 2009).  
Intimin-independent Tir activity is only a recently discovery, and is linked to 
suppressing EspG subversive activities and inhibiting signalling that induces anti-
microbial and inflammatory responses (Dean et al., 2010a; Ruchaud-Sparagano et al., 
2011).   
 
5.1.3 Intimin  
Intimin is a 939-residue autotransporter protein encoded by the LEE eae gene and inserted 
into the bacterial outer membrane (Frankel et al., 1998; Fairman et al., 2012). The Intimin 
N-terminal region (residues 1–550) containing a signal peptide region, which is 
responsible for its secretion to the bacterial surface and mediating its binding to the 
peptidoglycan (Leo et al., 2015). Whereas its C-terminal region binds to Tir, and this 
interaction between Intimin and Tir is important for intimate interaction to the infected 
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host cells and pedestal formation in a Tir tyrosine phosphorylation dependent manner 
(Kenny and Finlay, 1997). While Intimin’s critical virulence role is related to its binding 
to Tir, it can also interact with host receptor proteins including β-integrin and nucleolin 
(Frankel et al., 1996; Sinclair and O'Brien, 2002) linked to cellular alterations (Muza-
Moons et al., 2003; Dean and Kenny, 2011). However, Intimin has also Tir independent 
functions in subverting host pathways. For example, both Intimin and Tir deficient 
mutants display an independent intermediate anti-phagocytosis activity compared with 
EPEC (Goosney et al., 1999). Indeed, Intimin has been shown to be essential for EspF 
and Map to disrupt the intestinal barrier function without being interact with Tir (Dean 
and Kenny, 2004).  
The aim of this chapter was to confirm contributions for EspF, Tir and Intimin 
proteins in EPEC’s anti-phagocytic activity and to identify important features and/or 
domains. 
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5.2 Results 
5.2.1 EspF’s anti-phagocytic activity is linked to the N-terminal domain but not to N-
WASP recruitment  
While the recent evaluation of an espF mutant revealed an EPEC-like phenotype, 
contrasting with the published T3SS-like phenotype (Quitard et al., 2006), an EspF-
deficient quadruple (etmf) mutant always displayed a major defect which could be rescued 
by introducing an EspF-expressing plasmid. To confirm this and reported no roles for 
EspF binding of N-WASP in contrast to N-terminal 101 residues, anti-phagocytosis 
assays were carried out with the A3 variant which lacks the three putative N-WASP 
binding motifs and TirΔMTSEspF variants (pΔ101espF) as before. Infection studies were 
also carried out with HeLa cells with Western blots analysis revealing absence of EspF 
in the non-complemented strain with complementation linked to EspF protein delivery 
and, as expected, only the TirΔMTSEspF variant being detected by anti-Tir and anti-EspF 
antibodies (data not shown).  
As before (Chapter 3; Figure 17)(Quitard et al., 2006), the etmf mutant strain was 
readily internalised by macrophages with the majority (71.8 ± 6.2%) of bacteria inside 
the cells in contrast to only 31 ± 2.7% of EPEC bacteria (p<0.0001; Figure 42). 
Importantly, this work confirmed (Young, 2013) that the A3 variant rescued the anti-
phagocytic defect of the etmf mutant (Figure 42) supporting the inhibitory process to be 
independent of EspF binding N-WASP. By contrast, the TirΔMTSEspF variant failed to 
rescue the etmf mutant anti-phagocytic defect (Figure 42) as reported (Quitard et al., 
2006). The latter data supports the idea that EspF’s role in the anti-phagocytosis process 
requires features in the N-terminal 101 residues or that the Tir domain (or its impact on 
the C-terminal EspF domain) interferes with the anti-phagocytic process. To further 
examine the possible role of the N-terminal domain attempts were made to swap the N-
terminal MTS regions between EspF and Map but this was not successful. Thus, another 
strategy was undertaken to identify domains or features responsible for EspF to inhibit 
phagocytosis. 
 
5.2.2 Possible role for residues 51-73 in EspF is ability to inhibit phagocytosis  
To further explore EspF domains or features contributing to the anti-phagocytic process, 
we took advantage of variants previously constructed by Jon Scott (this lab). Prior to 
investigating their anti-phagocytic activity, the plasmids were isolated from the etmf  
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Figure 42. EspF’s N-terminal domain but not putative N-WASP binding sites is linked to inhibiting the 
uptake of the etmf quadruple mutant. J774.A1 macrophages were infected for 1 h (MOI 100:1) with 
indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria 
using antibodies to label extracellular bacteria (Red) with total cell-associated bacteria detected by plasmid 
expression of the Green Fluorescent Protein (Green). Fifty macrophages with 20-50 cell-associated bacteria 
were randomly chosen to count the number of extracellular and total cell-associated bacteria (Green) 
enabling the percentage internalisation to be calculated. Quantification studies were carried out in a semi-
blind manner with the percentage of internalised bacteria displayed as the mean value (± standard deviation) 
from at least three independent experiments (◊). * indicates statistically significant differences (Dunnett’s 
post-test) compared to EPEC data (ns not significant, 4* p< 0.0001; one-way ANOVA) or by Tukey's test 
for multiple comparisons between strains (ns not significant). Strains used were EPEC, etmf (lacks LEE-
encoded Intimin [eae gene product] plus Tir, Map and EspF effectors) and etmf carrying no plasmid (-) or 
plasmid  expressing variants that do not recruit N-WASP (pespF A3) or the first 101 residues replaced with 
those from Tir (pΔ101espF).  
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mutant for PCR analysis to confirm the presence and expected size of the espF genes. 
This work revealed that only eleven of fourteen samples displayed espF bands of the 
expected size (Figure 43) i.e. reflecting the expect size of expected deletion, leading to 
the PCR DNA fragments being sequenced to reveal the true identity of each variant 
(Figure 43). The confirmed strains were then used to infect HeLa cells to estimate the 
level of EspF variant expression (Triton X100 insoluble fraction), delivery (Triton X100 
soluble fraction) and secretion (obtained from extracellular media; noting DMEM does 
not contain FCS) with data given in Figure 44 and summarised in Table 9.  
Assuming there are no growth or binding differences between the strains, EspF 
levels in the insoluble fraction act as an indicator of EspF expression levels (i.e. within 
the cytoplasm of adherent bacteria) while EspF in the soluble fractions indicates delivery 
levels. Similarly, EspF levels in the extracellular media reveal how much protein is 
secreted, and not directed into the host cells. Strain genotype was supported by only 
detecting Tir expression in EPEC but not in etmf mutant strains with similar strain growth 
behaviour suggested by comparable EspB secretion levels (Figure 44C). This analysis 
detected EspF proteins of the expected molecular mass in all but two strains, #37 and #39, 
which have the largest deletion lacking 162 and 117 of 206, residues, respectively. The 
resulting peptides may be too small to be detectable (~5 and 10kDa) or become rapidly 
degraded. Interestingly, the L16E variant was linked to increased expression (~3 fold) 
and delivery (~3 fold) but not secretion levels. The observed differences probably reflect 
EspF expression from plasmids (comparing data to that from EPEC) which is known to 
increase delivery level (Young, 2013). Features of particular EspF mutants that affect 
expression, secretion or the translocation process are compiled in Table 9 and provide 
insight into domains impacting on EspF expression, stability, secretion and/or 
translocation levels. 
Of most interest to this study was the ability, or not, of these different strains to 
inhibit phagocytosis; comparing data from L16E-carrying variants to the EspF L16E 
control while variants lacking this substitution (#37 and 77) were compared to wild type 
EPEC data. Surprisingly, the L16E variant displayed an apparent, though statistically 
insignificant (due to data variability), defect in fully rescuing the anti-phagocytic defect 
(Figure 45) in contrast to previous studies (Quitard et al., 2006; Young, 2013). However, 
this phenotype was mirrored by other L16E variants (for example #80 [serine residue 47 
substituted to alanine] and #45 [missing 11 residues]) suggestive of a role for EspF in 
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Figure 43. Correct identity of espF variant gene on plasmid in etmf quadruple mutant strains. The indicated strains were assessed for the presence of an espF gene by PCR with 
resulting products visualised, alongside molecular mass markers 2-log (1000Kb ladder), on a 1% agarose gel to determine band size relative to the positive control, espF (700 
bp), gene. Strains used were EPEC, etmf (lacks LEE-encoded Intimin [eae gene product] plus Tir, Map and EspF effectors) carrying no plasmid (cont.-) or plasmid from strains 
number # 34, 35, 37, 39, 40, 42, 43, 45, 75, 77, 79 , 80) encoding EspF variants with various deletions or substitution. The table also shows expected and obtained espF gene 
size with the true nature of changes obtained by DNA sequencing leading to renaming the strains. * indicate presence of mutations (number indicated) that do not alter amino 
acid sequence. # indicate presence of a mutation that alter the amino acid sequence. 
. 
A B 
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Figure 44. Assessing the expression, delivery and secretion levels of EspF variants by etmf quadruple 
mutant strains during infection of HeLa cells. HeLa cells were infected (MOI of 100:1) with the indicated 
strains – identity as per Figure 43 - for 3 h before isolating A-D) Triton X-100 soluble fractions (contain 
host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and insoluble fractions (contain 
host nuclei and cytoskeleton plus adherent bacteria) or E) proteins secreted into the extracellular milieu. 
The samples were analysed by western blot (15% SDS-PAGE) probing for EspF and Tir. Arrows indicate 
the position of Tir (unmodified T0 and host kinase modified T’’ form) and EspF proteins.  
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Table 9. Summary of data from etmf quadruple mutants carrying plasmids expressing different EspF variants. Schematic of EspF variants DNA sequencing data (see Figure 
43) revealing substitutions and amino acid deletions        ).  Also given is the estimated size of the western-detected EspF protein in indicated fractions from HeLa infected cells 
(Triton X-100 insoluble/soluble fractions and extracellular supernatant) and the relative level of each band compared to the positive control (EPEC).  The last column summarises 
the phagocytosis data. The western data is only from a single experiment, while the phagocytosis data is from at least three independent experiments
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Figure 45. The anti-phagocytosis activity of EspF variants. J774.A1 macrophages were infected (MOI 100:1) with 
indicated strains (pre-grown in DMEM for 3 h) for 1 h prior to determining the percentage of bacterial 
internalisation following differential antibody strains labelling extracellular (Red) and total cell-associated (Green) 
bacteria. Fifty macrophages with 20-50 cell-associated bacteria were randomly chosen to count the number of 
extracellular and total cell-associated bacteria enabling the percentage internalisation to be calculated. 
Quantification studies were carried out in a semi-blind manner with the percentage of internalised bacteria 
displayed as the mean value (± standard deviation) from at least three independent experiments (◊). * indicating 
statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to L16E data (1* 
p< 0.05, 3* p< 0.001 and ns not significant; one-way ANOVA).* indicates statistically significant differences 
(one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* p< 0.0001). Strains used were EPEC, 
etmf (lacks LEE-encoded Intimin [eae gene product] plus Tir, Map and EspF effectors) carrying plasmids encoding 
EspF variants (# 34, 35, 37, 39, 40, 42, 43, 45, 75, 77, 79, 80) carrying alterations given in Table 9.
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targeting mitochondria to inhibit phagocytosis in this infection model. Several variants (Figure 
45) displayed a large, etmf mutant-like defect (Figure 45), linked to not expressing (#37 and 
#39) or delivering much (0-<10%) of the EspF variant (#34; #78; and #77) with significant 
defects compared to their controls. Of potential interest for future studies were strains that 
delivered an EspF variant to similar or greater levels than EPEC (#42, #79, #40, #43 and #75) 
but appear to display defects, however, the findings are difficult to interpret due to data 
variability (Figure 45).   
5.2.3. Intimin-dependent anti-phagocytosis activity  
To test the prediction (Chapter 4) that Intimin when expressed by adherent bacteria with a 
functional T3SS would provide an anti-phagocytosis response, an Intimin encoding plasmid 
(peae; See Material & Methods; Table 3) was introduced into the espGorf3core mutant as 
supported by PCR analysis (Figure 46A). The espGorf3core mutant strain lacks genes for 
Intimin, 4 LEE effectors (EspG, EspH, Tir, Map), a Nle effector (EspG2/Orf3) and the two 
effector-specific chaperones, CesF/CesT. While CesF is essential for EspF intra-bacterial 
stability and T3SS delivery (Elliott et al., 2002), CesT is required for the delivery of most LEE 
effectors (Tir, Map, EspH, EspZ) and many of the examined Nle effectors (NleB2; NleG; EspJ; 
NleH1; NleH2) (Thomas et al., 2005; Mills et al., 2013). However, CesT only promoted the 
delivery of other Nle effectors (NleB1; NleC) with no roles for CesT or CesF function in the 
delivery of other effectors (EspG; NleD; NleF) (Thomas et al., 2005; Mills et al., 2013). Thus, 
this strain is theoretically unable to express and/or deliver most LEE (including EspG, EspF, 
EspH, Map, EspZ and Tir except EspB) and many Nle effectors.  
Phagocytosis assays with the espGorf3core mutant confirmed that it had little, if any, 
ability to inhibit its uptake by J774A.1 macrophages in contrast to the peae-carrying variant 
which behaved in a statistically indistinguishable manner to EPEC (Figure 46B). This work 
demonstrates, for the first time, that Intimin has activities that (independent of functions of 
many effectors including Tir, Map, EspG, EspF and EspH) can directly or indirectly inhibit 
uptake of EPEC that express a functional effector-delivery system. It must be noted that the 
T3SS mutant has a functional Intimin surface protein but does not inhibit phagocytosis (Figure 
46B).   
 
5.2.4. Tir-dependent anti-phagocytosis activity  
A similar approach was taken to test the prediction (Chapter 4) that Tir has Intimin-independent 
activities that enable EPEC to inhibit its uptake. As Tir delivery is dependent on CesT, a plasmid 
encoding both proteins was introduced into the espGorf3core mutant.  
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Figure 46. Intimin bestows the espGorf3core mutant the capacity to inhibit phagocytosis in the J774.A1 
macrophage model. Indicated strains were used for PCR analysis (A) or to infect (B) J774.A1 macrophages. (A) 
Oligonucleotides specific to eae gene (encodes Intimin) were used in PCR analyses to determine the presence of 
an intact or deleted eae gene with PCR products visualised, alongside molecular mass markers 2-log (1000Kb 
ladder), on a 1% agarose gel. (B) J774.A1 macrophages were infected for 1 h (MOI 100:1) with the indicated 
strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria using differential 
antibody staining to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages 
with 20-50 cell-associated bacteria were randomly chosen to count the number of ‘Red’ and ‘Green’ bacteria. (B) 
Quantification studies were carried out in a semi-blind manner with the percentage of internalised bacteria 
displayed as the mean value (± standard deviation) from at least three independent experiments (◊). * indicates 
statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* 
p< 0.0001; ns = not significant). Strains used were EPEC, T3SS mutant (T3SS), or espGorf3core mutant (lacks 5 
effectors [EspG, Orf3/EspG2, EspH, Tir, Map], two chaperones [CesF, CesT] and Intimin protein) – latter with or 
without an Intimin-encoding plasmid (peae).  
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To confirm plasmid introduction, HeLa cells were infected before isolating soluble and 
insoluble fractions for western blot analysis probing for anti-Tir. This analysis confirmed the 
features of the espGorf3core mutant, i.e. no Tir signal and consistent with the absence of CesF  
a reduced EspF signal (Figure 47A) (Elliott et al., 2002). 
As expected, the introduction of pcesF::HA increased EspF levels while introducing the 
Tir/CesT-encoding plasmid resulted in a Tir signal and, as per EPEC-infected cells detection of 
host kinase-modified Tir forms thereby illustrating CesT and T3SS functionality (Figure 47A). 
Crucially, the phagocytic assays carried out with these strains confirmed that the espGorf3core 
mutant strain could not inhibit its uptake whether or not it carried the pcesF::HA plasmid to 
enable EspF delivery while Tir expression/delivery was linked to an EPEC-like phenotype 
(Figure 47B). These data reveal, for the first time, the existence of a Tir-dependent anti-
phagocytic activity that does not require activities of the Intimin, EspG, EspG2, Map, EspF or 
EspH proteins. 
As the re-introduction of CesT would enable the delivery of LEE EspZ and non-LEE 
encoded effectors (in latter given LEE sufficiency for anti-phagocytosis and no detectable roles 
for 14 Nles) further studies examined if EspZ may play a role by inactivating the espZ gene 
(Table 1; Materials & Methods). PCR analyses supported espZ gene inactivation in EPEC and 
espGorf3core backgrounds with introduction of the Tir/CesT-encoding plasmid (Figure 48A).  
Experiments using these newly generated strains to infect J774A.1 macrophages for the 
anti-phagocytosis assay suggested that EspZ may suppress the activity of, undefined, factors to 
inhibit EPEC uptake as significantly higher phagocytic activity was observed for 
espGorf3coreΔespZ than with espGorf3core (p<0.05) and T3SS mutants (p<0.01) (Figure 
48B). Crucially, introducing the Tir/CesT-expressing plasmid into the espGorf3coreΔespZ 
mutant lead to an EPEC-like phenotype, which was shared by the examined espZ single mutant 
(Figure 48B). This work failed to demonstrate a role for EspZ in EPEC capacity to inhibit its 
uptake by J774A.1 macrophages and that Tir can inhibit EPEC uptake although the mechanism 
are not clear.  
As the earlier results revealed an important role of Tir in the anti-phagocytosis process, 
initial studies were undertaken to identify Tir features needed for its anti- phagocytosis process. 
Thus, plasmids expressing Tir variants (See Material & Methods Table 3) were introduced into 
the espGorf3core mutant strain to examine if any of these plasmids can restore the anti-
phagocytosis defect of this mutant. It should be considered that no analysis was provided to 
confirm the presence of specific mutations. Due to the time constraint, anti-phagocytosis assay 
for most Tir variants was only done once or twice, thus, no statistical analysis was provided. 
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Figure 47. Tir bestows on the espGorf3core mutant the capacity to inhibit phagocytosis in the J774.A1 macrophage 
model. Indicated strains were used to (A) infected (MOI of 100:1) HeLa cells for 3 h prior to isolating Triton X-
100 soluble (contains host cytoplasmic and membrane proteins plus T3SS-delivered effectors) and insoluble 
(contains host nuclei and cytoskeleton plus adherent bacteria) fractions for western blot analysis probing for EspF 
and Tir. Arrows indicate the position of Tir (unmodified T0 and host kinase modified T’’ form) and EspF proteins. 
In (B) indicated strains were used to infect J774.A1 macrophages (MOI 100:1; pre-grown in DMEM for 3 h) for 
1 h prior to determining the percentage internalised bacteria using differential antibody staining to label 
extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages with 20-50 cell-
associated bacteria were randomly chosen to count the number of ‘Red’ and ‘Green’ bacteria. (B) Quantification 
studies were carried out in a semi-blind manner with the percentage of internalised bacteria displayed as the mean 
value (± standard deviation) from at least three independent experiments (◊). * indicates statistically significant 
differences (one-way ANOVA with Dunnett’s post-hoc test) compared to EPEC data (4* p< 0.0001and ns not 
significant). * indicates statistically significant differences (one-way ANOVA with Dunnett’s post-hoc test) 
compared to T3SS (4* p<0.0001and ns not significant). Strains used were EPEC, T3SS mutant (T3SS) and 
espGorf3Δcore mutant (lacks 5 effectors [EspG, Orf3/EspG2, EspH, Tir, Map], two chaperones [CesF, CesT] and 
Intimin protein); latter carried (+) or not (-) plasmids encoding Tir and CesT (ptircesT) or CesF as a CesF::HA 
fusion protein (pcesF::HA). 
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Figure 48. No detectable role for EspZ in anti-phagocytic mechanisms. Indicated strains were used for PCR 
analysis (A) or to infect (B) J774.A1 macrophages. (A) Oligonucleotides specific to tir or espZ genes were used 
in PCR analyses to determine the presence of an intact or deleted genes with PCR products visualised, alongside 
molecular mass markers 2-log (1000Kb ladder), on a 1% agarose gel. (B) J774.A1 macrophages were infected for 
1 h (MOI 100:1) with the indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of 
internalised bacteria using differential antibody staining to label extracellular bacteria (Red) and total cell-
associated bacteria (Green). Fifty macrophages with 20-50 cell-associated bacteria were randomly chosen to count 
the number of ‘Red’ and ‘Green’ bacteria. (B) Quantification studies were carried out in a semi-blind manner with 
the percentage of internalised bacteria displayed as the mean value (± standard deviation) from at least three 
independent experiments. * indicates statistically significant differences (one-way ANOVA with Dunnett’s post-
hoc test) compared to EPEC data (4* p< 0.0001) or by Tukey's test for multiple comparisons between strains (4# 
p<0.0001, 2# p<0.01, 1# p< 0.05 and ns not significant). Strains used were EPEC, T3SS mutant (T3SS), espZ 
mutant (lacks EspZ effector) or espGorf3core mutant (lacks 5 effectors [EspG, Orf3/EspG2, EspH, Tir, Map], 2 
chaperones [CesF, CesT] and Intimin protein). Some strains additionally lacked the EspZ effector (ΔespZ) or 
carried a Tir/CesT-encoding plasmid (ptircesT) with the control strain lacking this plasmid (-).
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No difference in the percentage of uptake was identified for cells infected with EPEC 
espGorf3core/pACYCtir R521. This mutation affects the putative arginine finger motif and is 
defective for filopodia downregulation and the results suggest no role of this motif in the 
phagocytosis inhibition (Figure 49). Importantly, all plasmids expressing Tir with different 
substitutions failed to restore the anti-phagocytosis defect in the espGorf3core mutant as all 
showed high levels of internalisation comparable to EPEC. Importantly, 
espGorf3core/pACYCtir S434/463A displayed a large T3SS mutant-like defect (Figure 49), 
suggesting that serine phosphorylation may be necessary for phagocytosis inhibition. Future 
work is therefore required to confirm these results, repeating the anti-phagocytosis analysis for 
each of these strains and including an analysis to confirm the correct sequence of the strains. 
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Figure 49. Anti-phagocytosis activity of Tir variants. J774.A1 macrophages were infected for 1 h (MOI 100:1) 
with indicated strains (pre-grown in DMEM for 3 h) prior to determining the percentage of internalised bacteria 
using antibodies to label extracellular bacteria (Red) and total cell-associated bacteria (Green). Fifty macrophages 
with 20-50 cell-associated bacteria were randomly chosen to count the number of extracellular and total cell-
associated bacteria (Green) enabling the percentage internalisation to be calculated. Quantification studies were 
carried out in a semi-blind manner. Strains used were EPEC, T3SS-deficient (T3SS) mutant, espGorf3core mutant 
(lacks 5 effectors [EspG, Orf3/EspG2, EspH, Tir, Map],two chaperones [CesF, CesT] and Intimin protein) carrying 
no plasmid or a plasmid encoding Tir  pACYC tirR521, pACYC tirS463A, pACYC tirY474F, pACYCtir Y474-
454F S434A-463A, pACYC tir polyproline, pACYCtir S434A, pACYCtir S434/463A (see Materials & Methods 
Table 3).   
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5.3 Discussion 
Previous data (Chapter 3) suggests that T3SS delivery of EspF is not sufficient to inhibit 
phagocytosis of EPEC; however, studies (Chapter 4) with a bank of 32 mutants (lacking genes 
encoding map, tir, espH, eae [encodes Intimin] in all combinations) implicated an indirect role 
of EspF in the inhibitory process. Thus, to gain insight into the EspF domains and/or features 
required for this indirect role, complementation studies were undertaken with available EspF 
variants. The latter variants were introduced into an etmf quadruple mutant as its failure to 
inhibit phagocytosis was always rescued by introducing an EspF-expressing plasmid. Initial 
complementation of etmf generated in this study is consistent with other studies (Young, 2013), 
confirming no role for EspF features linked to the recruitment of actin nucleating factor, N-
WASP. However, N-WASP does have an important role in other EspF disruptive activities, 
such as disruption of epithelial barrier function and effacement of absorptive microvilli (Dean 
et al., 2013). Importantly, our results also support an essential role for the EspF N-terminal 
domain, which is consistent with previous studies (Quitard et al., 2006). The latter study used 
a Tir- EspF fusion protein where the N-terminal 101 residue of EspF [carries the sequence for 
chaperone (CesF) binding and targeting to T3SS, mitochondria and nucleolus (Charpentier and 
Oswald, 2004; Nagai et al., 2005; Dean et al., 2010b)] were exchanged for those of Tir which 
carries the sequence for chaperone (CesT) binding, T3S signal sequence and kinase recruitment 
(polyproline-rich) region (Crawford and Kaper, 2002; Bommarius et al., 2007). However, as 
previously discussed, it is possible that the failure of Tir-EspF fusion protein to rescue the anti-
phagocytosis defect of etmf mutant could be due to the Tir domain interfering with the anti-
phagocytosis activity encoded in the remaining EspF sequence fusion protein. Nevertheless, 
this fusion protein was able to mimic the ability of the native EspF to cause barrier disruption; 
an event that requires the C-terminal domain, that carries this N-WASP binding motifs (Dean 
et al., 2013). Previous research with the L16E variant had discounted a need for EspF 
mitochondrial targeting sequence (Quitard et al., 2006) and features required to recruit sorting 
nexin 9 (a protein linked to N-WASP co-recruitment to remodel host membrane) in the 
phagocytosis inhibition (Weflen et al., 2010; Young, 2013). Unexpectedly, studies with the 
L16E EspF variant, which was used as a control for variants carrying internal truncations, 
revealed a partial complementation defect. The latter finding suggested that EspF’s targeting to 
the mitochondria contributed to its, indirect, role in the anti-phagocytosis process. However, 
the L16E variants data was linked to high level of variability (n=3 only), so the obvious 
difference between mean data was not statistically significant. Thus, it is likely that a higher 
number of repeats would decrease the associated error bars, and perhaps reveal a statistical 
difference between EPEC and etmf/espF L16E mutant strain. Nevertheless, similar data was 
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obtained with other data L16E variants such as L16E/S47A double substitution mutant, 
suggesting that this defect is real, at least in the J774.A1 macrophage model.              
Having re-examined the anti-phagocytic activity of variants lacking each of the key 
features associated with EspF’s subversive activities, studies focused on lab-available variants 
carrying internal truncations or specific substitutions. The internal truncations were made using 
espF encoding the L16E substitutions with oligonucleotides designed to reverse PCR reactions 
in which specific regions upstream of residue 20 (as residue 1-20 required for EspF 
translocation) were deleted. However, PCR analysis of available variants, following isolation 
for espF mutant background and introduction into etmf quadruple mutant, revealed unexpected 
fragment sizes leading to each insert being DNA sequenced to reveal the true extent of genetic 
change. Although how the observed discrepancies arise was unclear, the key finding was 
identifying these errors to enable data interpretation. As EspF role in the anti-phagocytosis 
would clearly be dependent on the level of expression and/or delivery into host cells, our study 
examined the impact of the genetic changes to this process. It is worthwhile noting that, due to 
the time constraint, this analysis related to a single western blot on samples from a HeLa cell 
infection experiment probing EspF levels in insoluble, soluble and extracellular protein used as 
an indication EspF protein expression, T3SS delivery and the T3SS delivery processes 
respectively. It was assumed that there was no difference in strain binding supported by similar 
levels of other EPEC proteins (such as EspB or bacterial protein non-specifically detected with 
antibodies) in the soluble, insoluble and extracellular samples and that EspF antibody detecting 
many epitopes distributed equally throughout the EspF protein. Plasmid expression of EspF is 
known to increase delivery levels (Nougayrède and Donnenberg, 2004; Young, 2013). 
Similarly, this work indicated that while the L16E substitution had no impact on secretion 
levels, it increased expression and delivery levels by three fold i.e. appeared to promote CesF 
delivery to the T3SS, chaperone release or delivery kinetics. However, this is not the case with 
the variant also carrying a S47A substitution, as it was delivered two fold more into HeLa cells 
with little or no EspF secretion, which may due to interaction with its chaperone, thus increasing 
the level of delivery and decreasing the level of secretion. Not surprisingly, variants carrying a 
large internal truncation could not be detected, due to no or few epitopes for detection, rapidly 
degraded or not captured on percentage of gel used. However, some variants carrying smaller 
deletion could only be detected at low levels, implicating these regions is chaperone binding or 
providing antibody-recognised epitopes. Our results are encouraging for future studies to 
determine features which are implicated in specifically targeting EspF’s translocation into cells.  
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Importantly, the anti-phagocytosis data of EspF variants generated in this chapter related to at 
least three independent experiments. However, these data must be interpreted with caution due 
to the unexpected intermediate defect with L16E variants (used as a control) and data 
variability. Two mutants lacked the L16E substitution and thus could be compared to EPEC 
data with one #37 behaving like the etmf quadruple mutant presumably as it lacks most EspF 
residues (21-183 from total 206 of EspF protein). Whereas the second mutant #77 (lacks residue 
21-73) displayed similar anti-phagocytosis activity as #37. However, the defect of the #77 
mutant could be linked to reduced expression (50%), secretion (90%) and translocation (90%) 
suggesting that the issues related to a translocation defect. Interestingly, mutants which 
delivered similar levels of EspF into cells as EPEC appear not rescue the anti-phagocytosis 
defect i.e. #79 (lacks residue 51-73), #75 (lacks residue 23-52) and possibly #43 (lacks the 
proline rich feature; A79-82P). Further studies are therefore required to re-examine the anti-
phagocytosis capacity for each mutants.  
In contrast, to the proposed indirect role of EspF, our studies with the single, double, 
triple, quadruple and quintuplet mutants implicated key roles for Tir and Intimin proteins in 
promoting EPEC’s anti-phagocytosis activity. To test this premise complementation studies 
were undertaken with a strain, espGorf3core, that expressed and/or delivered few T3SS 
effectors as it lacks genes of 5 effectors (EspG, EspG2, EspH, Tir, Map), Intimin, the 
chaperones CesF (required for efficient EspF deliver) and CesT (critical for the delivery of 
EspZ and many non-LEE-effectors, with remaining effectors delivered at reduced or normal 
levels. Importantly, re-introducing the cesF-encoding gene restored EspF delivery without 
rescuing its anti-phagocytosis defect. Noticeably, EspF delivery levels were supported by 
western blot analysis (HeLa cells) or immunofluorescent microscopy illustrating T3SS 
functionally and that EspF delivery is not sufficient to inhibit EPEC uptake (Chapter 3). 
Crucially, introducing a plasmid encoding Intimin rescued the anti-phagocytic defect of the 
espGorf3core, but there was an apparent small (though not statistically significant) defect. 
Whereas introducing a plasmid expressing Tir (with CesT to enable delivery into cells) led to 
data mirroring EPEC- infected macrophages. A concern on the latter data is that co-introduction 
of the cesT gene would restore the delivery of the LEE effector EspZ and many non-LEE 
effectors. However as we have shown EPEC anti-phagocytosis activity does not require the 
activity of 14 Nle (and EspG) effectors and is encoded on the LEE region, we only examined a 
role for EspZ in this event. Interestingly, deleting EspZ from espGorf3core mutant was linked 
to a low level of anti-phagocytic activity suggesting that EspZ supresses the anti-phagocytosis 
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activity of another factor (probably an effector) expressed by espGorf3core. However, this 
study also discounted a role of EspZ as the single mutant behaved like EPEC.  
This work did not provide any data related to Intimin variants, as they were not available 
at our laboratory and, therefore, studies focused on Tir variants. However, the anti-phagocytosis 
of Tir variants data is related to a single or two experiments, without support (DNA sequence 
data and/or western blot) the presence of specific variants. However, this preliminary data 
suggests no role for the Tir arginine finger-like motif (linked to down regulate GTPase activity) 
in the phagocytosis inhibition. In contrast, the substitution converting arginine 521 to an alanine 
demolished Tir’s capacity for filopodia downregulation (Kenny et al., 2002). Whereas our data 
suggests that Tir variants lacking residues or feature linked to recruiting host kinases and/or 
being substrates for host kinase could have role in Tir anti-phagocytosis activity. Future work 
therefore is required to re-examine the anti-phagocytosis capacity for each mutants with i) the 
bioinformatics analysis to confirm presence of required (DNA sequencing PCR-obtained tir 
gene fragment) and ii) increase the number of repeat anti-phagocytosis assay to rule out roles 
for individual or multiple Tir feature to enable it to bestow onto the espGorf3core mutant the 
capacity to inhibit its uptake by J774.A1 macrophages.  
In summary, this study confirmed key, but redundant roles for Tir and Intimin in EPEC’s 
anti-phagocytosis activity and discounted a need for EspZ effector activity. These studies have 
set the groundwork for future work to define the molecular mechanism by which Tir and Intimin 
inhibit EPEC uptake by J774.A1 macrophages. However, studies are also needed to examine 
the reported contribution with other effectors such as EspB. 
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Chapter 6. Final Discussion 
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Many bacteria have the capacity to inhibit their uptake by professional phagocytic cells, such 
as macrophages which phagocytose bacteria in order to kill them and present antigens to 
promote appropriate immune responses. The anti-phagocytic activity of many bacterial 
pathogens, including non-invasive EPEC, depend on a T3SS that transfers many effectors into 
infected cells. EPEC’s anti-phagocytic activity is thought to function to inhibit uptake by gut-
located M-cells to delay their delivery to associated macrophage and, thus, immune responses.   
EPEC’s capacity to inhibit phagocytosis has been assessed with a range of cultured 
macrophage cell lines (e.g. J774.A1), M-cell models and in vivo (Goosney et al., 1999; Celli et 
al., 2001; Quitard et al., 2006; Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun et 
al., 2011). These studies demonstrated that EPEC inhibits PI 3-kinase-dependent phagocytic 
pathways through the delivery of effectors with inhibitory roles described for four EspB, EspH, 
EspG and EspF  (Quitard et al., 2006; Iizumi et al., 2007; Dong et al., 2010; Humphreys et al., 
2016). It should be noted that only EspF’s key role has been examined in M-cell and/or in vivo 
models. The EPEC inhibitory mechanism is linked to blocking cytoskeleton rearrangement 
driving pseudopod membrane extension that engulfs and internalises microorganisms. It has 
been shown that EspB subverts myosin motor proteins required to drive membrane extension 
(Iizumi et al., 2007) while EspH block Rho GTPase signalling (by binding RhoGEFs) prevent 
actin remodelling needed to engulf bacteria (Dong et al., 2010) with EspG preventing WAVE 
regulatory activity needed for phagocytosis associated actin polymerisation (Humphreys et al., 
2016). While a critical role of EspF has been supported in studies with macrophages (Quitard 
et al., 2006; Marchès et al., 2008) and M-cells (in vitro and in vivo) the inhibitory mechanism 
has not been described (Martinez‐Argudo et al., 2007; Tahoun et al., 2011).  Therefore, the aim 
of my thesis project was to determine if EspF encodes sufficient information to inhibit EPEC 
uptake and to investigate the molecular details of the inhibitory mechanism.  
The first unexpected finding from my studies came from re-establishing the phagocytic 
assay, which included a non-pathogenic E. coli strain, which displayed higher level of 
internalisation (~85%)  than the T3SS mutant (~65%); noting ~40% of EPEC are internalised 
via PI-3 kinase-independent pathways. Thus, our studies suggested for the first time, as far as 
we know, a non-T3SS inhibitory contribution to EPEC’s anti-phagocytosis ability. This finding 
could be interesting for future studies to define the responsible factor(s) and inhibitory 
mechanism. Crucially, my work also confirmed a critical role for EspF in EPEC anti-
phagocytosis activity as both espF single and etmf multiple mutants (lacking genes expressing 
Intimin, Map, Tir and EspF) behaved like the T3SS mutant.  
An important, but not surprising, finding came from studies assessing the anti-
phagocytosis capacity of non-pathogenic E. coli to inhibit uptake carrying LEE (on a plasmid), 
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which revealed LEE sufficiency. However, this LEE region came from another EPEC strain, 
B171, with the non-pathogenic E. coli strain carrying another plasmid encoding other B171 
virulence-associated factors (important adhesin [BFP] and regulator [PerA-C] to drive LEE 
gene expression). Although, the BFP and Per operons did not enable E. coli K12 to inhibit 
phagocytosis studies need to rule out a direct role with LEE, though BFP (EPEC) has been 
shown not to be required for EPEC to inhibit its uptake (Goosney et al., 1999). Nevertheless, 
further work is needed to confirm sufficiency with the E2348/69 LEE region. Supporting the 
idea that all the important factors are LEE encoded was the finding that an E2348/69 strain, 
TOEA7, that lacks most (14 of 17) known Nle, plus EspG, effectors inhibited its uptake to a 
similar level as EPEC. This finding was surprising as this strain lacks EspG and EspG2 effectors 
while a recent study reported that an espG/espG2 double mutant failed to  inhibit phagocytosis 
(Humphreys et al., 2016). This discrepancy presumably reflects differences in the model 
system, reagents and/or protocols. Ruling out critical roles for the EspG effectors and most 
known Nle effectors, but apparent LEE sufficiency, suggests that the anti-phagocytosis activity 
of the TOEA7 mutant is driven by other LEE-encoded effectors linked to this inhibitory process 
i.e. EspF (Quitard et al., 2006), EspB (Iizumi et al., 2007) and/or EspH (Dong et al., 2010).  
Before investigating how EspF inhibited PI-3 kinase-dependent uptake, studies were 
undertaken to address whether T3SS-dependent delivery of EspF into host cells is sufficient to 
inhibit phagocytosis. This was achieved through using a previously described approach i.e. the 
T3SS of an other pathogen (Yersinia) as shown to deliver EPEC Tir into cells in a manner 
greatly promoted by co-expressing the Tir chaperone, CesT (Warawa and Kenny, 2001). 
Although my work demonstrated that Yersinia could deliver EspF into host cells (if co-
expressed with its chaperone CesF), the anti-phagocytosis data argued against EspF encoding 
sufficient information to inhibit phagocytosis. Yersinia’s ability to deliver a second EPEC 
effector into host cells may promote studies with other LEE and/or Nle effectors to investigate 
if they subvert cellular processes when delivered in the absence of other effectors or, indeed, 
whether EspH, EspB and/or EspG’s delivery would inhibit phagocytosis. As we were unable to 
prove that Yersinia delivered EspF into macrophages, a second strategy was undertaken to 
confirm that EspF does not encode sufficient information to inhibit phagocytosis. This work 
used a complex mutant, espGorf3core, which theoretically is unable to deliver most LEE 
(including EspF) and many Nle effectors, with EspF delivery restored by plasmid introducing 
a CesF-expressing plasmid. Crucially, immunofluorescence microscopy studies clearly 
demonstrated high levels of EspF delivery into macrophages but this failed to inhibit 
phagocytosis. Thus, we demonstrate that EspF does not encode sufficient information to inhibit 
phagocytosis implicating roles for other, presumably, LEE-encoded factors. As earlier work 
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ruled out roles for most non-LEE-encoded effectors, supporting the LEE sufficiency idea, 
EspF’s anti-phagocytosis activity presumably depends on activities of LEE factors missing 
from the espGorf3core mutant i.e. i) EspG; role excluded by TOEA7 strain data, ii) CesT 
dependent effectors i.e. EspZ (role excluded by examining espZ mutant) and, unlikely, Nle 
effectors, or iii) core region proteins: Tir, Map, EspH effectors and/or Intimin.  
The key findings from my work came from the decision to test the anti-phagocytosis activity 
of 32 strains in which the genes of implicated proteins (EspH, Map, Tir, Intimin as well as 
EspF) were inactivated in all combinations. It should be noted that PCR analysis, on non-
adherent bacteria isolated following macrophage infections, supported the genotype of each 
mutant by illustrating that each gene of interest was either intact or disrupted. Surprisingly, 
testing the anti-phagocytosis activity of these mutants failed to confirm essential roles for EspF 
and EspH. Examining espF clones from other frozen culture stocks and espH clones from two 
other laboratories, including the one reporting EspH’s role in inhibiting phagocytosis (Dong et 
al., 2010) generated similar findings. It is hard to explain why these mutants displayed an 
EPEC-like phenotype, especially as my initial data with a espF/pGFP strain revealed T3SS 
mutant-like phenotype with EspF’s roles demonstrated in in vitro and in vivo models (Quitard 
et al., 2006; Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 2011). An 
important future experiment would be to compare the phagocytosis activity of the T3SS mutant-
like the espF/pGFP strain and EPEC-like espF mutant to determine the reason for the 
difference; perhaps relates to genetic (bacterial or host genome), reagent, protocol and/or 
environmental changes. It should be noted that the variability is unlikely to be related to cells 
since the MOI used (100:1) consistently resulted in 70-80% of the macrophages having 20-50 
cell-associated bacteria, whichever strain was used. 
Although, my work revealed that EspF is not always required to inhibit phagocytosis it 
suggested that it could have indirect role(s). Indeed, the work also suggests that EspH may also 
have indirect contributions to perhaps help explain why the espH mutants behaved like EPEC 
in my model. It is possible that EspF and EspH can have critical or non-critical contributions 
dependent on environmental factors, for example, known FCS batch variability in cytokine 
composition could alter expression of receptors, regulators, signalling pathways or indeed 
effector expression/delivery levels to impact on the phagocytic processes and/or ability of one 
or more effectors to contribute to the inhibitory process. Support for this idea came from finding 
phenotype instability in the phagocytosis assay with a subset of multiple mutants, for example, 
the espF/tir (lacks EspF and Tir) displayed a T3SS mutant-like phenotype in three of six 
experiments with a prominent anti-phagocytic activity in the other three experiments. 
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Interestingly, this phenotype was not detected with espF/tir-related triple mutants suggesting 
that the presence or absence of specific EPEC genes can, directly or indirectly, impact on 
EPEC’s ability to inhibit phagocytosis. While studies were undertaken to define features needed 
for its indirect role (etmf quadruple) the data is too preliminary to discuss but the work shows 
the potential to define important features and insights on the process. Indeed, preliminary data 
suggests that EspF’s contribution to anti-phagocytosis, in the etmf mutant background, depends 
on EspH activity which could be explore in future projects. Other studies could focus on other 
potential interrelationships and hypothesis on how cooperative contributes to anti-phagocytosis 
suggested by the single, double, triple and quadruple mutant data. 
Although my work failed to confirm critical roles for EspH, EspG or EspF effectors 
(didn’t examine EspB’s reported role as provide mutant had binding issues) it revealed 
important, but redundant roles for both Tir and Intimin in EPEC’s anti-phagocytosis mechanism 
(at least in this J774A.1 model). Roles for both proteins was suggested by intermediate defects 
in a previous study (Goosney et al., 1999), while my work revealed a minor defect for the tir, 
not eae, mutant. This variability supports the idea that EPEC’s anti-phagocytic activity is 
sensitive to environmental, protocol and/or reagent differences. Importantly, Intimin’s role in 
the anti-phagocytosis was supported by rescuing the anti-phagocytosis defect of the 
espGorf3core mutant by introducing an Intimin-expressing plasmid. As T3SS mutants (express 
a functional Tir-binding Intimin protein) do not inhibit phagocytosis this argues that Intimin’s 
contribution depends on other espGorf3core mutant-encoded factors, perhaps EspB. The latter 
idea should be tested and complementation studies carried out with Intimin variants with defect 
in altering host cell physiology independent of Tir to perhaps provide insight to help define the 
molecular basis of inhibition.   
A similar strategy was used to support the idea that Tir has activities that inhibit 
phagocytosis but data interpretation was hindered by the need to co-introduce the cesT gene to 
enable delivery of Tir and, unfortunately, another LEE effector (EspZ) and many Nle effectors.  
Given the LEE sufficiency finding and no critical role for 14 (of 17) examined Nle effectors 
studies examined, and ruled out a key contribution for EspZ in the Tir-associated anti-
phagocytic process. However, it was surprising to find that inactivating espZ in the 
espGorf3core mutant restored some (p<0.05) anti-phagocytic activity as this strain should not 
deliver EspZ (Ruchaud‐Sparagano et al., 2007) and thus deleting espZ should have no impact. 
The latter finding suggests that EspZ may have an additional, indirect or direct, role and, thus, 
could be the focus of future studies. While this study provided encouraging data on some Tir 
variants enabling the espGorf3core mutant to inhibit phagocytosis, the findings are too 
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preliminary and further studies are needed to confirm introduction of the correct variant and 
carry out repeat experiments. It is likely that such data could provide information to help define 
the molecular details of how Tir activity enables EPEC to inhibit phagocytosis. It would also 
be interesting to examine whether this Tir activity depends on other EPEC factors (for example, 
EspB) by introducing Tir into macrophages without other effectors (for example, via the 
Yersinia delivery) or use of the EspB variant that delivers effectors but cannot inhibit 
phagocytosis (Iizumi et al., 2007).  
To conclude, this study has provided valuable insights into the role of the EPEC effector 
repertoire in the phagocytosis inhibitory mechanism. Furthermore, by screening mutants where 
genes encoding five proteins were inactivated in all combinations, this study proposes a critical 
role for Intimin and its translocator Tir in EPEC’s anti-phagocytosis activity. Indeed, this work 
reveals an unknown complexity behind EPEC’s ability to inhibit its uptake by macrophages. 
These experiments have set the groundwork to enable future studies to identify the virulence 
factors responsible and to uncover the mechanism for inhibiting phagocytosis, thus providing 
insights into the role of phagocytosis inhibition in EPEC induced disease. 
 
Implications for the future   
• Considerably more work will need to be done to enable the comparison of the 
phagocytosis activity of different mutants such as the T3SS like mutant espF/pGFP 
strain or EPEC-like espF mutants. Experiments to determine the reason for the 
differences could focus on the genetic background of both bacteria and host, 
alternatively reagents, protocols and/or environmental factors could have an impact.   
• This study suggested a T3SS-independent inhibitory contribution, which may implicate 
roles for other EPEC-specific T3SS-independent factors. Thus, further work is required 
to define the EPEC factors and mechanisms mediating this T3SS-independent 
inhibitory mechanism. Possible mediators would be T2SS-dependent substrates 
required for EPEC virulence, the EspC protein (autotransporter link to cell cytotoxicity) 
or surface components such as pili, membrane proteins or capsule.  
•  As mentioned in chapter four, this study suggests that anti-phagocytosis, at least in the 
J774A.1 model, is a more complex process than recognised. Future research should, 
therefore, concentrate on confirming the relationships between EPEC effectors in 
phagocytic inhibition such as cooperative mechanisms between Intimin and Tir or 
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antagonistic mechanisms as our data argues for Map, EspF and EspH being able to 
suppress EPEC’s anti-phagocytic activity.  
• A future study investigating factor(s) and mechanism by which Intimin and Tir inhibit 
uptake of EPEC by macrophages would be very interesting.  
• The T3SS of Yersinia can be used as a good model to examine Tir suffecncy and the 
reported contribution with other effectors such as EspB in the inhibitory mechanism in 
the absence of all other EPEC effectors.  
• Although extensive research has been carried out on a key role for EspF to enable EPEC 
to inhibit its uptake in cultured macrophages and M-cells (in vitro and in vivo) models 
(Quitard et al., 2006; Martinez‐Argudo et al., 2007; Marchès et al., 2008; Tahoun et al., 
2011), no single study exists which adequately examined the role of other effectors such 
as EspH, Tir, EspB and the outer membrane Intimin using M-cells models. Future 
studies using M-cells models (in vitro and in vivo) are therefore recommended to test 
the role of Tir and Intimin and other EPEC effectors in the phagocytic inhibition.  
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7.1 Bioinformatics analysis 
 
7.1.1 espF-L16E strain  
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT  
#35= ∆21-74, no BglII, it is L16E but it has no deletion  
espF-L16E 
>429520801_35_pbrespF sequence exported from 
429520801_35_pbrespF_E03.ab1NNNNNNNNNNNNNNNNNNNNTNTATTATTCGTTTTGATATATATGAGAGTTAGC
CAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAG
GTATCGCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGA
GTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTA
CTCCCTCTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGG
CATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGC
CGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTG
CCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAG
GCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGG
GTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAAATAAAAACCGATATCAAATTGCGTGG 
MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSRPAPPP 
PTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKAS 
ETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
 
 
Alignment of Sequence_1:  [35] with Sequence_2: [EspF native]  
 
Similarity: 618/621 (99.52 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
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Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
Seq_1  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  601   GAGCAATCGAAGAAAGGGTAA  621 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
Alignment of Sequence_1:  [Fragment of 35 [1-621]] with Sequence_2: [Fragment of 
EspF native [1-621]]  
 
Similarity: 205/206 (99.51 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
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7.1.2 espF-L16E /34 strain  
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG  
BglII=AGATCT 
#34= ∆ 298bp-548bp= 100-183 A.A.  
espF-L16E / 34 
>429520801_34_pbrespF sequence exported from 
429520801_34_pbrespF_G03.ab1NNNNNNNNNNNNNNNNTTTTATTATTCGTTTTGATATATATGAGAGTTAGCCAAG
ATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTAT
CGCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCA
TTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCT
CTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCAAGA
TCTGGTGGTCTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAACCAACT
AATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAATTGCGTGG 
MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSRPAPPP 
PTSGQASGASRPLPPIAQARSGGLPPLAQALKDHLAAYEQSKKG 
 
Alignment of Sequence_1:  [34] with Sequence_2: [EspF native]  
 
Similarity: 368/621 (59.26 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
Seq_1  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
132 
 
 
 
Seq_1  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCA---  297 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||    
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  298   ------------------------------------------------------------  297 
                                                                          
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
Seq_1  298   ------------------------------------------------------------  297 
                                                                          
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  298   ------------------------------------------------------------  297 
                                                                          
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  298   ------------------------------------------------------------  297 
                                                                          
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  298   --AGAT-CTGGTGGTCTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  354 
                |   ||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  355   GAGCAATCGAAGAAAGGGTAA  375 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
 
 
Alignment of Sequence_1:  [Fragment of 34 [1-375]] with Sequence_2: [Fragment of 
EspF native [1-621]]  
 
Similarity: 122/124 (98.39 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQA---------------------  99 
             |||||||||||||||||||||||||||||||||||||||                      
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  100   -RS---------------------------------------------------------  101 
              |                                                           
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  102   ---GGLPPLAQALKDHLAAYEQSKKG  124 
                ||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
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7.1.3 espF-L16E /37 strain  
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCT
TGCACAGGCACTAAAAGCATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
#37 = It is not L16E # 37 missing 485 bp from (63bp-547bp) missing 21 A.A-183A.A  
 
espF-L16E /37 
>430181001_37_FW sequence exported from 430181001_37_FW_A01.ab1 BglII=AGATCT 
NNNNNNNNNNNNNNTTTNATTATTCGTTTTGATATATATGAGAGTTAGCCAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGG
AATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGATCTGGTGGTCTACCGCCCCTTGCACAGGCACTAAAAGA
TCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAA
AAACCGATATCAAATTGCGTGG 
MLNGISNAASTLGRQLVGIARSGGLPPLAQALKDHLAAYEQSKKG 
 
Alignment of Sequence_1:  [37] with Sequence_2: [EspF native]  
 
Similarity: 135/621 (21.74 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AG----------------------------------------------------------  62 
             ||                                                           
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  63    ------------------------------------------------------------  62 
                                                                          
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
Seq_1  63    ------------------------------------------------------------  62 
                                                                          
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  63    ------------------------------------------------------------  62 
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Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  63    ------------------------------------------------------------  62 
                                                                          
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  63    ------------------------------------------------------------  62 
                                                                          
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  63    ------------------------------------------------------------  62 
                                                                          
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  63    ------------------------------------------------------------  62 
                                                                          
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  63    ----AT-CTGGTGGTCTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  117 
                    ||||||| ||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  118   GAGCAATCGAAGAAAGGGTAA  138 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
 
 
Protein  
 
Alignment of Sequence_1:  [Fragment of EspF native [1-621]] with Sequence_2: 
[Fragment of 37 [1-138]]  
 
Similarity: 45/45 (100.00 %) 
 
Seq_1  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             |||||||||||||||||||| |:                                      
Seq_2  1     MLNGISNAASTLGRQLVGIA-RS-------------------------------------  22 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
                                                                          
Seq_2  23    ------------------------------------------------------------  22 
 
 
Seq_1  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
                                                                          
Seq_2  23    ------------------------------------------------------------  22 
 
 
Seq_1  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
                ||||||||||||||||||||||| 
Seq_2  23    ---GGLPPLAQALKDHLAAYEQSKKG  45 
 
 
 
 
135 
 
7.1.4 espF-L16E /39 strain  
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
39= ∆151bp-505BP missing (51AA-168AA) =117AA 
espF-L16E /39 
>430181001_39_FW sequence exported from 
430181001_39_FW_C01.ab1NNNNNNNNNNNNNAANNNTTTTATTATTCGTTTTGATATATATGAGAGTTAGCCAAGA
TTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATC
GCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCAT
TCCCCCTTTTCTAGATCTCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCCTT
GCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCGG
TATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAATTGCGTGG 
MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSRSRQAPPPPTSGQASGPGGLPPLAQ
ALKDHLAAYEQSKKG 
Alignment of Sequence_1:  [39] with Sequence_2: [EspF]  
 
Similarity: 269/621 (43.32 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCT------------------------------  150 
             ||||||||||||||||||||||||||||||                               
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
Seq_1  151   ------------------------------------------------------------  150 
                                                                          
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  151   ------------------------------------------------------------  150 
136 
 
                                                                          
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  151   --AGATCT----------------------------------------------------  156 
               |||||                                                      
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  157   ------------------------------------------------------------  156 
                                                                          
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  157   ------------------------------------------------------------  156 
                                                                          
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  157   ------------------------CGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  192 
                                     |||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  193   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  252 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  253   GAGCAATCGAAGAAAGGGTAA  273 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
Alignment of Sequence_1:  [Fragment of 39 [1-273]] with Sequence_2: [Fragment of 
EspF [1-621]]  
 
Similarity: 88/90 (97.78 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFS--------RS  52 
             ||||||||||||||| ||||||||||||||||||||||||||||||||||        |  
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  53    ------------------------------------------------------------  52 
                                                                          
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  53    ------------------------------------------------RQAPPPPTSGQA  64 
                                                             |||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  65    SGPGGLPPLAQALKDHLAAYEQSKKG  90 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
 
 
 
 
 
 
 
 
 
 
137 
 
7.1.5 espF-L16E /40 strain  
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
#40= ΔCCAACC only  
espF-L16E /40 
>430181001_40_FW sequence exported from 
430181001_40_FW_D01.ab1NNNNNNNNNNNNNNNNNNNNNNTNNNNTTTTATTATTCGTTTTGATATATATGAGAG
TTAGCCAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGA
AGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGT
GAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCA
TTTACTCCCTCTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCA
CAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCA
CCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTA
GCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGAGATCTCGTCAGGCACCACCGCCACCGACAAGTGG
ACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGA
AAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAAATTGCG
TGN 
Alignment of Sequence_1:  [EspF NATIVE] with Sequence_2: [40]  
 
Similarity: 614/621 (98.87 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
 
138 
 
Seq_1  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
             ||||||||||||||||||  | | |||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGAGATCTCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  601   GAGCAATCGAAGAAAGGGTAA  621 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
Alignment of Sequence_1:  [Fragment of 40 [1-621]] with Sequence_2: [Fragment of 
EspF NATIVE  [1-621]]  
 
Similarity: 203/206 (98.54 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKRSRQAPPPPTSGQA  180 
             ||||||||||||||||||||||||||||||||||||||||||||||  |||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
 
 
139 
 
7.1.6 espF-L16E /42 strain  
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
42= ∆151-220 bp with two mutation= 23A.A. ( 51AA.- 73 A.A.) 
 espF-L16E /42 
>430181001_42_FW sequence exported from 
430181001_42_FW_E01.ab1NNNNNNNNNNNNAAANCNNTTTATTATTCGTTTTGATATATATGAGAGTTAGCCAAGA
TTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATC
GCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTCCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCAT
TCCCCCTTTTCTAGATCTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCC
ATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGT
CCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATCAAAAGA
TCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGAC
AAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAAT
CGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAA
TTGCGTGG 
MLNGISNAASTLGRQEVGIASRVSSAGGTGFPVAPQAVRLTPVRVHSPFSRSRPAPPPPTSGQASGASRPLPPIAQALKD 
HLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQASKDHLAAYELSKASETVSFKPTRQAPPPPTSGQASG 
PGGLPPLAQALKDHLAAYEQSKKG 
 
Alignment of Sequence_1:  [42] with Sequence_2: [EspF NATIVE]  
 
Similarity: 549/621 (88.41 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTCCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCT--AGA-------------------------  153 
             ||||||||||||||||||||||||||||||  ||                           
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
140 
 
 
 
Seq_1  154   ---------------------------------------TCTCGTCCGGCACCGCCGCCA  174 
                                                    ||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  175   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  234 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  235   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  294 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  295   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  354 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  355   CCGCCCATTGCACAGGCATCAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  414 
             ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  415   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  474 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  475   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  534 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  535   GAGCAATCGAAGAAAGGGTAA  555 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
Alignment of Sequence_1:  [Fragment of EspF NATIVE [1-621]] with  Sequence_2: 
[Translation of  42]  
 
Similarity: 181/184 (98.37 %) 
 
Seq_1  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             ||||||||||||||| ||||||||||||||| ||||||||||||||||||        |  
Seq_2  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFPVAPQAVRLTPVRVHSPFS--------R-  51 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
                          ||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  52    -------------SRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  98 
 
 
Seq_1  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
             |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Seq_2  99    TRPAPPPPTSGQASGASRPLPPIAQASKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  158 
 
 
Seq_1  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
             |||||||||||||||||||||||||| 
Seq_2  159   SGPGGLPPLAQALKDHLAAYEQSKKG  184 
 
 
 
 
 
141 
 
7.1.7 espF-L16E /45 strain  
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGC
GGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGG
TTCGTCGAATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACC
GCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATT
TAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACA
AGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGA
ACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA
TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAG
GGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQV
TSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGA
SRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSK
KG 
BglII=AGATCT 
#45= ∆182-219= 62-73 A.A (11 A.A) and there is one mutation, this is exactly similar to 36  
espF-L16E /45 
>430724901_45_espffw sequence exported from 430724901_45_espffw_B01.ab1 
NNNNNNNNNNNNNNNNTTTTATTATTCGTTTTGATATATATGAGAGTTAGCCAAGATTAGATATAAAGAGGCATA
AATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCAAGTCGAGTGAGC
TCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCT
CCAGGTTCGTCGAATGTTAATGCGAGGACGAGATCTCGTCCGGCGCCGCCGCCACCGACAAGTGGACAGGCATCCG
GGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT
GAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGAC
CTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCT
TTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGC
ACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCG
GTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAATTGCGTG 
MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTRSRPAPPPPTSGQASGASRP 
LPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAP 
PPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
 
 
 
Alignment of Sequence_1:  [#45] with Sequence_2: [EspF NATIVE]  
 
Similarity: 579/621 (93.24 %) 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
142 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
Seq_1  181   A------------------------------------GATCTCGTCCGGCGCCGCCGCCA  204 
             |                                      ||||||||||| ||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  205   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  264 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  265   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  324 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  325   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  384 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  385   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  444 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  445   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  504 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  505   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  564 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  565   GAGCAATCGAAGAAAGGGTAA  585 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
 
Alignment of Sequence_1:  [Fragment of #45 [1-585]] with Sequence_2: [Fragment of  
EspF native  [1-621]]  
 
Similarity: 192/194 (98.97 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  61    R------------SRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  108 
                          ||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  109   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  168 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  169   SGPGGLPPLAQALKDHLAAYEQSKKG  194 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
143 
 
7.1.8 espF-L16E /75 strain 
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
#75= ∆63-156 bp (30 AA from 23-52) mutation in two A.A. # (21 and 22 A.A.)  
espF-L16E /75 
>430181001_75_FW sequence exported from 
430181001_75_FW_H01.ab1NNNNNNNNNNNNNNNCNTTTTATTATTCGTTTTGATATATATGAGAGTTAGCCAAGAT
TAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCG
CAAGATCTTCGTCGAATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGC
ACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTT
AGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTG
GACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGA
AAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGT
GGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAACCAACTAATTTA
AAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAATTGCGTGG 
MLNGISNAASTLGRQEVGIARSSSNVNARTIFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELS 
KASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLA 
QALKDHLAAYEQSKKG 
 
 
Alignment of Sequence_1:  [75] with Sequence_2: [EspF NATIVE]  
 
Similarity: 525/621 (84.54 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGATC-------------------------------------------------------  65 
             ||                                                           
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
 
 
144 
 
Seq_1  66    -----------------------------------TTCGTCGAATGTTAATGCGAGGACG  90 
                                                ||||||||||||||||||||||||| 
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
Seq_1  91    ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  150 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  151   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  210 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
Seq_1  211   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  270 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  271   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  330 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  331   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  390 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  391   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  450 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  451   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  510 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  511   GAGCAATCGAAGAAAGGGTAA  531 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
Alignment of Sequence_1:  [Fragment of EspF NATIVE [1-621]] with Sequence_2: 
[Fragment of 75 [1-531]]  
 
Similarity: 176/176 (100.00 %) 
 
Seq_1  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
             |||||||||||||||:||||::                              |||||||| 
Seq_2  1     MLNGISNAASTLGRQEVGIARS------------------------------SSNVNART  30 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  31    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  90 
 
 
Seq_1  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  91    TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  150 
 
 
Seq_1  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
             |||||||||||||||||||||||||| 
Seq_2  151   SGPGGLPPLAQALKDHLAAYEQSKKG  176 
 
 
 
 
145 
 
7.1.9 espF-L16E /77 strain 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
#77= It is not L16E missing 63bp- 220bp (157bp) = missing 21-73 A.A (53A.A)  
espF-L16E 77 
>430181001_77_FW sequence exported from 
430181001_77_FW_A02.ab1NNNNNNNNNNNCNNNNNNTNNNNNNNNTTTTATTATTCGTTTTGATATATATGAGAG
TTAGCCAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTT
GTAGGTATCGCAAGATCTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCC
CATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCG
TCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAG
ATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGA
CAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAA
TCGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAA
ATTGCGTGG 
MLNGISNAASTLGRQLVGIARSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQ 
ASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
 
Alignment of Sequence_1:  [77] with Sequence_2: [EspF native]  
 
Similarity: 465/621 (74.88 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AG---A------------------------------------------------------  63 
             ||   |                                                       
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  64    ------------------------------------------------------------  63 
                                                                          
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
 
 
146 
 
Seq_1  64    ---------------------------------------TCTCGTCCGGCACCGCCGCCA  84 
                                                    ||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  85    CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  144 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  145   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  204 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  205   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  264 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  265   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  324 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  325   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  384 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  385   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  444 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  445   GAGCAATCGAAGAAAGGGTAA  465 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
 
Alignment of Sequence_1:  [Fragment of 77 [1-465]] with Sequence_2: [Fragment of 
EspF native [1-621]]  
 
Similarity: 154/154 (100.00 %) 
 
Seq_1  1     MLNGISNAASTLGRQLVGIA-R--------------------------------------  21 
             |||||||||||||||||||| |                                       
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  22    -------------SRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  68 
                          ||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  69    TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  128 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  129   SGPGGLPPLAQALKDHLAAYEQSKKG  154 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
 
 
 
 
147 
 
7.1.10 espF-L16E /78 strain 
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
#78= ∆ 151bp- 219bp and 350bp- 490bp and 3 mutations   
Missing 51-73 A.A. and 117A.A-162 A.A and mutation with one amino acid #199 A.A.   
espF-L16E /78 
>430181001_78_FW sequence exported from 
430181001_78_FW_B02.ab1NNNNNNNNNNNNNNCNNNNNNNNNNNNNTTATTATTCGTTTTGATATATATGAGAGT
TAGCCAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAA
GTAGGTATCGCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTG
AGAGTTCATTCCCCCTTTTCTAGATCTCGTCCGGCGCCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCT
TTACCGCCCATTGCACAGGCATTAAAAGATCACTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAG
CCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACT
AAAAGATCATTTAGCTGCCCATGAGCAATCGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTT
GTTTTCCAACTAATAAAAACCGATATCAAATTGCGTGG 
 
Alignment of Sequence_1:  [78] with Sequence_2: [EspF native]  
 
Similarity: 405/621 (65.22 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCT------------------------------  150 
             ||||||||||||||||||||||||||||||                               
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
 
148 
 
Seq_1  151   ------------------------------------AGATCTCGTCCGGCGCCGCCGCCA  174 
                                                    ||||||||||| ||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  175   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  234 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  235   AAAGATCACTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAA-----------  283 
             |||||||| ||||||||||||||||||||||||||||||||||||||||            
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  284   ------------------------------------------------------------  283 
                                                                          
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  284   ------------------------------------------------------------  283 
                                                                          
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  284   ----------GCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  333 
                       |||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  334   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCCAT  393 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  394   GAGCAATCGAAGAAAGGGTAA  414 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
Alignment of Sequence_1:  [Translation of 78] with Sequence_2: [Fragment of EspF 
native [1-621]]  
 
Similarity: 136/137 (99.27 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFS--------R-  51 
             ||||||||||||||| ||||||||||||||||||||||||||||||||||        |  
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  52    -------------SRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETV----  94 
                          |||||||||||||||||||||||||||||||||||||||||||     
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  95    -------------------------------------------SFKPTRQAPPPPTSGQA  111 
                                                        ||||||||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  112   SGPGGLPPLAQALKDHLAAHEQSKKG  137 
             |||||||||||||||||||:|||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
 
 
 
 
149 
 
7.1.11 espF-L16E /79 strain 
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
BglII=AGATCT 
#79= ∆151bp-219bp = 51A.A- 73A.A (23A.A) with one amino acid mutation #148 A.A.  
espF-L16E /79 
>430181001_79_FW sequence exported from 
430181001_79_FW_C02.ab1NNNNNNNNNNNNNNNNNNNTNNNNNNNNTTTATTATTCGTTTTGNATATATATGAGA
GTTAGCCAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGG
AAGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTCCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCG
GTGAGAGTTCATTCCCCCTTTTCTAGATCTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGA
CCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTA
AGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAG
GCATCAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCA
CCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGC
CTATGAGCAATCGAAGAAAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAA
CCGATATCAAATTGCGTGG 
MLNGISNAASTLGRQEVGIASRVSSAGGTGFPVAPQAVRLTPVRVHSPFSRSRPAPPPPTSGQASGASRPLPPIAQALKD 
HLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQASKDHLAAYELSKASETVSFKPTRQAPPPPTSGQASG 
PGGLPPLAQALKDHLAAYEQSKKG 
 
Alignment of Sequence_1:  [79] with Sequence_2: [EspF native]  
 
Similarity: 549/621 (88.41 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTCCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
 
 
150 
 
Seq_1  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCT--AGA-------------------------  153 
             ||||||||||||||||||||||||||||||  ||                           
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
Seq_1  154   ---------------------------------------TCTCGTCCGGCACCGCCGCCA  174 
                                                    ||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  175   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  234 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  235   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  294 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  295   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  354 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  355   CCGCCCATTGCACAGGCATCAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  414 
             ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  415   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  474 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  475   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  534 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  535   GAGCAATCGAAGAAAGGGTAA  555 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
Alignment of Sequence_1:  [Fragment of 79 [1-555]] with Sequence_2: [Fragment of 
EspF native [1-621]]  
 
Similarity: 181/184 (98.37 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFPVAPQAVRLTPVRVHSPFS--------R-  51 
             ||||||||||||||| ||||||||||||||| ||||||||||||||||||        |  
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  52    -------------SRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  98 
                          ||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  99    TRPAPPPPTSGQASGASRPLPPIAQASKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  158 
             |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  159   SGPGGLPPLAQALKDHLAAYEQSKKG  184 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
 
151 
 
7.1.12 espF-L16E /80 strain 
 
EspF native   
ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGG
GGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCG
AATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCACCG
ACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAA
CTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGG
GGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGAC
TGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCATCCGGGCCTGGTGGACTACCGCCCC
TTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAGAAAGGGTAA 
MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNARTIFNVSSQVTSFTPSR
PAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKPTRPAPPPPTSGQASGASRPLPPIAQALKDH
LAAYELSKASETVSFKPTRQAPPPPTSGQASGPGGLPPLAQALKDHLAAYEQSKKG 
#80= S74A It is L16E but there is no deletion only two mutation (in amino acid #47) Serine to Alanine no 
BglII,  
 BglII=AGATCT 
espF-L16E /80 
>430181001_80_FW sequence exported from 
430181001_80_FW_D02.ab1NNNNNNNNNNNNNNNNNNTNNNNNNNNTTTTATTATTCGTTTTGATATATATGAGAG
TTAGCCAAGATTAGATATAAAGAGGCATAAATTATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGA
AGTAGGTATCGCAAGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTTACTCCGGT
GAGAGTGCATGCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACGATTTTTAATGTGAGCAGCCAGGTGACTTC
ATTTACTCCCTCTCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGC
ACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCAACCCGTCCGGC
ACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTAAAAGATCATTT
AGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTG
GACAGGCATCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTATGAGCAATCGAAG
AAAGGGTAACCAACTAATTTAAAACGATTAATCGGTATTGATTATTTGTTTTCCAACTAATAAAAACCGATATCAAATTGCG
NN 
Alignment of Sequence_1:  [79] with Sequence_2: [EspF native]  
 
Similarity: 616/621 (99.19 %) 
 
Seq_1  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGGAAGTAGGTATCGCA  60 
             |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Seq_2  1     ATGCTTAATGGAATTAGTAACGCTGCTTCTACACTAGGGCGGCAGCTTGTAGGTATCGCA  60 
 
 
Seq_1  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    AGTCGAGTGAGCTCTGCGGGGGGAACTGGATTTTCTGTAGCCCCTCAGGCTGTTCGTCTT  120 
 
 
Seq_1  121   ACTCCGGTGAGAGTGCATGCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
             |||||||||||||| ||| ||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   ACTCCGGTGAGAGTTCATTCCCCCTTTTCTCCAGGTTCGTCGAATGTTAATGCGAGGACG  180 
 
 
152 
 
Seq_1  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  181   ATTTTTAATGTGAGCAGCCAGGTGACTTCATTTACTCCCTCTCGTCCGGCACCGCCGCCA  240 
 
 
Seq_1  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  241   CCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTACCGCCCATTGCACAGGCATTA  300 
 
 
Seq_1  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  301   AAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCTGAGACTGTAAACTTTAAGCCA  360 
 
 
Seq_1  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  361   ACCCGTCCGGCACCGCCGCCACCGACAAGTGGACAGGCATCCGGGGCATCCCGACCTTTA  420 
 
 
Seq_1  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  421   CCGCCCATTGCACAGGCATTAAAAGATCATTTAGCTGCCTATGAACTATCGAAAGCGTCT  480 
 
 
Seq_1  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  481   GAGACTGTAAGCTTTAAGCCAACCCGTCAGGCACCACCGCCACCGACAAGTGGACAGGCA  540 
 
 
Seq_1  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  541   TCCGGGCCTGGTGGACTACCGCCCCTTGCACAGGCACTAAAAGATCATTTAGCTGCCTAT  600 
 
 
Seq_1  601   GAGCAATCGAAGAAAGGGTAA  621 
             ||||||||||||||||||||| 
Seq_2  601   GAGCAATCGAAGAAAGGGTAA  621 
 
 
Alignment of Sequence_1:  [Fragment of 79 [1-621]] with Sequence_2: [Fragment of 
EspF native [1-621]]  
 
Similarity: 204/206 (99.03 %) 
 
Seq_1  1     MLNGISNAASTLGRQEVGIASRVSSAGGTGFSVAPQAVRLTPVRVHAPFSPGSSNVNART  60 
             ||||||||||||||| |||||||||||||||||||||||||||||| ||||||||||||| 
Seq_2  1     MLNGISNAASTLGRQLVGIASRVSSAGGTGFSVAPQAVRLTPVRVHSPFSPGSSNVNART  60 
 
 
Seq_1  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  61    IFNVSSQVTSFTPSRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVNFKP  120 
 
 
Seq_1  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  121   TRPAPPPPTSGQASGASRPLPPIAQALKDHLAAYELSKASETVSFKPTRQAPPPPTSGQA  180 
 
 
Seq_1  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
             |||||||||||||||||||||||||| 
Seq_2  181   SGPGGLPPLAQALKDHLAAYEQSKKG  206 
 
 
 
 
 
 
 
153 
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